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Abstract 
Blood transfusion is an important element of health care which saves millions of lives each year 
but has life-threatening risks. In low-resource countries in Africa, a significant proportion of 
donated blood remains unsafe if blood units are not screened appropriately for all major 
transfusion-transmitted infections (TTIs). Syphilis, one of the TTIs, remains a public health 
problem in developing countries including Ghana if testing is not performed in a well-controlled 
manner. Thus, there is the possibility of infecting recipients with syphilis which may have long-
term sequelae.  
The study investigated syphilis testing practices in transfusion facilities in Ghana, test cross-
reactions between various techniques, and the potential infectivity of ‘true’ positive blood samples, 
in the Ghanaian blood donor population. The goal of the research was to guide transfusion policies 
and practices, and advance transfusion medicine research in Ghana by improving syphilis testing.  
Data collection was in three parts based on five specific objectives. The first part was a survey, 
carried out in 149 transfusion facilities in Ghana and found a syphilis seroprevalence of 3.7% for 
blood donors. The laboratories used predominantly non-approved test kits at variable costs.  In the 
second part, using rapid diagnostic test, Fortress RDT, and rapid plasma reagin (RPR), syphilis 
testing was performed on 16,016 prospective blood donors who came to donate blood for the 
Komfo Anokye Teaching Hospital (KATH) blood bank. Positive predictive values of the RDT and 
RPR were found to be 90.9% and 97.1% respectively. The third part was a quality assessment to 
determine the performance of the frequently used syphilis test in Ghana, the ABON RDT, in four 
selected facilities. Sensitivity and specificity were found to be 99.2% and 82.5% respectively. 
Finally, we determined the relative proportions of confirmed syphilis antibody positive donors 
with clinical histories attributable to yaws rather than syphilis. 
Our data from the surveys showed a considerable mismatch between recommendations and 
practice of syphilis testing in Ghana, with potential serious consequences for blood safety and 
public health. This study found that the combination of syphilis RDT and RPR which have a 
relatively good PPV, as a novel strategy, could contribute to improving blood safety when 
screening blood donors for syphilis. It was confirmed that quality systems for syphilis testing are 
generally weak in Ghana, but are important for any laboratory or testing site to ensure accuracy, 
consistency, and reliability of test results which directly contributes to the safety of blood supply. 
Finally, the question, whether some of the syphilis positivity in blood donors could be attributable 
to yaws rather than syphilis remained speculative. 
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CHAPTER 1 
1. INTRODUCTION 
1.1 Transfusion of unsafe blood 
Blood transfusion is an important element of health care which saves millions of lives each year. 
Every second, someone in the world needs blood for surgery, trauma, severe anaemia or 
complications of pregnancy. However, millions of people are exposed to avoidable, life-
threatening risks from the transfusion of unsafe blood every year 1. About 7.5% (6/81 million units) 
of blood collected annually in 178 countries are not tested for transfusion-transmissible infections 
(TTI) 2. In low-resource countries in Africa, a significant proportion of donated blood remains 
unsafe as it is either not screened for all major TTIs or not in a quality-controlled manner 3. 
Particularly in sub-Saharan Africa (SSA) blood screening programmes have limitations, and safety 
from infection risk can often not be guaranteed. Thus, while blood transfusion can be life-saving, 
there are associated risks, including TTIs.  
Syphilis is a chronic, systemic infection, caused by an organism called Treponema pallidum 
subspecies pallidum. It affects large numbers of people through sexual transmission, from mother 
to offspring and via blood transfusion. Being one of the TTIs, it represents a major public health 
problem because of its worldwide occurrence in the most neglected and troubled regions. The past 
five years have seen a number of outbreaks in many countries involved in blood donations 4-8.  
Serologic tests are the most common tests used for screening for syphilis. This is because 
Treponema pallidum cannot be cultured in vitro. Additionally, T. pallidum nucleic acid 
amplification tests are not widely available for use by clinical laboratories. There has been 
development of rapid treponemal-based syphilis tests which was driven by the need for simple, 
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point-of-care tests in resource-poor countries and this will be discussed further in the coming 
chapters. 
1.2 Syphilis prevalence  
Treponema pallidum, the aetiologic agent of syphilis 9, is prevalent but rarely transmitted via blood 
transfusions in developed countries because the blood supply is safe due to a combination of donor 
education, donor screening, willingness to donate, treatment, safe sex, and strict laboratory testing 
procedures. Thus, the risk of TTI is extremely low in these countries. However, syphilis infection 
is much more common in developing countries where prevalence can reach 23.5% amongst blood 
donors 10. In Ghana, data on T. pallidum seroprevalence are scanty, although antibodies are thought 
to occur as frequently as HBV antibodies 11.  Published studies from Ghana show syphilis 
seroprevalence of between 7.5% and 13.5% 7,12. For example, the Central Area Blood Centre in 
Accra, which serves the Korle Bu Teaching Hospital and its environs in Ghana, has shown an 
increasing trend in the prevalence rate of syphilis infection from 1.23%, to 2.89% and 4.86% 
respectively among blood donors in 2009, 2010 and 2011, in performance reviews respectively 13.  
Yaws is a neglected non-venereal endemic treponematosis caused by the bacterium Treponema 
pallidum subspecies pertenue and spread by skin to skin contact 14. It often starts as a single lesion 
of swelling on the skin but may progress to multiple lesions all over the body. In the late stages,  
if untreated, the disease can progress to cause destructive lesions of bones and cartilage leading to 
disabilities and disfigurement in 10% (figure 7.1) 14. It is closely related to syphilis 15 and the cross-
reactivity between them  leads to problems for blood services since yaws may cause false positive 
screening tests for syphilis. Both syphilis and yaws are distinguishable by epidemiological 
characteristics and clinical manifestations. Yaws is mostly seen in children below the age of 15 
years, whilst syphilis affects individuals of any age. A primary chancre on mucous membranes is 
INTRODUCTION-Sarkodie thesis 
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seen in individuals with syphilis but not in yaws, where the primary lesion is in the skin. This 
comparison between yaws and syphilis is important for blood services since they need to 
distinguish between these two conditions in the absence of a specific differentiating test, and will 
be explained further in the next chapter. 
1.3 Problem Statement 
Delivery of safe blood for transfusion is a big challenge for countries in SSA including Ghana. A 
contributing factor to this is high rates of donor deferrals, which adds to difficulties in retaining 
voluntary non-remunerated donors (VNRD). Blood donors who test positive for syphilis may 
contribute to the lack of safe blood in low resource countries so it is important to try and 
differentiate between donors who are infective and should be excluded, and those who are non-
infective but screen positive during donor testing. Cost of reagents and labour must be considered 
when determining the best strategy for syphilis testing 16. Although syphilis testing of blood donors 
is recommended and mandatory in many countries, the cost-effectiveness may be questionable. 
Firstly, blood donors who are positive for syphilis antibodies may not be infectious either because 
they do not carry active infections or because they are false positives, e.g. not infected with 
syphilis. Secondly T. pallidum is less infectious after cold storage, rendering the risk of 
transmission through transfusion via red blood cells or plasma components very low 17.  
Serological testing for syphilis (STS) is a principle of measuring either specific (anti-T. pallidum 
antibody detection) or non-specific (anti-lipoid antibody detection) antitreponemal antibodies 
which will be explained further in the next chapter. The advantage of specific syphilis antibody 
testing is the relatively high sensitivity and specificity. However, for the screening of blood donors 
in an area with high prevalence of syphilis antibody reactivity, the disadvantage is that specific 
syphilis tests stay positive persistently after the infection has been cured. However, the 
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identification of donors carrying previous syphilis infections may be useful in many settings as 
syphilis positivity may be a marker of high-risk sexual behaviour. Unfortunately, in West Africa 
where yaws is prevalent 18, it can be assumed that previous yaws infections may also contribute 
considerably to the high proportion of blood donors who screen positive for syphilis. Treponemal 
tests are commercially available in the formats of rapid diagnostic testing with minimal cost, 
minimal training and equipment requirement and availability of results within 5-20 minutes 19. 
However, positive results of these rapid syphilis tests need confirmation with quantitative non-
treponemal testing to determine whether there has been recent infection and the response to 
treatment. 
The present study investigates the processes and variations in syphilis testing and the associated 
testing costs in Ghana. Recently, there was a case of syphilis transmission through blood 
transfusion in Ghana where an 8-year-old girl with severe malarial anaemia showed 
seroconversion after receiving a syphilis reactive unit of blood that had been refrigerated for only 
1 day 6. With data from Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana, the project 
explores the value of rapid diagnostic testing of blood donors for syphilis. The approach to the 
study was as follows: the positive predictive values of syphilis tests in routine use in blood donor 
screening in Ghana (i.e. donors being truly syphilis antibody positive with potential active 
infections) was determined by the combination of subsequent composite gold standard testing and 
unspecific rapid plasma reagin (RPR) testing. Donors that tested positive on initial screening, but 
did not test positive in subsequent gold standard testing were considered false positives whereas 
donors testing negative in RPR testing but positive with initial testing were considered previously 
infected only. Finally, among donors that were truly syphilis antibody positive, the study examined 
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to what degree previous syphilis or yaws could be suspected as the cause of the positive result in 
the individual donors.  
The data generated shall serve as evidence not only to guide transfusion policies, practices and 
ensure quality of transfusions, but would hopefully also be of importance in the advancement of 
transfusion medicine research in Ghana and beyond. 
1.4 Justification for the Study 
Over the years, much controversy has arisen over the need for syphilis testing of blood donors 20. 
In most of the transfusion centres in Ghana, syphilis testing is not done, probably because it is 
believed that stored blood renders the organism that causes syphilis non-viable. At KATH, which 
was one of the study site, between 18,000 and 20,000 blood donors donate blood every year with 
70% being voluntary non-remunerated donations and the rest being family/replacement donations. 
Routine pre-donation testing with rapid diagnostic tests (RDT) of all blood donors for human 
immuno-deficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) have been 
performed for more than 15 years 21,22, whereas syphilis testing only started in June 2013. It is 
recommended that syphilis unscreened blood is stored for period >72 hours 17 because  T. pallidum, 
the causative agent of syphilis, cannot withstand the lower temperatures (between 2 and 6 degrees 
Celsius). Unfortunately, in many countries where blood shortages are common, units of blood that 
are collected from donors typically do not stay in the blood bank fridge for more than 48 hours 
because of the demand for it 6. The consequence is that patients who receive these unscreened units 
of blood may get infected with syphilis. 
Furthermore, other spirochaetes like T. pallidum ssp. pertenue causing yaws may be present in 
blood in the early latent seropositive stage, when the microbes just become detectable causing 
strong cross reactivity 23.  
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The WHO recommends that syphilis testing is performed before transfusion, and that enzyme 
immuno assay (EIA) and T. pallidum haemagglutination assay (TPHA) are used as specific tests, 
while venereal disease research laboratory (VDRL) and  RPR are used as non-specific tests 24. For 
quality and consistency, the policy of the National Blood Service, Ghana (NBSG), advocates 
streamlining of purchasing test kits and their validation before use, adherence to the standard 
operating procedures (SOPs) for laboratory testing and implementation of effective TTI guidelines 
of donor care 25. This will increase proper documentation and effectiveness for blood safety. 
Almost all the blood banks in the country screen for HIV, HBV and HCV, but only a small and 
(prior to this study) unknown proportion screen for syphilis 
1.5 Research Questions 
1. What is the existing syphilis testing practice of transfusion facilities in various parts of 
Ghana?  
2. What is the positive predictive value of the RDT that is used most commonly in KATH 
and Ghana for syphilis testing?  
3. What proportion of syphilis reactive blood donors are really infectious through transfusion? 
4. What is the performance of a predominant syphilis RDT as used in some selected 
transfusion facilities in Ghana? 
5. Could some of the syphilis positivity in blood donors be attributable to yaws rather than 
syphilis?  
1.6 Study Objectives 
1.6.1  Main Objective 
To investigate syphilis testing practices in transfusion facilities in Ghana, test cross reactions, the 
potential infectivity of ‘true’ positives in the Ghanaian blood donor population, and to make 
recommendations in guiding transfusion policies and practices. 
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1.6.2  Specific Objectives 
1. To investigate syphilis testing practices of transfusion facilities in various parts of Ghana.  
2. To determine the positive predictive value of the RDT that is most commonly used in 
KATH and Ghana for syphilis testing.  
3. To estimate the proportion of blood donors in KATH, Kumasi who are really infectious 
through blood transfusion.  
4. To determine the performance of a predominant syphilis RDT in selected transfusion 
facilities in Ghana.  
5. In confirmed syphilis antibody positive donors, determine the relative proportions of those 
with clinical histories attributable to yaws rather than syphilis. 
1.7 Summary 
In this chapter, an overview of syphilis testing in blood donors worldwide and the current status 
of syphilis-related blood transfusion safety in SSA including Ghana have been presented. The 
problem statement, justification, research questions, and study objectives have also been presented. 
In the next chapter, a background and review of the literature on syphilis prevalence and testing 
worldwide with emphasis on Ghana is presented. 
1.8 Thesis outline 
As stated earlier, chapter one presented an overview of syphilis testing in blood donors worldwide 
and the current status of syphilis-related blood transfusion safety in SSA including Ghana.  
Chapter two provides a background and review of the literature that this thesis is based upon. A 
brief summary of the study background, the aetiology of the causative organism, stages of infection 
of the disease, global syphilis epidemiology, syphilis detection by various techniques, prevalence 
of syphilis infection in blood donors, various recommendations for syphilis testing, 
pathophysiology of yaws, and finally the comparison of syphilis and yaws are presented. The 
review also examines how various screening methods and tests are applied in SSA. 
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Chapter three focuses on the conceptual framework of the study and ethical considerations. 
Chapter four surveys syphilis testing practices in transfusion facilities in Ghana, discussing policy 
and practice of syphilis testing in the country. Chapter five focuses on improving syphilis testing 
of blood donors with RDT and RPR in KATH, Kumasi, with emphasis on calculating positive 
predictive values of these test kits to improve blood safety. Chapter six is a quality assessment 
study of a selected syphilis RDT performed at four selected transfusion sites in Kumasi. Chapter 
seven focuses on the relationship of yaws and syphilis, potential transmission of yaws via 
transfusion, and describes the recalled medical history, clinical manifestations, and treatment of 
yaws and syphilis by syphilis seroreactive blood donors when these donors were interviewed. 
Chapter eight gives the general conclusion and recommendations of the study. 
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CHAPTER 2 
2.Background and literature review 
2.1 Study background 
2.1.1 Ghana as study location 
Ghana, a country of a population of 28,308,301 as of 2016 26 officially called the Republic of 
Ghana, is a sovereign multinational state and unitary presidential constitutional democracy which 
is situated along the Gulf of Guinea and the Atlantic Ocean, in the sub-region of West Africa. It 
has a land mass of 238,535 km2, with 2,093 kilometres of international land borders. It shares 
borders with Ivory Coast to the west, Burkina Faso to the north, Togo to the east and the Gulf of 
Guinea and the Atlantic Ocean in the south.  
The Ministry of Health (MoH) is responsible for the health of Ghana. It is involved in providing 
public health services, managing Ghana's healthcare industry, and building Ghana's hospitals and 
medical education system.  In 2013, the Government of Ghana spent US$63 annually on each 
person’s health in order to provide basic health services 27. The planned 2016 budget decreased 
this to US$3128, less than half the target. Because the government does not spend enough, the 
burden of paying for health falls heavily on households. Despite the National Health Insurance 
Scheme (NHIS) which aims to accomplish universal health insurance coverage in Ghana 29, 67% 
of all health spending in the country was spent by households up-front, e.g. out-of-pocket 
expenditure, without insurance, in 2014 30. This has more than doubled since 201131, and the 
poorest in Ghana are likely to be excluded from care or pushed further into poverty by 
unsustainable payments. In addition, despite pregnant women in Ghana having a  subsidized health 
insurance, a recent report has found that pregnant and postpartum women registered with the NHIS 
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continue to pay for services including medicines, ultrasound scans, and some laboratory tests 
including blood products for transfusion 32.  
Figure 2.1 Map of Ghana showing catchment areas of Blood Centres 
 
 
Under the MoH is the Ghana Health Service (GHS) a government body established in 1996 as part 
of the Health Sector Reform of Ghana. The Health service principally administrates the health 
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services provided by the government and in implementing government policies on health. Some 
of the functions of the GHS are to promote a healthy style of living and good health habits by 
people in Ghana and to establish an effective mechanism for disease surveillance, prevention, and 
control in Ghana. The MoH furthermore is ultimately responsible for the safety and adequacy of 
the blood supply in the country and takes measure to secure Government commitment and support 
for the National Blood Programme. 
2.1.2 National Blood Service, Ghana 
The National Blood Service, Ghana (NBSG) is one of the newest agencies under the MoH. The 
NBSG provides blood and blood products, as well as in relation to research and training. The 
NBSG is responsible for ensuring a coordinated national approach to the provision of safe, 
adequate and efficacious blood and blood products, making it timely, available and affordable to 
all patients requiring blood transfusion therapy in both public and private health care institutions 
in the country 25. The strategy of the blood service is to be centrally coordinated and have a network 
of area centres, well-distributed in the country to provide effective coverage. There has been 
several TTIs that have been studied in Ghana, and these include HIV, HBV, HCV, Human 
erythrovirus B19, West Nile virus, GB virus, and malaria33-38. Currently, Ghana has 4 major TTIs 
that are screened for prior to transfusion namely HIV, HBV and HCV, which are screened at all 
blood transfusion facilities, whereas syphilis, is reportedly screened in 20% of the facilities 39. 
According to the NBSG annual report in 2007, the average national prevalence rates in donors for 
HIV, HBV, HCV and syphilis were 1.27%, 10.14%, 0.99% and 1.48% respectively 39 with higher 
seroreactivity among family donors (FD) than voluntary non-remunerated donors (VNRD). 
Presently, the NBSG comprises a National Headquarters and three (3) Area Blood Centres (ABCs) 
– Southern Area Blood Centre (SABC) located at Korle-Bu Teaching Hospital (KTH), Accra; 
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Central Area Blood Centre (CABC) located at Komfo Anokye Teaching Hospital (KATH) in 
Kumasi; and Northern Area Blood Centre (NABC) at the Tamale Teaching Hospital (TTH).  
The NBSG coordinates the activities of one stand-alone blood centre, the SABC which is located 
in Accra in the southern zone of Ghana and of over 149 hospital-based blood collection points. 
The SABC is responsible for procuring and supplying blood and blood products to the five 
southern administrative regions of Ghana with a total population of 13.04 million. The Transfusion 
Medicine Unit (TMU) of the Komfo Anokye Teaching Hospital (KATH) and the Tamale Teaching 
Hospital Blood Bank (TTH-BB), function as blood centres in the middle and northern zones of 
Ghana, and form the pivots for the proposed Central Area Blood Centre (CABC) and Northern 
Area Blood Centre (NABC) of the NBSG respectively. 
2.1.3 Ghana national blood policy 
The national policy for the blood service of Ghana provides directives to guide the MoH to ensure 
safety, efficacy, and adequacy of blood and blood products for all patients in all health institutions 
of the country both public and private, making it accessible and affordable. The Ghana national 
blood policy which was approved by cabinet in 2006 stated that all blood units collected must be 
tested prior to transfusion for TTIs and any other microbial diseases that may be thought to be 
relevant, using approved well-controlled techniques and procedures in accordance with WHO 
guidelines 25. Furthermore, the NBSG is responsible for purchasing approved test kits, and for 
distributing them to the various transfusion facilities before use. The policy additionally indicated 
that detailed methods and standard operating procedures (SOPs) should be available for all 
activities of the NBSG. 
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2.1.4 Testing of donated blood in sub-Saharan Africa (SSA) with emphasis on Ghana 
Blood units that are donated can be lifesaving for individuals who have lost blood because of 
accidents or surgery, as well as for people who have become severely anaemic through medical 
conditions and/or treatments.  
Testing donated blood in SSA for infectious diseases helps to maximize the safety of blood 
donation for both the donor and the recipient. Laboratory testing of donated blood preceding 
transfusion is intended to ensure that recipients receive the safest possible blood products. 
Depending on the transfusion testing site requirements, all infectious disease screening assays must 
be nonreactive in order to release the blood unit or its components to hospitals for transfusion 1. 
In some transfusion facilities in Ghana, syphilis testing is not done because it is believed that 
storing blood renders the organism that causes syphilis non-viable 40. Most of the facilities also 
have challenges in terms of procuring reagents for testing. But if testing for diseases like syphilis 
prior to transfusion is not done or not accurately done, there is the possibility of infecting recipients 
with syphilis with consequent potential long-term sequelae. 
2.1.5 Study areas 
While Ghana is the area of study regarding chapters 1-4 and 7, and has been described in the 
foregoing, chapters 5, 6 and 8 relate to the Kumasi area.  
Kumasi is the regional capital of Ashanti region. The population of Kumasi metropolis (1,730,249) 
depicts a broad base population pyramid which tapers off with a small number of persons who are 
elderly (60 years and older). The age dependency ratio for the Metropolis is 58; the age dependency 
ratio is 59.9 for males and 56.3 for females 41.  
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The main occupations in Kumasi are professional occupations such as services and manufacturing 
whilst the major export items are gold, hardwood, and cocoa. Of the employed population, 38.9 
percent are in the service and sales work, 22.8 percent are in craft and related trades, 10.3 percent 
are into elementary occupation, 2.6 percent are skilled agricultural forestry, and the rest are fishery 
workers 41. Public transport in the city is provided by transit buses, a mix of privately owned mini-
buses known as Tro-Tros, taxicabs, and buses. However, when blood donation is organized by 
transfusion facilities, a majority of the blood donors rely on transit buses and Tro-Tros which are 
affordable.  
2.1.6 Study site 
 The Komfo Anokye Teaching Hospital (KATH) in Kumasi, the study site, is the second-largest 
hospital in Ghana, and the only tertiary health institution in the Ashanti Region. KATH is the main 
referral hospital for the Ashanti, Brong Ahafo, Western, Central and Eastern regions of Ghana. 
The geographical location of the 1200-bed KATH, the road network and commercial nature of the 
city make the hospital accessible to all the areas that share boundaries with Ashanti Region and 
others that are further away. 
The vision of the hospital is to become a medical centre of excellence which offers clinical and 
non-clinical services of the highest quality standards comparable to any international standards. 
KATH manages blood transfusions which are required for several reasons; 
• Most patients, who have a major surgical procedure, will have a blood transfusion to 
replace any blood loss during their surgery. 
• Some patients have blood transfusion due to serious injuries from car crashes or natural 
disasters. 
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• Other individuals with an illness that causes anaemia, such as malaria, sickle cell disease, 
obstetric bleeding, leukaemia or kidney disease will often be the recipients of blood 
transfusion. 
2.1.7 Transfusion Medicine Unit 
The transfusion medicine unit (TMU) of KATH was created in 2002 as an autonomous entity 
operating under the Medical Director of the hospital. Although managed by the hospital, this unit 
is closely connected with the NBSG regarding regulations and recommendations applied to staff 
training, donor selection and quality of products. It provides blood units primarily to KATH but 
also to other public and private health care settings in Kumasi and its environs.  
The functions of TMU are defined as follows: 
1. To provide blood transfusion services to KATH and other health care facilities in Northern 
Ghana. 
2. To provide clinical support regarding indications of blood products and monitoring adverse 
transfusion reactions. 
3. To train medical and paramedical staff on blood relating issues. 
4. To audit clinical use of blood products. 
5.  To conduct research with the aim of improvement of blood-related therapies at KATH and 
Ghana in its entirety. 
6. It also has a role in surveillance of infectious diseases in the hospital such as HIV. 
The TMU performs laboratory tests for multiple infectious disease markers on every unit of 
donated blood. These tests include: HBV, HCV, HIV 1, 2 and Syphilis (Treponema pallidum). 
The unit has been practicing pre-donation screening with viral RDTs for blood donors since 2000 
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22,42, managing approximately 18 000 blood donations tested on site a year currently. KATH relies 
on two types of blood donors namely; voluntary non-remunerated donors (VNRD) constituting 
70% of blood collection, and family/replacement donors (FD) constituting 30% of blood collection 
for over a decade now according to 2015 annual performance review.  A high proportion of blood 
donors are students from secondary or tertiary institutions, and blood shortages can occur during 
vacations, examination periods in addition to high seasons of malaria.  
2.1.8 KATH transfusion committee 
The hospital transfusion committee (HTC) systematically scrutinizes blood supply, blood safety, 
donor care, clinical use of blood products, and costs. This committee has been influential in 
initiating and welcoming new screening strategies, showing the critical role such committees can 
play in the implementation of evidence-based measures to improve blood safety and availability 
even when resources are limited 43. In July 2014, pre-donation screening of blood donors for 
syphilis was introduced with an anti-treponemal rapid diagnostic test (RDT; Fortress Quick Test, 
Fortress Diagnostics, UK). This was because it was realized that refrigerated storage times of 
donated blood was shorter than those recommended to inactivate syphilis organisms, due to the 
high demand and turnover, and because  a study in the hospital had  reported syphilis seroreactivity 
of 8% 6. The introduction of this syphilis testing in a preliminary study, demonstrated a 
seroreactivity rate of 7.0% and the overall deferral rate for all TTIs increased from 9.5% to 16.5%. 
This had a critical and negative effect on the blood supply for the hospital. The TMU, therefore 
instituted a novel and pragmatic syphilis screening algorithm, where all initially syphilis 
seroreactive blood units are tested further with nontreponemal test to detect suspected active 
infections, to balance improved blood safety with the protection of the blood supply 44.  
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2.2 LITERATURE REVIEW 
2.2.1 Pathogenic treponemes 
Pathogenic treponemes are related with the following 4 diseases: 
• Venereal syphilis, caused by T.  pallidum spp. pallidum 
• Yaws, caused by T.  pallidum spp. pertenue 
• Endemic syphilis (bejel), caused by T.  pallidum spp. endemicum  
• Pinta, caused by T.  carateum 
The treponemes responsible for these diseases cannot be distinguished serologically and 
morphologically, and they have not been successfully cultivated on artificial media because the 
bacteria cannot be cultured in vitro. Of the many spirochaete–like organisms, the only pathogenic 
one that has proven capacity to infect humans via transfusion is T. pallidum. 
2.2.2 Aetiology of the disease 
Syphilis, once known as the Great Pox, is a chronic, systemic infection, and the causative 
organism, Treponema pallidum subspecies pallidum is a spirochaete, under the Family 
Spirochaetaceae of the Order Spirochaetales. Pathogenic members of this genus consist of T. 
pallidum, T. pertenue, and T. carateum. The genus name, Treponema, is a derivative of the Greek 
term for "turning thread". The T. pallidum organism is a spiral-shaped, extremely mobile, Gram-
negative bacterium and a helical to sinusoidal bacterium which ranges from 5 to 15 microns in 
length 45. It consists of an outer envelope and a protoplasmic chamber, between which lie axial 
threads (flagella) 46. It multiplies by binary transverse fission and normally enters the body through 
mucous membranes. Between 1905 and 1910, Schaudinn and Hoffman identified the organism T. 
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pallidum as the causative agent of syphilis, and Wasserman described it with the demonstration of 
spirochaetes in Giemsa-stained fluid from syphilitic lesions 47.  
 The disease is mostly transmitted by sexual contact with a person who has been infected or 
congenitally, but transmission has also been reported through blood and blood products and 
intravenous drug use 48. Several hypotheses have been put forward to explain the low number of 
documented transfusion-transmitted syphilis (TTS). TTS was first described in 1915. By 1941, a 
total of 138 cases had been defined in the literature 49. It was the first transfusion-transmitted 
disease described and was reported before 1950 50. Because of the inability to culture the organism 
and the restrictions of direct microscopy, serological testing has been the basis of laboratory 
diagnosis 51.  
2.2.3 Pathophysiology of syphilis 
Syphilis is usually contracted during sexual intercourse by the passage from genital lesions of one 
partner through the skin or mucous membranes of the other partner. The organism multiplies at 
the primary site of infection 52 in local lymph nodes within minutes and systemic dissemination 
within hours  47. Within few days, the spirochaetes disseminate by the invasion of the local lymph 
nodes causing swelling (lymphadenopathy) followed by seeding to the bloodstream in large 
numbers 52.  
If left untreated, the infection progresses, with varied and often delicate clinical manifestations, 
which can result in potentially life-threatening cardiovascular and neurological disease. Syphilis 
is untreated a lifelong infection that progresses in several stages based on its clinical presentation, 
infectivity, and progression. It can present in one of four different stages: primary, secondary, 
latent, and tertiary 53. Blood donors at any stage of disease, including late, latent syphilis, can 
transmit the infection 54. 
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2.2.4 The primary stage 
This stage is defined by an ulcer (also called a chancre) at the site of inoculation. The primary 
chancre can be found in up to 97% of infected individuals, although up to 60% may not remember 
having had a lesion 55. The chancre is a firm painless ulceration, 5-15 mm, sharply demarcated, 
and usually appears 3 to 90 days (average, 21 days) after contact 56. Chancre progression from 
primary to secondary disease occurs in approximately 46 days (range 30 - 70 days) 56. The primary 
lesion, which contains infectious treponemes, arises within hours after infection and can persist 
throughout primary and secondary stage of the disease. However, lesions usually heal 
spontaneously without treatment within 6 weeks although lymphadenopathy persists 52. 
2.2.5 The secondary stage 
 If untreated, the spirochaete begins migrating to the bloodstream, and the disease progresses to 
the secondary stage 6 to 12 weeks after exposure (2 - 8 weeks after development of the chancre), 
with a corresponding vigorous antibody response 57. This stage is characterized by a polymorphic 
rash, lymphadenopathy, and other systemic manifestations, which develop 6 weeks to several 
months after untreated primary syphilis. This stage of rapid spirochaete multiplication and 
dissemination may bring an invasion of the entire body. Once the organism has invaded the 
bloodstream, it continues to infiltrate all organs and body fluids 58. Peak spirochaetemia with high 
organism load and general infection occur during the secondary stage of syphilis infection 55. The 
secondary stage is the most clinically apparent which may usually involve the scalp, palms, and 
soles and is characterized by an acute infection symptom, caused by multiplication and systemic 
dissemination of the organism. During secondary syphilis, spirochaetes are cleared from the 
bloodstream, perhaps by a lytic process that involves complement 55. The untreated secondary 
disease lasts a mean of 3.6 months, with a range of 1 to 12 months 56. In 50% of cases, the patient 
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will no longer be infectious or exhibit any symptoms and will be considered cured. The other 50% 
will go on to a latent phase 52.  
2.2.6 The Latent stage 
A variable asymptomatic latent period (serologic evidence without any signs) follows, which for 
epidemiologic purposes are divided into early (<1 year) and late (>1 year) stages. Early latent 
syphilis is when the persistent abrasions of secondary syphilis are most likely to occur. No relapses 
occur after the first year; what follows is late syphilis, which may be either asymptomatic (i.e. late 
latent) or symptomatic (i.e. tertiary). Late latent syphilis is associated with resistance to both 
reinfection and relapse where syphilis is non-infectious but the bacteria can remain inactive in the 
lymph nodes and the spleen. In this stage, a positive serologic test for syphilis will be the only 
indicator of infection 56. There are no cutaneous manifestations or clinical symptoms, but the 
organism may be actively replicating in target organs like the heart, eyes, brain, nervous system, 
bones, and joints. 
Although most patients with late latent syphilis remain asymptomatic, one-third progress to tertiary 
syphilis 10  years afterward 58. This latent stage could persist for life or advance several years or 
decades later to tertiary syphilis. 
2.2.7 The tertiary stage 
 Tertiary syphilis can manifest in various ways, marked by cardiovascular and neurologic sequelae 
and gummatous involvement of any organ system. The destruction of the nerve cells in the cerebral 
cortex at this stage leads to a combination of psychiatric manifestations and neurologic findings. 
The central nervous system (CNS) syphilis -  infection of the brain or spinal cord caused by T. 
pallidum - is the most common presentation of late syphilis observed in current clinical practice 
59. It usually occurs in people who have had chronic, untreated syphilis, usually about 10 to 20 
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years after first infection and develops in about 25%–40% of persons who are not treated 60. 
Neurosyphilis (CNS syphilis) begins with the invasion of the cerebrospinal fluid (CSF), a 
development that probably occurs shortly after the acquisition of T. pallidum infection 61. The 
organism can be identified in the CSF from roughly a quarter of untreated patients with early 
syphilis 62. The manifestation of tertiary syphilis also includes insanity, blindness, and paralysis 
63. At this stage, the person may no longer be contagious but the damage is irreversible. 
2.2.8 Congenital Syphilis 
Congenital syphilis is caused by trans-placental transmission of spirochaetes; the transmission rate 
reaches 90% if the mother has untreated primary or secondary syphilis. Fetal infection can develop 
at any time during gestation 64, though mostly after the first trimester. Manifestations are defined 
as early if they are seen in the first 2 years of life and late if they progress after age 2 years. 
According to the Centre for Disease Control and Prevention report, untreated syphilis, especially 
early syphilis, at the time of pregnancy can lead to deafness, neurologic impairment, bone defects, 
stillbirth, and neonatal death 65. Most pregnant women with syphilis are asymptomatic and can 
only be identified through serological screening 66. 
2.2.9 Syphilis global epidemiology 
Approximately 349 million people are actively infected with this treatable sexually transmitted 
disease. The WHO 67 during 1999, estimated that more than 12 million new cases of adult syphilis 
occur worldwide each year and almost two-thirds of these cases were in SSA and south/southeast 
Asia 68. In 2008, the total number of new cases of syphilis in adults was estimated to be 10.6 
million which was the same figure as 2005 whilst during the same year, the number of adults 
infected was estimated to be 36.4 million 69. 
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Globally, syphilis affects between 700,000 and 1.6 million pregnancies a year that has resulted in 
spontaneous abortions, stillbirths, and congenital syphilis, contributing to approximately 20% of 
perinatal deaths 70. Syphilis infection rates in pregnant women in Africa as a whole have been 
estimated to be between 3 and 15%. Of those, 30% of the untreated cases result in stillbirth and in 
another 30% the child will be born with congenital syphilis 71. The disease congenitally affects 
500,000 or more infants annually in SSA alone 66. The current incidence of syphilis shows that 
there is still the need to improve on our control efforts.  
Syphilis remains prevalent and a major public health problem in many developing countries with 
a resurgence in developed countries 72, including North America, Asia, and Europe, especially 
Eastern Europe.  The prevalence of T. pallidum infection in the general population and blood 
donors has been increasing over the last two decades and varies by region which could be possibly 
due to sexual behaviour. Additionally, the poor quality of laboratory screening due to the lack of 
equipment, trained personnel, reagents and standard procedures compounds the problem.  
The highest rates of syphilis were in South and Southeast Asia, followed closely by Africa. The 
third highest rates were in the regions of Latin America and the Caribbean 67. 
 In Western Europe, 
syphilis prevalence has declined considerably since the peak after the second world war, with 
incidence rates below 5 per 100 000 in the majority of countries73-75. 
In contrast with the decline in rates observed in Western Europe, since 1989 there was an alarming 
increase in rates in the newly independent states of the former Soviet Union where syphilis 
incidence increased from 5-15 per 100 000 observed in 1990 to as high as 120-170 per 100 000 of 
the population in 1996 76. In some regions of Siberia, as of 1999, syphilis prevalence was 1300 
cases per 100,000 populations 77. 
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In the 2012 data shown below in table 2.1, the prevalence and incidence rates for the African region 
became relatively high compared to the rest of the regions globally. This could be as a result of 
improved lifestyle and technology in the developed regions compared to limited resources for 
testing and population growth in the African region. Some or most of the increased prevalence of 
syphilis in Africa is caused by population growth.  From the table below, it is seen that the 
population increase in syphilis in Africa is very modest. 
Additionally, particularly in low-resource countries, a substantial proportion of donated blood 
remains unsafe because it is either not screened for all major TTIs or not in a quality-controlled 
manner 78.  
Table 2.1 Population growth and syphilis prevalence in Africa 
Africa 1995 1999 2012 
Syphilis prevalence 4.14 4.19 7.45 
Total population 586 651 923 
Proportion (%) 0.71 0.64 0.81 
(All numbers in millions) 
In Europe, between 2006 and 2009, the number of reported cases decreased in 10 countries and 
increased in 18, resulting in an overall decrease of 7%. This was mainly due to a substantial 
decrease of cases in a number of countries that have reported very high rates of syphilis in the past. 
In the Western Pacific, relatively high syphilis prevalence rates were found in Cambodia (4%), 
Papua New Guinea (3.5%) and the South Pacific (8%) 79.  
The rise in the late 1980s and early 1990s coincided with the widespread use of crack cocaine and 
exchange of sex for money and/or drugs.  Moreover, syphilis has acquired a higher potential of 
Background and literature review-Sarkodie thesis 
24 
 
morbidity and mortality with the increasing prevalence of HIV infection. But this has reduced with 
the introduction of anti-retroviral therapy (ART). 
Table 2.2 Global and regional estimates of prevalent and incident cases of syphilis infection (in 
millions) among adults, 2012 
Region Prevalence  
Total 
Incidence  
Total Male Female Male Female 
 America 0.992 1.003 1.995 0.466 0.471 0.937 
Europe 0.368 0.366 0.734 0.221 0.219 0.44 
Eastern Mediterranean 0.816 0.792 1.608 0.253 0.243 0.496 
 Africa 3.726 3.723 7.449 0.923 0.920 1.843 
South and South-East Asia 1.856 1.791 3.647 0.451 0.435 0.886 
Western Pacific 1.109 1.179 2.288 0.551 0.482 1.033 
Global total 8.938 8.783 17.721 2.825 2.769 5.626 
 
Another similar reason was that men having sex with men (MSM) with multiple partners as well 
as HIV infection in MSM was the cause of the surge in the late 80s and early 90s 80,81.  
As syphilis rates declined in the Unites States of America (USA) in the late 1990s, the Centre for 
Disease Control (CDC) proposed a plan to eliminate syphilis in the USA 82.  It may, however, be 
noted that the decline in the late 1990s could partly be due to the control of HIV through safer sex 
and other acquired immune deficiency syndrome (AIDS) control campaigns 81. 
Over the past decade, diagnosis of syphilis in the United Kingdom (UK) has increased greatly 
notably among males 83 which might partly be due to ongoing unsafe sexual behaviour. MSM 
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continue to experience high rates of sexually transmitted infections (STIs) and remain a priority 
for targeted HIV and STI prevention and health promotion work 84. 
A quarter of an estimated 12 million cases of syphilis in the world each year occur in Africa 85. 
Infection rates in major African cities of Zambia and Cameroon were reported at 10% and 6% in 
both genders 86. In addition to this, syphilis prevalence rates amongst pregnant women vary from 
2.5% in Burkina Faso to 17.4% in Cameroon 87,88. In circumstances like this, if 90% of children 
are born with untreated syphilis as stated in page 21 under congenital syphilis, then situations can 
be worse in terms of disease prevention. In Ethiopia, the seroprevalence of antibodies to syphilis 
among blood donors is 12.8% 89. A similar prevalence rate (12.7%) of syphilis antibodies has been 
reported in blood donors from Dar es Salaam, Tanzania 90. 
There was little information available regarding the seroprevalence of syphilis and other potential 
transfusion-related pathogens in Ghana 91. Published studies from Ghana show seroprevalence of 
syphilis ranging between 3.7% and 13.5% 7,92,93. A recent study 6 in Ghana demonstrated syphilis 
prevalence of 8%  among blood donors in Kumasi, Ghana and concluded that syphilis is prevalent 
among healthy blood donors in Ghana and that there is a need to introduce syphilis testing all 
donated blood.  
2.2.10 Transfusion-transmitted syphilis (TTS) 
T. pallidum, the spirochaete that causes syphilis,  can be transmitted by transfusion of blood or 
blood components from donors with active syphilis 94. The first case of TTS was reported in 1915 
95. The numbers increased to 138 by 1941, but since then the number of cases has declined all over 
the world. A case of TTS was reported more than forty years ago in the USA 96, but in the past 35 
years, and since then, only three cases of TTS have been originally reported. Recently, there has 
been a case of TTS reported in Ghana 6. The absence of TTS in many developed countries 
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challenges the justification for continuing syphilis testing of blood donors 55. This is probably 
because the treponemes are relatively fragile and sensitive to cold; hence the risk of transmission 
through transfusion of blood stored below 200 C for more than 72 hours is very low55,97,98. Units 
of blood directly transfused few hours after collection without testing comprises a higher risk of 
transmitting syphilis.  This is the case in many developing countries with limited blood supply, 
where blood is collected from family donors and frequently transfused in the following hours or 
days 6. But, the high prevalence of syphilis seropositivity in blood donors and seroconversion of a 
transfusion recipient shows that in centres where screening is not conducted, patients who receive 
blood through transfusion are at risk for contracting syphilis 6. Universal testing of blood donors 
played a role in the abolition of TTS.  
Various strategies have been proposed by the WHO, International Society of Blood Transfusion, 
and American Association of Blood Banks to prevent TTS. These include: 
(i) Selection of low-risk donors and screening for T. pallidum using well-organized 
laboratory methods, 
(ii)  Application of pathogen reduction technology; and 
(iii)  Rational use of blood products.  
However, blood safety begins with the implementation of organized blood centres, a quality 
system, hemovigilance programmes and adherence to SOPs 99. 
2.2.11 Risk factors of syphilis infection in blood donors 
The risk of TTS is closely related to risk factors in the blood donor, in particular, sexual behaviour 
since the disease is primarily transmitted by the sexual route, thereby compromising the safety of 
blood used for transfusion. Donor selection is important because donors with high-risk behaviours 
and other risk factors may be infected by syphilis and compromise the safety of blood used for 
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transfusion. The rates of infection are high among homosexual men 100. Older age, MSM, two or 
more sexual partners, a past history of syphilis treatment and HIV seropositivity are closely related 
to TTS 101. Other risk factors associated with TTS include prostitution, bisexuality (men having 
sex with both men and women), intravenous drug use and skin scarification (tattooing, blood 
rituals) 102.  Donors can be deferred during selection, which is particularly useful in the early period 
of infection when laboratory tests are not efficient 103.  
2.2.12 Prevalence of syphilis among blood donors 
The global incidence of syphilis among blood donors is variable. In developed countries, the 
prevalence of T. pallidum infection has declined in blood donors probably because there have been 
an improved donor selection criteria coupled with current testing methods with improved 
laboratory equipment 104. However, there is a different situation in developing countries of the sub-
Saharan region where the syphilis prevalence may reach 25% 105. The prevalence of syphilis 
antibodies in healthy African blood donors is relatively high compared to other regions 90. For 
example, the prevalence of syphilis among blood donors in India was recently reported to be 0.7% 
106. An incidence of 12.7% was noted among Tanzanian donors by Matee et al. 107 whereas Bhatti 
et al. 108 found an incidence of 0.75% among Pakistani donors. In such cases in developing 
countries, the inefficient manner of laboratory screening due to the lack of equipment, trained 
personnel, reagents and standard operating procedures makes it complex, thus, there is the need 
for systematic and better screening for syphilis to help ensure a safer blood supply 101. 
2.2.13 Sources of blood supply and syphilis infection in SSA 
In SSA, blood donations are collected from two main donor categories which are VNRD and FD. 
Family donors – who are individuals prompted to provide blood units to replace blood transfused 
to their relatives or friends 109 – remain dominant on the African continent as a response to 
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difficulties in recruiting and attracting VNRD 110. There are published data indicating that the 
prevalence of syphilis is higher among family donations than in voluntary donations 106. In Ghana, 
as elsewhere, there is a higher proportion of syphilis seroreactive donations among FD possibly 
because they are mostly older than VNRD and therefore have had longer exposure to sexual risks 
111. A study carried out, as part of this research, found that the higher prevalence among FD was 
partly due to higher age and more males. However, FD status which may also have riskier lifestyles 
contributing to syphilis risk, was an independent positive predictor of syphilis reactivity in a 
logistic regression analysis 112. 
2.2.14 Antibody response to T. pallidum  
There has been a wider study of serum immunoglobulin (IgM and IgG) antibody responses to T. 
pallidum in experimentally infected animals and humans 113. Around 2 weeks after exposure, 
antitreponemal IgM antibodies are produced followed by IgG antibodies 2 weeks after IgM 
production 114. Both antitreponemal IgM and IgG antibodies may be detectable within 3 days of 
lesion onset in primary syphilis 115.  
T. pallidum disseminates from the primary chancre through the blood, although the timing of 
spirochaetemia in primary syphilis and its relationship to the serological window 116 is not well 
characterized. However, spirochaetemia can occur early, because transfusion-transmission has 
been reported in this serological window 56.  
Early antibody responses (IgM and IgG) are against TpN15, followed by TpN17 and TpN47 57. 
IgG antibodies appear to be highest in patients with a longer duration of symptoms 115. After 
therapy in primary and secondary syphilis, T. pallidum IgM antibodies decrease rapidly, becoming 
undetectable within 6–12 months. Several studies suggest that decreasing IgM levels indicate 
adequacy of treatment 117. Merlin et al 118 demonstrated the absence of IgM antibodies in 84% of 
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patients with previously treated syphilis. In patients with syphilis, the level of IgM antibodies 
against T. pallidum, and the decline after treatment, is currently used as a marker for evaluating 
the effects of treatment 119. However, levels of IgG antibodies do not change significantly with 
treatment in most instances, and they are generally thought to have little bearing upon the 
assessment of the efficacy of treatment 120-123. 
Tanaka et al in 1990, followed patients with syphilis from the beginning of treatment by 
measurements of levels of IgM and IgG, by the T. pallidum immune adherence (TPIA) test, and 
their data showed a decrease in levels of IgG antibodies after treatment, even though the decrease 
was not as rapid and complete as in the case of IgM antibodies 120. 
2.2.15 Recommendations for syphilis testing for blood donors 
The WHO recommends that, to minimize the risk of syphilis infection through the route of 
transfusion: 
1. Screening should be performed using a highly sensitive and specific test for treponemal 
antibodies: either TPHA or EIA. 
2.  In populations where there is a high incidence of syphilis, screening should be performed 
using a non-treponemal assay: VDRL or RPR 124. This is probably because these assays 
are primarily used as qualitative assays for screening in the traditional algorithm or as 
quantitative assays to help stage infection and to assess the response to treatment. 
Additionally, all nontreponemal assays detect both IgM and IgG antibodies, which are 
commonly detectable as early as 6 days’ post-infection 125-127. 
According to the guidelines published by the U.S. Centres for Disease Control and Prevention, the 
diagnosis of syphilis should be based on the results of at least two tests: one treponemal and the 
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other non-treponemal 128. VDRL and RPR are sensitive for recent syphilis infection, but not for 
past infection. Although the traditional RPR has been used successfully in many settings, its 
accuracy is often improved by coupling with a treponemal haemagglutination (TPHA) or particle 
agglutination (TPPA) 129. Additionally, false negatives may occur both in early primary cases and 
in patients with secondary syphilis, as a result of prozone reactions 130. This may limit the 
sensitivity of the test. 
The Ghana national blood policy for the Health Sector of MoH, which was approved by the 
Cabinet in February 2006 reiterated that, all units of blood collected must be tested prior to 
transfusion for HIV I & II, HBV, HCV and syphilis, and any other transfusion transmissible 
microbial diseases that may be thought to be relevant by the NBSG, using approved well-
controlled techniques and procedures according to WHO guidelines 25.  
2.2.16  T. pallidum detection by PCR 
The diagnosis of syphilis is complicated because T. pallidum is one of the few major bacterial 
pathogens of humans that cannot be cultivated on an artificial medium. Current methods for 
detection of T. pallidum in clinical specimens are either insensitive, as in the case of dark-field 
microscopy 131, or impractical, as with rabbit intratesticular inoculation (rabbit infectivity testing 
or RIT) 132,133. 
At present, deoxyribonucleic acid (DNA) amplification by the polymerase chain reaction (PCR), 
the most sensitive and specific in vitro technique, has found growing application in the laboratory 
diagnosis of infectious diseases 134. PCR is a technique which is used to amplify nucleic acid 
sequences of microorganisms which may be present in the blood or other body fluids. PCR can 
selectively amplify the copy number of a target gene more than 106-fold 135. PCR, therefore, has 
great potential for improving the ability to diagnose infectious diseases caused by fastidious or 
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slowly growing microorganisms 134. In addition to its obvious diagnostic applications, detection 
of T. pallidum by PCR may prove to be a valuable tool for clinical and laboratory investigation of 
syphilis. 
A number of PCR-based methods have been developed worldwide for the detection of the 
organism T. pallidum DNA or RNA in clinical specimens. These assays are based on the detection 
of various target genes including bmp, 39-kDa basic membrane protein 136; tpp47, polA, DNA 
polymerase I 137; tmpC, a 35kDa membrane protein 138, and 16SrRNA 139. 
There has been a report on the development of an exquisitely sensitive assay for T. pallidum that 
is based upon amplification of the gene encoding the pathogen-specific and highly conserved 47-
kDa membrane immunogen (tpp47) 140,141. Detection of T. pallidum by amplification of a portion 
of the tmpA gene (a 45kDa membrane protein) was reported by Hay et al 142 which was the first 
application of PCR in clinical samples from patients with syphilis. 
There is also a sensitive assay for T. pallidum, the agent of venereal syphilis, based upon PCR 
where a 658-bp portion of the gene encoding the 47-kDa membrane immunogen was amplified, 
and the PCR products were also probed by DNA-DNA hybridization with a 496-bp fragment 
internal to the amplified DNA 143.  The assay detected approximately 0.01 pg of purified T. 
pallidum DNA, and positive results were found normally from suspensions of treponemes 
calculated to contain 10 or more organisms and from some suspensions calculated to contain a 
single organism. Specific PCR products were obtained for the closely related agent of yaws, 
Treponema pallidum subsp. pertenue 144. 
In addition to T. pallidum subsp. pallidum of the Burstain et al study, specific PCR products were 
obtained only from genomic DNA of T. pallidum subsp. pertenue 56. Their result was not 
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surprising given the extraordinarily close genetic relatedness of the pathogenic treponemes 145 and 
the highly conserved antigenicity of their 47-kDa immunogens 146. Amplification of tpp47 as 
performed in the Burstain et al study, therefore, was not able to distinguish syphilis and yaws any 
better than conventional diagnostic modalities 143. 
It has been determined that whole blood in heparin or EDTA (but not serum), lesion exudate, and 
punch biopsy as well as swabs of lesions are useful specimens for examination by the PCR or the 
detection of T. pallidum 58. 
The suitability of whole blood as a potential specimen to be tested by PCR for T. pallidum was 
also examined by Wicher et al. where extraction of larger volumes of samples, e.g. 250µl yields 
an increase in the sensitivity. The sensitivity in their experiments was similar to that reported by 
Hay et al and Burstain et al. 142,143 who reported that 1 to 10 organisms per 50 ml of sample was 
needed for a positive PCR. 
At early stages of T. pallidum infection where serological tests are non-reactive, PCR has the 
ability to identify T. pallidum infection and further differentiate T. pallidum from other 
treponemes, making it most advantageous over serological testing in terms of its high level of 
specificity 147. 
New molecular tests for syphilis are unlikely to replace serology in the short term because they 
require sophisticated equipment 58. Although PCR has shown to be effective at diagnosing primary 
syphilis with sensitivities between 73% and 95% and specificities 95% 148,149, sensitivities of blood 
samples in primary syphilis are as low as 18% 148.  
PCR assay which is more sensitive than standard diagnostic tests for the detection of T. pallidum 
and other TTIs is rather costly and not affordable for most sub-Saharan African blood banks and 
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requires an extensive capital investment 150. Advanced set-up is required for training personnel, 
quality control, and maintenance of equipment 151. However, PCR testing for blood donors is not 
able to differentiate between viable and dead spirochaetes 51. This is a limitation because it is the 
viable and active ones which are potentially infectious to be transmitted through blood transfusion. 
2.2.17 Serologic syphilis testing 
Serological tests for syphilis contribute greatly to the detection of T. pallidum infection in blood 
donors and especially in those who are not identified during donor selection which is important 
because donors with high-risk behaviours and other risk factors are deferred before laboratory 
testing. Wassermann 152,153 developed the first test (nonspecific reaginic) of syphilis in 1906. 
Although it had some false positive results, it has been a major advancement in the prevention of 
syphilis because it has helped to diagnose the disease before the clinical manifestations appear and 
thus prevent its spread. In the scientific literature, the ranges of stage-dependent sensitivity and 
specificity of diagnostic assays for the serological detection of syphilis have been reported to be 
70 to 100% and 97 to 99%, respectively 51. Serologic testing remains the mainstay of laboratory 
diagnosis for secondary, latent, and tertiary syphilis as efforts to cultivate the organism in vitro 
have been largely unsuccessful. In addition, PCR is too insensitive, and is only able to confirm 
about 25% of infections154. Thus, serologic tests are the foundation of syphilis screening, and 
knowledge of their diagnostic limitations is critical for clinicians and blood transfusion services. 
Two main categories of serologic tests for syphilis are available, tests for nonspecific reaginic 
antibody and, tests for specific treponemal antibody 155. 
None of the serologic tests (non-treponemal and treponemal) are sufficient for definitive diagnosis. 
Antibody detection by non-treponemal tests (anti-lipoid antibody detection) and treponemal tests 
(anti-T. pallidum antibody detection) is still regarded as the basis for diagnosing syphilis and for 
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monitoring the success of subsequent antibiotic treatment 156. However, the quality of routine 
serological diagnosis of syphilis has been questioned by several studies that found significant inter- 
and intra-laboratory variability of test results 157,158. 
2.2.18 Non-treponemal tests 
Non-treponemal tests are based on non-treponemal lipid antigens (cardiolipin), frequently using 
the flocculation technique as initiated by Wassermann since 1906. In 1941, Pangborn 159 
successfully isolated the active antigenic component, a phospholipid, cardiolipin from beef heart. 
Cardiolipin, - (IUPAC name "1, 3-bis (sn-3’-phosphatidyl)-Sn-glycerol") - is an important 
component of the inner mitochondrial membrane, where it constitutes about 20% of the total lipid 
composition. It can also be found in the membranes of most bacteria. When combined with lecithin 
and cholesterol, it forms a serologically active antigen for the detection of syphilitic antibody. With 
the advent of these new purified antigens, microflocculation tests, such as the VDRL test were 
developed 160.  
The RPR teardrop card test 161, was developed as a screening procedure to be used in the field 162. 
Laboratory equipment was not essential because all test materials were contained in a disposable 
kit. Plasma from blood obtained by finger prick is collected on a plasma collection card and then 
placed in a teardrop-shaped test area on a plastic-coated card. Next, a stabilized modified RPR 
antigen suspension, incorporating charcoal particles to aid in reading the reaction, is added to the 
plasma, and the test card is rocked by hand. The results are read macroscopically as reactive or 
nonreactive. The RPR teardrop card test is still employed in field work and as a screening 
procedure in some laboratories, but recent reports have found the test to be less sensitive than the 
currently used RPR 18-mm circle card test with serum as a sample source 163. The RPR 18-mm 
circle card test measures IgM and IgG antibodies to lipoidal material released from damaged host 
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cells as well as to lipoprotein-like material, and possibly cardiolipin released from the 
treponemes164,165.  If antibodies are present in the donor sample, they combine with the lipid 
particles of the antigen, causing them to agglutinate. The charcoal particles co-agglutinate with the 
antibodies and show up as black clumps against the white card. If antibodies are not present, the 
test mixture is uniformly grey. Qualitative results are reported as either reactive (clumps) or 
nonreactive (no clumps). However, quantitative results are reported based on serial dilutions 
ranging from undiluted (1:1), and in 1:2, 1:4, 1:8, and 1:16 dilutions. Thus, quantifiable titres can 
establish a baseline to evaluate treatment response 166. Without some other evidence for the 
diagnosis of syphilis, a reactive nontreponemal test does not confirm T. pallidum infection 51 but 
rather a suggestion. 
The VDRL and RPR tests are the most commonly used. These tests are inexpensive, fast, simple 
to perform and more sensitive than treponemal specific tests 167. They are able to identify infected 
blood donors few days before the treponemal test and thus useful for acute infection. However, 
VDRL and RPR cannot be automated and are time-consuming if used for large scale testing. 
Additionally, the results may be difficult to interpret and they require training of health personnel 
to ensure testing is carried out and results are read correctly. Compared to treponemal tests, false-
positive test results for non-treponemal tests are associated with viral infections, pregnancy, 
malignant neoplasms, autoimmune diseases, and advanced age 51. Still, these tests are routinely 
used to screen blood donors. After effective treatment, non-treponemal tests usually become 
nonreactive 168,169 within a period of three years, in contrast to many treponemal test, which is a 
major strength of these tests.  
For these reasons, classical syphilis screening uses nontreponemal RPR or VDRL tests. Reactive 
specimens are confirmed using treponemal assays like TPHA or fluorescent treponemal antibody 
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absorption (FTAAbs) tests. Most high-volume laboratories have adopted the “reverse algorithm” 
- screening with treponemal assays where reactive specimens are confirmed with nontreponemal 
RPR or VDRL - syphilis screening to improve efficiency and lower costs 170,171.  
Despite the advantages and disadvantages of each diagnostic algorithm, the choice to use a 
treponemal or nontreponemal assay as the first screening test should be based on a combination of 
factors: local syphilis prevalence, the expected workload, the requirement for automation, and the 
available budget for labour and consumables 172. 
2.2.19 Treponemal antibody tests 
2.2.19.1 Treponemal manual  
Initial attempts to develop a test using an antigen derived from the treponeme itself were 
unsuccessful until 1949, when Nelson and Mayer developed the first treponemal antibody test, the 
T. pallidum immobilization (TPI) test 173. It was rapidly accepted as a specific test for syphilis 
although it was complicated, technically difficult, time-consuming, and expensive to perform. A 
collection of treponemal tests was later developed, some of which became popular in a short period 
of time 174,175.  
In 1957, a major breakthrough in treponemal antigen tests occurred with the development of the 
fluorescent treponemal antibody (FTA) test 176. This was later developed into a more specific and 
sensitive FTA absorption (FTA-ABS) test 177 and this remains the standard treponemal tests for 
syphilis today. 
Treponema pallidum haemagglutination assay (TPHA) detects the presence of treponemal 
antibody in the patient’s serum but is simpler to perform than the fluorescent-antibody tests. TPHA 
tests have detectable reactivity approximately 4 weeks after exposure. 
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Currently, some of the tests that are considered standard treponemal tests are FTA-ABS, FTA-
ABS double staining, TPHA and MHA-TP. All of these tests use T. pallidum as the antigen and 
are based on the detection of antibodies directed against treponemal components.  
2.2.19.2 Treponemal automated (Enzyme immunoassay)  
In the 1990s, various enzyme immunoassays (EIA) that could detect both anti-treponemal IgG and 
IgM antibodies became commercially available. EIA reported in the literature have used different 
approach to determine sensitivities and specificities. These assays used microtitre plates of wells 
that were coated with wild-type T. pallidum antigens and had a clinical sensitivity of 98.4% and 
specificity of 99.3% when compared with TPHA and FTA-ABS 178.  
2.2.19.3 Immunochemiluminescence assay (CLIA) 
Since 2000, the options have expanded to include automated chemiluminescence immunoassay 
(CLIA) 179 and multiplex flow immunoassay 180 which have higher testing output and objective 
interpretation. As part of this study, Vitros Syphilis TPA assay (a CLIA using the Vitros ECi/ECiQ 
Immunodiagnostic Systems) was used as gold standard to confirm initially syphilis sero-reactive 
blood donor samples. This CLIA is a qualitative assay that detects total antibodies (IgG and IgM) 
to T. pallidum reacting with biotinylated and horseradish peroxidase (HRP)-labelled recombinant 
TP antigens TpN15, TpN17, TpN47 and is bound to streptavidin-coated wells.  
It has a specificity of 99·8% (CI 98·7–100%) and a sensitivity of 100% using Syphilis Mixed Titre 
Performance Panel PSS202 (BBI Diagnostics, Bridgend, UK) and clinical samples from known 
syphilis-treated patients of both Caucasian and African origin 181. 
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2.2.19.4 The Abbott ARCHITECT Syphilis TP assay 
The Abbott ARCHITECT Syphilis TP assay - which has also been used in this study as a secondary 
gold standard - is a two-step sandwich chemiluminescent microparticle immunoassay (CMIA) for 
the qualitative detection of antibody to T. pallidum in human serum or plasma based on 
recombinant antigens TpN15, TpN17 and TpN47. Antibody present in the sample binds to T. 
pallidum recombinant antigen coated paramagnetic particles. After wash step, murine anti-human-
IgG/anti-human-IgM acridinium-labelled conjugate is added. Following a further wash step, pre-
trigger solution (hydrogen peroxide) and trigger solution (sodium hydroxide) are added. The 
resulting chemiluminescent reaction is measured in relative light units (RLUs) which are directly 
proportional to the amount of anti-T. pallidum present in the sample. The Architect Syphilis is 
highly sensitive in detecting primary syphilis (97.5%) with a specificity of 99.1% 182 and good 
performance on reproducibility and intra-assay coefficient variation 183.  
The advantages of EIA include the production of objective results, ability to link EIA readers 
directly to laboratory computer systems (reducing the potential for errors in transcription of 
results), and the facility for automation. They also have the capacity to process large numbers of 
samples. One limitation of treponemal tests is that they can remain positive even after treatment 
184,185, in contrast to non-treponemal tests, so that someone previously treated for syphilis may be 
misdiagnosed as having a new, untreated case of syphilis if only treponemal tests are used and 
overtreatment could occur. Additional limitations of the EIAs are time and costs when small 
numbers of samples are to be processed.  
2.2.19.5 Western Blot (WB) and Immuno-blot assays 
Immunoblotting allows for the detection of antibodies to individual proteins. In the Treponemal 
Western blot (Tp-WB), solubilized T. pallidum proteins are separated by gel electrophoresis 
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according to their molecular size. The separated proteins are then transferred onto a nitrocellulose 
membrane which is dried and cut into strips. After incubating the strips with patient’s serum, 
antigen-antibody complexes are visualized by adding enzyme-conjugated anti-human globulin 
followed by substrate, which causes a colour reaction. It is generally agreed that detection of 
antibodies to immuno-determinants with molecular masses of 15, 17, 44.5 and 47kDa (TpN15, 
TpN17, TpN44.5 and TpN47) are diagnostic for acquired syphilis 186. 
2.2.20 The INNO-LIA Syphilis test (Innogenetics) 
There are other line immunoassays (INNO-LIA syphilis test, Innogenetics) (Furijebio, Ghent, 
Belgium) detecting individuals binding to the same recombinant TP antigens TpN15, TpN17 as 
well as to TpN47 and a synthetic peptide TmpA derived from T. pallidum proteins 187. The INNO-
LIA Syphilis test had sensitivity of 99.6% and specificity of 99.5% 187. 
Treponemal tests are conventionally used primarily to verify reactivity in the nontreponemal tests. 
Unfortunately, treponemal tests are technically more difficult and costly to perform than 
nontreponemal tests and cannot be used to monitor treatment as mentioned above. However, a 
reactive treponemal test result on a sample that is also reactive in a non-treponemal test is highly 
indicative of active-ongoing infection. Currently, treponemal tests in the form of rapid diagnostics 
are easy to perform and cheaper worldwide which is discussed below. 
 
2.2.21 Syphilis rapid diagnostic tests (RDT) 
In developing countries and areas with limited resources, laboratory facilities are often unavailable 
for standard syphilis tests. These countries are characterized by a difficult epidemiologic, 
sociological and economic environment, which limits the implementation of a high quality of 
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blood safety. A rapid serologic test for blood banks could greatly enhance public health efforts to 
decrease the spread of this infection through transfusion as this technique does not require 
sophisticated laboratory materials 103. The availability of individual T. pallidum antigens through 
recombinant DNA techniques 188 has resulted in the use of these antigens for serologic tests by 
lateral-flow technology. Antibodies in the specimen bound at antigen site on the strip and are 
revealed with dye bound anti-immunoglobulin or dye bound antigen and a positive reaction 
appears as a coloured line. Although several different manufacturers have developed rapid tests 
using lateral-flow technology and recombinant antigens in the late 1990s, there are few published 
evaluations of these tests 189. These assays are visually read, qualitative immunoassay for the 
detection of antibodies to the antigens of T. pallidum. The syphilis RDTs use serum, plasma, or 
whole blood specimens to detect IgM, IgG, and IgA antibodies 190 and involve 
immunochromatographic strips (ICSs) in which one or multiple T. pallidum recombinant antigens 
are applied to nitrocellulose strips as capture reagents 191. Abbott Determine rapid syphilis TP 
assay had a high sensitivity (95.6 to 98.4%) and specificity (95.7 to 97.3%) with serum samples 
and TPHA as the reference test 192.  
Over twenty rapid tests for the serological diagnosis of syphilis are commercially available 188,with 
lower costs compared with the traditional tests, and these provide opportunities to scale up syphilis 
screening in many transfusion settings where traditional tests are unavailable.  
More syphilis rapid tests are commercially available, primarily because of less stringent 
procedures for their development internationally than automated ones 193. Development of rapid 
treponemal-based syphilis tests was driven by the need for simple, point-of-care tests in resource-
poor countries 194.  Overall, syphilis RDTs are highly sensitive and specific 166. However, less 
sensitivity has been reported in field settings using whole blood rather than serum 195,196. The WHO 
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compared the performance of eight rapid syphilis tests to a combined reference standard of TPHA 
and T. Pallidum Particle-agglutination Assay (TPPA), reporting sensitivities of 84.5%–97.7% and 
specificities of between 92.8%–98% 197,198. 
The advantages of rapid syphilis tests include their affordable costs (ranging from US$ 0.2 to US$ 
2.0.) 93 clear interpretation of results, availability of results within 5–20 minutes 198, and requiring 
minimal equipment and training, which is ideal for clinical and non-clinical settings. However, 
they cannot distinguish between active and treated syphilis, and false-positive reactions can occur 
199. Positive results would have to be confirmed with non-treponemal test to determine recent 
infection and response to therapy 101. 
2.2.22 Yaws 
Yaws is a communicable, non-venereal treponematosis caused by the bacteria Treponema 
pallidum ssp. pertenue 200 which is a gram negative spirochaete. It predominantly affects children 
under 15 years of age in the most underprivileged, remote, tropical rural communities. Favourable 
climate conditions such as humidity and a constant warm temperature appear to be especially 
important factors for yaws to flourish 201.  
For decades, Ghana has been a major yaws endemic country in West Africa. It is the only country 
in Africa to maintain its yaws control programme after the early 1990s when many yaws 
programmes were discontinued. In 2008, the National Yaws Control Programme (NYCP) was 
reconstituted as the National Yaws Eradication Programme with the principal aim to eliminate 
yaws by 2012. Surveys carried out in 2008 by the MoH, Ghana, among children in schools and 
communities, showed prevalence of yaws in Ghana at 0.681% with prevalence in some rural 
communities up to 20% 202 although the mode of detection was unclearly defined. According to 
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the MoH in Ghana, all the 10 regions and nearly all the 170 districts reported yaws. A total of 
28,000 cases were reported in 2008 and 25, 000 in 2010 202.  
2.2.22.1 Pathophysiology of Yaws 
Children aged 2–15 years are the most vulnerable to yaws infection, which targets the skin, bones 
and cartilage, causing destruction of tissue and deformities in the late stages 203.In similarity with 
syphilis, the evolution of yaws is revealed in three stages of clinical manifestations 204. Early yaws 
encompass both the primary and secondary stages (active yaws cases). During the primary stage 
(3–4 weeks incubation), patients display papillomatous raspberry-like lesions located mainly on 
the feet and legs. They also have ulcerations of variable size on other sites of the body that are 
highly contagious. Patients may spontaneously recover from the primary stage or progress to the 
second stage. The secondary stage consists of several episodes, lasting three to six months, of both 
contagious and non-contagious lesions. These primary and secondary stages usually last up to five 
years from the time of infection, with periods of latency in between symptomatic episodes 201. 
About 10% of patients with untreated secondary stages pass into the tertiary stage (late yaws), 
which can occur up to 15 years after the secondary stage 205. Late lesions may involve the skin and 
subcutaneous tissues, the mucosa, the bones, and the joints. Tissue destruction is common and 
characteristic. Third stage lesions are not contagious but disable people in their daily activities 
201,206. There is evidence that any potential abnormality resulting from latent yaws include 
congenital, visceral, and tertiary CNS lesions 206,207. Thus, this may increase significant osseous, 
neurological, and ophthalmologic complications. Since the 1940s, a single intramuscular injection 
of long acting benzathine penicillin has been successfully used for treatment 208. It is suggested 
that by using a modified strategy to focus investigation and control efforts on infectious yaws cases 
and their contacts, and by taking advantage of effective methods to obtain more accurate diagnosis 
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of yaws cases in the field, it should be possible to control yaws more effectively and efficiently, 
and perhaps to eradicate it 209.  
2.2.22.2 Yaws global epidemiology 
In the early 1950s an estimated 50 to 100 million people were infected in tropical areas particularly 
in Africa, Southeast Asia and South America 210. In 1995, the last WHO estimate was that, there 
were 2.5 million cases of endemic treponematoses (mostly yaws) globally, including 460 000 
infectious cases 211. The epidemiological status of yaws globally today is unknown; however, there 
is growing evidence that the number of cases of yaws and other endemic treponematoses is 
increasing in some countries, while they have disappeared in other previously endemic countries. 
Yaws is transmitted by skin-to-skin contact with fluid from a lesion on an infected person among 
people with poor hygiene practices living in warm and humid tropical areas of Africa, the Americas 
and Asia. Because of latency and late recurrence, up to 15 years after primary infection, as 
described above, yaws may also have implications for potential blood donors, including in Ghana 
It remains one of the most neglected tropical diseases, affecting primarily the poorest and most 
vulnerable populations: tribal and indigenous people living in remote, rural areas. The disease has 
not attracted global attention recently, although it can be highly controlled in eradication 
epidemiologically, technologically and in terms of cost-effectiveness.  
In 1952, a yaws control programme was started in India with assistance from WHO and UNICEF. 
This campaign from 1952 to 1964, administered >50 million anti-yaws treatments in 46 countries, 
reducing the prevalence of the disease by about 95% 212. In the context of neglected tropical 
diseases, WHO launched the global yaws elimination initiative in 2007 to address the persistence 
and resurgence of this disease 213. In May 2016, WHO declared India free of yaws 214. 
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2.2.23 Relationship between syphilis and yaws  
Among the pathogenic treponemes, most comparisons have been made between T. pallidum and 
T. pertenue; several experiments have demonstrated variable degrees of cross-immunity based 
upon symptomatic reinfection to challenge with heterologous organisms 215 and serological cross-
reactivity 216. Although T. pallidum subspecies differ pathogenically, they are >95% homologous 
by DNA-DNA hybridization 217. Yaws and venereal syphilis can only be distinguished by 
epidemiological characteristics and clinical manifestations as the commonly used serological tests 
cannot discriminate one disease from the other 218. However, there are minor 219-221 or substantial 
222 genetic differences existing between both pathogens that have been reported. Subspecies-
specific genetic signatures permit molecular differentiation using methods that involve PCR, 
restriction fragment length polymorphism (RFLP), and DNA sequencing 223. This is another 
critical usage of PCR that enables to make differential diagnosis of treponemal species. Recently, 
however, a genetic signature was defined in the 59-flanking region of the 15-kDa lipoprotein gene 
(tpp15) that distinguishes T. pallidum subsp. pallidum from T. pallidum subsp. pertenue and 
endemicum 223. Although PCR method can be useful for blood banking, they are costly, laborious, 
and time-consuming because of demand for blood. It is the usage of PCR only that enables to make 
differential diagnosis of treponemal species. Despite differences in the mode of transmission, 
geographic distribution, tendency to invade the central nervous system, or infect the foetus, the 
two subspecies share striking similarities at both the genomic and antigenic level 15,223,224 
When PCR is not used routinely for screening blood donors, as remains the case in Ghana, yaws 
and syphilis remain indistinguishable in practice. Consequently, these methods are not suitable for 
rapid screening applications. Whether donor history may be used to differentiate between sero-
reactive donors is among the research questions for this thesis.  
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2.2.24 Challenges of syphilis testing in relation to blood donation 
Syphilis may be transmitted via blood and blood products, and intravenous drug use 225. 
Transfusion syphilis, now rare, does still occur 226,227, and although questions have been raised 
about routine screening of blood donors for syphilis 228, it is still recommended. There have also 
been several conferences that sought to include discussions on the extent to which tests for syphilis 
contributed to transfusion safety and whether their use as in current practice should be continued 
or modified. The resulting recommendation from the National Institutes of Health (NIH) consensus 
conference (1995) was to continue syphilis screening of all blood donors until more information 
was available regarding the effect of component storage conditions on T. pallidum survival and 
molecular techniques could assess the absence of T. pallidum in serologically positive donated 
blood 229.  Furthermore, there is an increasing requirement to use blood products like platelets 
which are held at 22°C, at which temperature, T. pallidum can survive for longer periods than at 
the normal refrigeration temperature of 4°C. There is thus a continuing need for an effective, 
practicable, and economical serological test to not only provide evidence for public health practice 
but also improve safety of stored blood for transfusion purposes. 
Although syphilis testing is a recommendation from the WHO, not all blood transfusion centres in 
Ghana and other countries test blood donors for syphilis which is problematic in public health if 
undetected in blood donors. Ampofo 92 recommended that routine blood screening prior to 
transfusion should include tests for T. Pallidum antibodies and HCV, and that periodic study to 
investigate transfusion-transmissible infectious diseases is required to enable safety reviews of the 
blood supply. 
Better methods of testing can make the process of identifying and curing infected individuals more 
cost effective and consequently more feasible. WHO reported in 2006 that 56 out of 124 countries 
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surveyed did not use appropriate basic tests on all blood donations 230, thereby increasing the 
likelihoods of contracting infectious diseases from blood donors via transfusion. In blood donor 
populations with high prevalence of HIV or HBV, the surrogate value of syphilis testing will be 
easier to justify due to the fact that HIV and syphilis co-facilitate transmission of each other 231. 
Syphilis is also likely to be more common in these high HIV and HBV-prevalence populations, 
and thus the value of syphilis testing to prevent TTI may also be clearer 232 . 
2.2.25 Quality systems in laboratory testing for syphilis 
Laboratory testing consists of pre-examination, examination, and post-examination processes, 
which require strict implementation of a quality management system. The maintenance of a quality 
management system is crucial to a laboratory for providing the correct test results every time. 
Important elements of a quality management system include: 
• Documentation 
• Standard operating procedures (SOP's) 
• Quality control samples 
• Internal and external quality assessment scheme 233. 
Quality control (QC) are procedures used in each assay to assure a test run is valid and results are 
reliable especially the kit controls and quality control samples 124. QC measures in serological 
syphilis testing are designed to ensure that reliable and reproducible test results are obtained within 
a laboratory and among different laboratories performing the same tests 234. Strict adherence to 
recommended technique and the use of standardized reagents eliminates most technical errors 234. 
Departures from predetermined reactivity of control serum samples detects day-to-day variability 
in testing and indicates any need for corrective action. Occasionally deterioration of test kits causes 
the variation, but other factors like storage and shelf-life of reagents under tropical conditions are 
more frequently responsible. Longer shelf-life reduces the pressure on the supply chain and the 
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probability of wastage of expired tests; a minimum of 18 months is recommended in remote, poorly 
resourced areas 235. Testing facilities should make sure proper storage conditions are met (4-30ºC) 
in additions to using the kits within required shelf life so as not to affect kit performance. 
Results of laboratory samples can be properly interpreted based upon how complex the sample is, 
stability factors based on transport and timing, and the competency of the laboratory staff. Test 
kits’ efficacy is difficult to describe or follow if they are not daily controlled internally as they are 
prone to errors. This is because results of clinical testing obtained from laboratories or testing sites 
at or near the point of care must be as accurate as possible as they have a direct impact on care and 
treatment, prevention, and control of diseases 236. The components of a quality system include 
internal quality (process) control, proficiency testing (PT), and quality improvement 237. It is only 
when these components are implemented together that quality improvement or the highest 
attainable quality of testing can be achieved and consequently can improve health outcomes in 
terms of disease prevention and control, care and treatment 237. 
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CHAPTER 3 
3. Conceptual framework and ethical considerations 
3.1 Conceptual Framework for the study 
Laboratory testing across the transfusion centres in Ghana is performed on all the blood samples 
that are collected from the prospective blood donors prior to transfusion. This is to ensure that 
recipients receive the safest possible blood products. Testing measures help to maximize safety of 
blood donation for the donor and the recipient. The concept for this study was to document the 
current processes for screening blood donors for syphilis in Ghana, and to build on this to arrive 
at a screening strategy that would be sensitive enough to detect the true positive blood donors 
while minimizing deferrals and consequently the impact on the blood supply, due to false positive 
reactions.  
The methods outline is that blood samples were taken from potential blood donors and tested for 
markers of other TTI and syphilis with RDT (fig. 3.1). The seroreactive samples were tested using 
RPR to detect potentially active infectious blood donors. The RDT seroreactive samples were also 
tested with Vitros TPA and Abbott Architect TP, which were used as gold standards to detect true 
positives. Furthermore, a specific immunoblot called Inno-LIA was also included as a quality 
control measure for a sub-set of the syphilis RDT reactive samples. The Vitros TPA, Abbott 
Architect TP, and the LIA were used as gold standards because they detect antibodies binding to 
the recombinant TP antigens TpN15, TpN17 and TpN47, with higher performance, as used in 
developed countries like Denmark. 
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Potential blood donors 
Test for other infections (HIV, HBV, HCV - 
these were not part of the study and will not 
be discussed further)                             
Test for syphilis with RDT 
TPA; T. pallidum assay, RPR; rapid plasma reagin, QC; quality control 
RPR positive (Potentially infectious - discard)  RPR negative (non-infectious - use) 
Non -reactive for 
syphilis 
Reactive for syphilis 
True positives 
 
False positives 
15% of reactive samples 
tested with INNO-LIA as QC 
measure 
Test with RPR 
Negative Positive 
Confirmatory testing with Vitros TPA 
and Architect  
Figure 3.1 The algorithm for the syphilis study at KATH 
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3.2 Ethical clearance  
Ethical approval for the study was obtained from the Research and Ethics Committee (REC), 
Liverpool School of Tropical Medicine (LSTM), University of Liverpool, UK (18/02/2014) 
(appendix 3.1).  We additionally obtained another approval from the Committee on Human 
Research, Publications and Ethics (CHRPE/AP/423/13), School of Medical Sciences, Kwame 
Nkrumah University of Science and Technology (KNUST), Kumasi (appendix 3.2). An 
introductory letter for the survey of the syphilis testing was sent to the respondents from the head 
of the NBSG, explaining to them the aims of the study, collaborations and benefits (appendix 3.3). 
After the explanation of the study to the respondents, they were assured of their anonymity in the 
use of their data. Syphilis sero-reactive blood donors included in the study were informed about 
the study aims and objectives, risks, and possible benefits which included referral to an appropriate 
clinic for treatment in case the screening tests detected active infection with syphilis. After the 
explanation of the study and assessment of their understanding by a set of standard questions, 
participants were requested to sign or thumbprint an informed consent form (appendix 5.1). The 
study was thus, conducted in accordance with ethical principles.  
Ethical considerations and blood donors 
Donors are conventionally classified as voluntary non-remunerated (donors considered to have 
received no compensation for their donation), family replacement (donors donate with the intent 
of replacing or directly contributing to blood used by a specific patient), and paid (donors openly 
compensated monetarily for their donation). 
In Ghana blood has been collected from both voluntary, family replacement and paid donors, but 
now is limited to voluntary and family replacement. This is because the nation does not have 100% 
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voluntary donation and sometimes has to rely on family donors especially when the schools are on 
vacation.  
The issue of compensating donors has been a controversial and emotive one in blood transfusion 
for many decades. Recent statements from the WHO reiterate the belief that uncompensated 
donation contributes to safety from transfusion transmitted diseases238,239. It has also been shown 
that, In localized, controlled environments, viral marker rates for paid and unpaid donors were 
similar for the established transfusion transmitted infections240. 
Ethical considerations/limitations of using family members as donors 
Family replacement donors (FRDs) are still a significant and sometimes predominant part of the 
blood supply in developing countries. These blood donors for many years, have been considered 
less safe than volunteer non-remunerated blood donors (VNRD) and actively discouraged by 
international organisations and well-off countries support agencies for developing countries. In 
addition to safety, it was considered unethical based on pressure and coercion. However, these 
beliefs were not evidence based. In comparing viral marker data confirmed seroprevalence in first-
time VNRD and FRD corrected for gender and age, it showed no significant difference between 
the two groups42. Evidence has been provided that for both volunteer and family donors, 
compassion is more appropriate than altruism. The two groups join for psychological attitude to 
donation for which knowing someone needing transfusion is a powerful incentive to give blood. 
Excluding a life or death situation found in areas where severe blood shortage justifies replacement 
donation, pressures are exerted on both volunteer and family replacement donors. There is no 
evidence of putting pressure on FRD. FRDs thus meet all criteria for VNRD and are willing to 
become VNRD and to repeat donation. Banishing FRD is illegitimate and damaging to the blood 
supply in resource poor areas. In some countries, it makes no difference between the two groups 
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of donors which represents similar populations when asked to give blood in different 
circumstances. FRDs therefore, remain a critical source of volunteer, non-remunerated, blood 
meeting all standard principles of VNRD and are considered ethical and essential at this point in 
time instead of discouraged. FRDs, as well as VNRDs, are both altruistic, and both submitted to 
pressures of various kinds but should not be considered as coerced.  
A study conducted in Kumasi, Ghana, clearly illustrated this point by showing that most FRDs 
gave blood “because they were asked” by patients or family members241. Thus, there is no ethical 
or safety reason to exclude FRD from participating in the blood supply. FRDs have the right to 
have clear and appropriate information, including the purpose of donor selection, and the 
consequences of failure to provide the relevant information to the blood service.  
There are ethics governing paid donors and this discourages blood facilities from using their blood 
units. A level of stigma, based on safety and ethical considerations, has been attached to paid 
donation. This is because commercial supply of paid blood discourages altruistic, voluntary 
donation, hence leading to supply shortfalls242 and increasing cost. Additionally, Paid blood 
donation is inherently unsafe as the financial motive makes people in high-risk groups for certain 
diseases lie about their status to get money.  
Considerations about disclosing test results for blood donors 
The blood service in Ghana provides safe and pleasant environment for both VNRD and FRDs. 
They are made to understand the need and reasons why they donate for the needy and their 
relatives, treat them with respect and obtain their informed consent before blood donation. These 
donors are given all relevant information and, in particular, provided with TTI test results. The 
blood service ensures and assures donors of the confidentiality of all personal information they 
provide, notably those related to health and exposure to TTI risks. The service is obliged to blood 
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donors to ensure the notification of positive test results and the availability of appropriate 
counselling and referral.  
They have the responsibility to provide the service with all relevant information to the best of their 
knowledge about health conditions that may pose risks for their health and about activities or 
behaviours that increase their risk for a TTI. They have the responsibility to self-defer from blood 
donation if they believe they are unsuitable to donate. They have right to withdraw from blood 
donation at any time during the procedure for any reason, including doubts as to their suitability 
as a blood donor, without any need to explain this decision. 
Ethical considerations of approaching school children as donors 
According to the National Blood Service, not all school children can be approached except they 
are 17 years of age and above. In SSA where VNRDs are mostly secondary school students, peer 
pressure is considerable and ethical so that in some schools, over 70% of students present 
themselves for blood donation243. This pressure is further increased when leaders of the schools 
(principals and teachers) lead by giving blood themselves. 
Blood donor recruitment and cost-effectiveness 
Several arguments against compensated donation have little basis in evidence and would lead to 
many of today’s voluntary donors being designated as paid, because of the large range of incentives 
used to recruit and retain them. In SSA, most collected blood originates from accessible and 
cheaper replacement donors while recruiting and retaining volunteers requires considerable costs 
not all countries can afford. The TMU of KATH, Kumasi, and many local FM radio stations have 
developed partnership calling more than once a year for donation at the radio stations where music, 
entertainment, and token gifts are available. 
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It has been demonstrated that the use of a culturally and socially adapted environment to make the 
gift of blood a pleasurable and festive experience generated a new pool of blood donors 
spontaneously repeating donations. This program indicates that retaining Ghanaian blood donors 
is possible at little extra cost to the blood centre and that such an approach may represent a 
substantial help in the efforts of SSA to collect volunteer blood. 
The best cost-effectiveness for voluntary donors as far as I know is a study in Zimbabwe in 2016, 
where a unit of blood was costed to be $118.4216. This involved recruitment, collection, testing, 
processing and storage/distribution. Although the supply was inadequate and inconsistent, there 
was lower TTI prevalence and good quality assurance.  
Variably, the cost in collecting blood from a family replacement donor in Malawi in 2007 was 
found to be $16.00244. Although the supply was inadequate and higher levels of TTI, the supply 
was consistent. Factors affecting these relative costs are complex but are in part due to the cost of 
donor recruitment in centralized systems. In the family replacement system, the cost of donor 
recruitment is entirely borne by families of patients needing a blood transfusion. 
3.3 Study collaborators 
Collaborators in this study included the Transfusion Research Capacity (T-REC) project which 
was initiated from 2011 to 2015, funded by the European Union Seventh Framework Programme 
(FP7/2007-2013) under Grant Agreement No. 266194. The T-REC project was coordinated by the 
Capacity Research Unit (CRU) at the LSTM with the National Blood Service, Zimbabwe and 
universities in Groningen and Copenhagen as partners, and the Rigshospitalet of Copenhagen 
(National University Hospital), Denmark. Other collaborators were, NBSG, TMU, Research and 
Development Unit (RDU) of KATH, KNUST, Kumasi, all in Ghana. 
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CHAPTER 4  
4. Syphilis screening practices in blood transfusion facilities in Ghana 
The work described in this chapter has been published by Elsevier Ltd on behalf of International 
Society for Infectious Diseases (appendix 1.1). This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
4.1 Introduction 
The objective was to investigate syphilis testing practices of transfusion facilities in various parts 
of Ghana. 
Early reports of the transfusion-related transmission of syphilis led to the World Health 
Organization (WHO) recommendations for syphilis testing of blood donors 245. These 
recommendations have been questioned, since syphilis antibodies among blood donors can often 
be the result of previous infections or even unspecific reactions. Nevertheless, syphilis screening 
continues to be a requirement in many countries.  
In Ghana, as in many other African countries, the purchase of blood bank reagents is poorly 
regulated, with local blood banks purchasing whatever reagents are available and affordable. 
Additionally, the reagent cost per test for syphilis testing in Ghana depends mainly on the 
bargaining power of the facility management system in the open market. This decentralized 
purchasing system may lead to increased costs of reagents, as well as failures in quality and 
consistency. In addition to decentralized reagent purchasing, the lack of written SOPs and effective 
TTI guidelines for donor care may hamper quality and care. 
To achieve this objective 1, a survey was conducted among facilities across that screened blood 
donors. The survey compared current syphilis screening practices in Ghana with the 
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recommendations of the WHO and NBSG regarding the use of assays for screening blood donors 
for syphilis and the performance of the assays. The prevalence of syphilis antibodies in blood 
donors was also estimated. Additionally, the survey determined whether written SOPs or 
guidelines were in place for syphilis screening and whether donors with positive syphilis tests were 
referred for clinical follow-up. 
4.2 Methods 
4.2.1 Study Design 
The study was designed to interview the in-charges of all health facilities undertaking blood 
transfusion testing in Ghana in order to get as close to a national survey as possible.  
Out of the many different categories of hospitals in Ghana, a total of 149 health facilities across 
the country practice blood transfusion under the NBSG. Three of the facilities were teaching 
hospitals located in the Greater Accra, Ashanti, and Northern regions. Ghana has 10 administrative 
regions and each of them has a regional hospital which have less beds than the teaching hospitals. 
There are 58 district hospitals that are distributed across the country based on the level of 
development of the region, so some regions have more transfusion centres than others. There are 
also other health facilities that screen blood donors such as 36 mission hospitals, eight private 
hospitals, and seven clinics that are distributed across the country.  
4.2.2 Facilities included in the survey 
The NBSG in Ghana has a register of 149 blood transfusion facilities which screen blood for 
transfusion. An attempt was made to survey all of these laboratory heads by telephone interview 
and/or email questionnaire. However, for a few of the smaller, more remote facilities, a lack of 
accurate contact details meant that some could not be contacted and therefore did not participate 
in the survey. The respondents who were interviewed to represent the facilities were laboratory 
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technical heads (health professionals) with enough experience to release all available laboratory 
information. These respondents were interviewed between January 2014 and February 2015 about 
information on their January – December 2012 syphilis screening results. Because of limited 
resources and time, it was not possible to physically visit all the facilities in person.  
4.2.3 Development of the interview questions for the telephone/email survey  
The survey was developed based on information obtained from the NBSG about the syphilis 
testing practices in the various health/transfusion facilities in Ghana.  The survey questions focused 
on the aims and objectives of the study. An introduction was included in the survey to explain to 
the respondents the importance of the study. The respondents were briefed that there were no 
wrong or no right answers and asked to provide honest opinions and answers, and they were 
assured of anonymity. The respondents then agreed to participate before they were interviewed. 
Each facility was asked questions (for telephone interviews) or sent the same questions by email 
(Appendix 4.1) pertaining to syphilis screening practices. Samples of the interview questions were 
pilot tested with nine transfusion facilities in Ashanti region. Corrections and modifications were 
made to clarify some of the questions and they were retested on two sites before being finalized 
for the interviews with the various facilities. The nine transfusion facilities were interviewed again 
using the revised questions and their responses, as well as all those from the other facilities, were 
included in the analyses.  
4.2.4 Inclusion criteria 
1. Transfusion facilities under the NBSG with laboratories testing for TTIs. 
2. Transfusion facilities under the NBSG who gave their consent to participate in the study 
and who could be contacted. 
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3. Health professional available (biomedical laboratory scientists who were technical heads) 
who could be interviewed on behalf of the health facility. 
4.2.5 Training of research assistants 
Majority of the interviews, e-mails and data entry were done by myself but because of the volume 
of work, two research assistants were recruited and trained to assist in the interviews, with e-
mailing the questions to the facilities and with data entry. These research assistants were employees 
of KATH/TMU, Ghana so they were already familiar with blood donor screening processes. It was 
ensured that their involvement in this project did not disrupt their regular working activities. 
4.2.6 Data collection 
Contact numbers and e-mail addresses of the technical heads of facilities were obtained from the 
NBSG headquarters in Accra and other laboratory science colleagues in the various transfusion 
facilities in the country. Seventy-three of the 149 (60%) technical heads responded immediately 
by telephone, while 24 (20%) of them were interviewed twice before providing all of the 
information by telephone; 25 (20%) provided information through a semi-structured questionnaire 
by e-mail. The total number of non-respondents or facilities that could not be contacted, was 27 
(18.1%); most of these were in remote areas with small catchment areas (figure 4.1).  
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Figure 4.1 A flow chart describing the participation of the transfusion facilities in the 
telephone/e-mail survey 
4.2.7 Data Management 
Data obtained after interviewing technical heads of the various transfusion facilities in the country 
were checked every day for completeness. Validation of the data entry was done at the end of 
every week by myself to make sure they were properly recorded from the data received from 
interviews and email sources.   
4.2.8 Statistical analysis 
Data from the interviews were collected using Epi Info version 3.5.3 (US Centre for Disease 
Control and Prevention, Atlanta, GA, USA). Data were transferred into an Excel spreadsheet, 
corrections were made by cleaning the data, and data were exported into Stata version 12.0 
statistical software (StataCorp LP, College Station, Texas, USA) for analysis. Descriptive statistics 
of the variables were analysed and are presented in the form of tables and graphs. Proportions for 
149 transfusion facilities planned to 
be interviewed
122 (81.9%) facilities 
responded
73 (60%) responded once 
by telephone
24 (20%) responded a 
second time by telephone
25 (20 %) responded by 
email
27 (18.1%) transfusion 
facilities  could not be 
contacted
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the various potential predictor variables (independent) and the outcome variables (dependent) were 
calculated and presented as percentages. Proportions were compared using chi-square (X2) and t-
test. Prevalence was estimated by calculating proportions and providing their respective 
confidence intervals (95% CI). Independent variables with p-values less than or equal to 0.05 were 
considered significant. 
4.3 Results 
4.3.1 Facilities and testing 
Of a total of 149 health facilities known to be undertaking blood transfusion and screening for 
TTIs, 122 (81.9%) responded to the survey. In 2012, the total number of donations collected and 
screened for TTIs other than syphilis (i.e. HIV, HBV, and HCV) from the 122 transfusion facilities 
responding to the survey was 143,787 (table 4.1).  
The total number of transfusion facilities not screening for syphilis was 64 (52%). When asked for 
the reasons, 49 facilities (77%) reported lack of funds to purchase reagents. Fourteen facilities 
(21%) reported that although syphilis screening is recommended, the refrigeration of blood units 
for more than 5 days, kill T. pallidum. One transfusion facility (2%) reported that screening for 
syphilis was not mandatory.  
The total number of donations at the 58 (48%) transfusion facilities screening for syphilis was 
91,386 units, of which 3,371 were syphilis antibody seroreactive, resulting in an estimated 
seroprevalence of 3.7% (95% CI 3.6–3.8). Of the facilities screening for syphilis, two of the three 
(67%) teaching hospitals screened for syphilis and contributed the highest percentage (40.4%) of 
the total donations (figure 4.1). Furthermore, 8 of the 10 (80%) regional hospitals screened for 
syphilis, but contributed only 17.7% (16 009/91 386) to the total donations, whilst 12 of the 36 
(33%) mission hospitals screened for syphilis and contributed 15.4% (14,064/91,386) to the total 
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donations, as shown in table 4.1. Among the seven clinics, only three (43%) screened for syphilis 
and these contributed the least (1%) donations. However, the teaching hospitals reported the lowest 
syphilis rate of seroreactivity (3.2%), with the highest coming from the mission facilities (4.4%). 
Notably, almost half of the district hospitals did not test for syphilis. 
4.3.2 Donor type and syphilis seroreactivity  
The total number of donations screened for syphilis was 91,386 (63.6% of 143,787). The total 
number of voluntary donations screened for syphilis was 26,180 (28.6%, 95% CI 28.4–28.9), with 
757 (2.9%) testing positive. Of the total of 65,206 (71.4%) family/replacement donations, 2,614 
(4.0%) tested positive for syphilis (table 4.1). This indicates that the rate of syphilis seroreactivity 
from FD in its totality for this survey was significantly higher than the rate from VNRD (p = 
0.008). However, there were differences in syphilis seroreactivity depending on the health facility 
in terms of VNRD and FD: while there was no difference between VNRD and FD in syphilis 
seroreactivity in the teaching facilities (table 4.1), there were differences in the other health 
facilities, where FD seroreactivity was significantly higher than VNRD seroreactivity, except at 
the mission facilities, where VNRD seroreactivity was significantly higher than FD seroreactivity. 
However, the data received from the transfusion facilities across the country did not indicate the 
sensitivity and specificity of the type of syphilis test used. 
 
 
 
 
 
Syphilis screening practices in blood transfusion facilities in Ghana-Sarkodie thesis 
62 
 
Table 4.1 Results of syphilis screening survey in Ghana – (January – December) 2012 
Health 
facility type 
Number 
of 
screening 
sites 
Number of 
donations 
screened for 
TTIs other 
than syphilis 
Centres 
screening 
for 
syphilis 
n (%) 
Number of 
Donations 
(Proportions) 
screened for 
syphilis -2012 
Av. Number of 
donations 
screened for 
syphilis per 
health facility 
per day (m) 
Number and 
Proportion of 
donor types 
screened 
Sero-reactive and estimated 
prevalence (%) 
VNRD FD Total VNRD FD 
Teaching   
 
3 56951 2 (67) 36951 
 (64.9) 
51 13390 
(36.2) 
23561 
(63.8) 
1176 
 (3.2) 
424 
(3.2) 
 
752  
(3.2) 
 
Regional  
 
10 19768 8 (80) 16009  
(81.0) 
6 5241 
(32.7) 
10768 
(67.3) 
578 
(3.6)  
74 * 
(1.4) 
504* 
 (4.9)  
District   
 
58 36650 30 (52) 20571 
 (56.1) 
2 4305 
(20.9) 
16266 
(79.1) 
853  
(4.1) 
95*  
(2.2) 
758* 
 (4.7) 
Clinic      7 2343 3 (43)          879  
(37.5) 
1 99 
(11.3) 
780 
(88.7) 
35 
(4.0) 
3* 
 (3.0) 
32*  
(4.1)   
Private     
 
8 4503 3 (38) 2913  
(64.7) 
3 383 
(13.1) 
2530 
(86.9) 
107 
(3.7)  
11* 
 (2.9) 
96* 
 (3.8)  
Mission  
 
36 23572 12 (33) 14063  
(59.2) 
3 2762 
(19.6) 
11301 
(80.4) 
622 
(4.4)  
150* 
(5.4) 
472*  
(4.2)  
TOTAL/Ave
rage  
 
122 143787 58 (48) 91386 
 (63%) 
4 26180 
(28.6) 
65206 
(71.4) 
3371 
 (3.7) 
757* 
(2.9) 
 
2614*
(4.0) 
 
TTIs –transfusion-transmitted infections, VNRD-voluntary non-remunerated donors, FD-family donors, HIV 
Human Immunodeficiency Virus, HBV-Hepatitis B Virus, HCV-Hepatitis C Virus, Av.-Average, m-mean and * 
denotes statistically significant. 
 
4.3.3 Types of assays used for syphilis testing 
Of the total donations screened for syphilis in this survey, 28 565 (31.3% of 91 386) were tested 
using a recommended assay (TPHA; Fortress Diagnostics Limited, Antrim, UK). The non-
recommended methods used as shown in table 4.2, were all syphilis rapid diagnostic tests (RDTs), 
with 60% (35 of the 58 transfusion facilities that test for syphilis) reporting ACON as the brand 
name (ACON Laboratories, Inc., San Diego, USA). Of the others, 11 of the 58 facilities (19%) 
reported First Response (Premier Medical Corporation Limited, Kachigam, India), seven of the 58 
(12%) reported ABON (Abon Biopharm Company Limited, Hangzhou, China), three of the 58 
(5%) reported Fortress (Fortress Diagnostics Limited, Antrim, UK), two of the 58 (3%) reported 
Wondfo (Guangzhou Wondfo Biotech, Guangzhou, China), and only one facility out of the 58 
(1%) reported  Determine (Allere Medical Company Limited, Matsuhidai, Japan) as RDT for 
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syphilis testing. From the survey, it was found that none of the facilities was using a second test 
after the initial RDT, to re-screen syphilis-reactive donations. Of the 58 transfusion facilities that 
test for syphilis, 47% validated their syphilis test kits before screening, while only 7% had written 
SOPs (table 4.2). The hospital management of 52 (89.7%) transfusion facilities purchased syphilis 
screening reagents on the open market (table 4.2). The variation in cost per test strip for syphilis 
screening varied 10-fold, from US$ 0.2 to US$ 2.0. 
4.3.4 Follow-up of syphilis seroreactive donors 
 Of the 58 facilities that test for syphilis, 33 (56.9%) of them referred syphilis-reactive blood 
donors for clinical advice with 16 (16/58; 31%) facilities as the highest coming from the districts 
whilst only one each (1/58; 1.7%) being the lowest from both clinic and private facilities (table 
4.2). 
Table 4.2 Results of syphilis screening survey in Ghana – 2012 
Health 
facility type 
Number of 
centres that 
validate test 
kits 
n=58, (%) 
Number of 
centres with 
written SOPs  
n=58, (%) 
Number of 
centres that 
refer for 
clinical advice 
n=58, (%) 
Number (%) of 
reagents 
purchased by 
Hospital Mgt 
n=58, (%) 
Donations screened 
with recommended 
assays (TPHA) 
n=91386, (%) 
Non-recommended 
assays (RDTs) used in 
the screening sites 
Teaching   2 (3.4) 1 (1.7) 2 (3.4) 2 (3.4) 25726 
 (69.6) 
Fortress 
Regional  7 (12.1) 1 (1.7) 7 (12.1) 8 (13.8) 0 ACON, First Response 
and Determine 
District   12 (20.7) 1 (1.7) 16 (31.0) 28 (48.3) 612 
 (3.8) 
ACON, ABON, First 
Response and Wondfo 
Clinic     0 0 1 (1.7) 1 (1.7) 165 
   (18.8) 
ABON 
Private     1 (1.7) 1 (1.7) 1 (1.7) 1 (1.7) 2062 
 (67.7) 
Syphilis ultra-rapid test 
Mission  5 (8.6) 0 8 (13.8) 12 (20.7) 0 ACON and First 
Response 
Total 27 (46.5) 4 (6.9) 33 (56.9) 52 (89.7)           28565 (31.3)  
SOPs, standard operating procedures; TPHA, Treponema pallidum haemagglutination assay; RDTs, rapid diagnostic 
tests; n, total number. *Validate: prove the efficiency of a test kit. 
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Figure 4.2 The use of RDTs for testing in the facilities that test for syphilis – 2012 N=58 
 
 
 
4.4 Discussion 
This survey aimed to describe syphilis screening practices and seroprevalence of syphilis for blood 
donors in transfusion facilities in Ghana. The estimated national syphilis seroprevalence of 3.7% 
in this survey is similar to that found among healthy blood donors in Ghana and elsewhere in the 
region 7,246,247. However, the prevalence varies from one facility to another and from a country to 
another. In such settings with these seroreactivity rates, the study also found poor quality of 
laboratory screening due to the lack of equipment, training personnel, reagents and standard 
procedures, and this highlights the need for systematic and better screening for syphilis to help 
ensure a safer blood supply.  
The study found that about half of the studied facilities in Ghana were not screening blood 
donations for syphilis, which could lead to syphilis transmission through blood transfusion. Of 
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those facilities that were found to screen donated blood for syphilis, only a third used a 
recommended test. Among those facilities that were screening, half were not validating the kits, 
and of donors found to be syphilis-seropositive, more than a third was not referred for further 
clinical management.  
The study additionally found that, there was significantly high syphilis sero-reactivity rates among 
FD compared with VNRD.  Many parts of the world have also reported syphilis seroreactivity 
rates among FD similar to that found in the present study 111,248.  One of our findings (table 4.1) 
was that there was no difference in syphilis seroreactivity rates between VNRD and FD in teaching 
hospitals but there were in all other facility types. This could possibly be explained by a high 
proportion of VNRD in the teaching hospitals. Besides, infections in first-time VNRD are similar 
to FD since they are mostly first-time, non-repeat donors, so both groups could be considered to 
represent a single population with respect to infection rates. It is when a donor, either VNRD or 
FD, becomes a repeat donor that seroreactivity reduces. A study performed in one of the Ghanaian 
teaching hospitals indicated that the viral safety of replacement and first-time volunteer donors 
was similar, so they could be considered to constitute a single population of donors 42. It went on 
to reveal no significant difference in prevalence of TTIs between first-time volunteer and 
replacement donors. From experience, the teaching hospitals have low repeat donations in 
volunteer donors where the majority of blood donors are either first-time volunteer or replacement 
donors, and this also happens in other SSA blood centres 249. There is clear evidence that repeat 
donation brings a significant increase in blood safety and this could be equally applied to volunteer 
and to replacement donors 91.  
Despite recommendations that all blood donors should be voluntary and non-remunerated, FD are 
common throughout SSA 250. One reason for the higher rates of syphilis-positivity in FD is that 
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FD are older than VNRD and therefore have had a longer time to acquire syphilis antibodies. 
However, FD may be under pressure to donate blood when their relatives are admitted to hospital 
and in need of a blood transfusion, even when they know that they are potentially at risk of sexually 
transmitted diseases as a result of high-risk behaviours. They may be more likely to conceal a 
relevant medical history and the risky sexual behaviours that predispose them to infections and 
thus pose a threat to the safety of the blood supply. Despite this, family donations remain dominant 
in the African continent because family and community ties are often considerably stronger than 
in other types of society; making the gift of blood a natural contribution to relieve sufferers in 
hospitals 251.  Conversely, potential donors may be less willing to donate to someone not known 
to them. The WHO recommended that reliance on family donations should be phased out due to 
their association with an increased risk of TTIs 109. The WHO states that blood from VNRDs who 
give blood out of altruism is the safest source of blood 252. Establishing a panel of regular, 
voluntary, non-remunerated blood donors is therefore the most effective way of ensuring adequate 
ongoing supplies of safe blood. 
There have been several policies and recommendations from the WHO that each transfusion 
service should develop written SOPs as guidelines covering all procedures in the testing of donated 
blood 253. Written and followed SOPs are an integral part of a quality system, as they facilitate 
consistency in the performance of procedures in accordance with standards. 
The survey demonstrated that only 6.9% of the facilities followed written SOPs, indicating poor 
quality systems where these should play a vital role in blood safety. The WHO has specified that 
consistency and reliability of performance in conformity with specified standards raises the quality 
of systems in promoting blood safety. Unfortunately, an earlier exercise carried out by MoH of 
Ghana, (which was reported in the Ghana National Blood Policy) to determine the status of the 
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blood services in regional and district health facilities in 2006, revealed that the quality assurance 
programme including SOPs that had been written and followed was under-developed and that the 
equipment at all sites was generally inadequate 25.  
The present survey confirmed the existence of major problems within quality assurance systems 
and the supply of logistics services. Previously the NBSG had an external quality assessment 
(EQA) programme operating only at its headquarters. However, the NBSG checks internal quality 
assessment (IQA) processes at other blood banks elsewhere in the country by visiting the various 
facilities with quality audit and control samples. As indicated earlier, because the NBSG does not 
have control over the purchasing of reagents at individual health facilities, it becomes challenging 
to make recommendations on IQA. 
The finding that 56.9% of facilities referred syphilis-reactive blood donors for clinical advice 
suggests that, at the other facilities, syphilis reactive donors remained untreated and potentially 
infectious and could be transmitting the disease to others. This represents a substantial public 
health risk. 
The variation in costs for syphilis screening has significant implications, particularly in resource-
poor settings in SSA. There is little published information on the variation in costs per test for 
syphilis, but reported costs in this study ranged from US$ 0.2 to US$ 2.0. In Ghana, the cost 
variation in syphilis test kits exists due to a lack of guidelines to indicate the effective and accepted 
test kits and their costs. As a result, many test kit types are available on the open market without 
proper validation and at different costs. For quality and consistency, the NBSG should be 
responsible for purchasing approved test kits before use in order to standardize the tests for syphilis 
screening of blood for transfusion. Screening for TTIs among blood donors can be a cost-effective 
approach to monitor the prevalence, distribution, and trends of the infections among blood donors. 
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However, cost of TTI testing is a major challenge to the provision of safe blood and blood products 
SSA. A report has indicated that, treponemal, non-treponemal, immunochromatographics assays 
for syphilis testing, are affordable and can significantly contribute to blood transfusion safety, as 
in most resource-poor countries 254. The present survey did not indicate whether centralized 
purchasing would necessarily lead to lower prices, but it may help to reduce the cost variations 
and more importantly, would ensure proper validation. 
The techniques used for syphilis screening are different from one country to another: the VDRL 
or RPR alone for some, and the VDRL and TPHA for others 252. Tests and algorithms should be 
selected so that they correspond with the prevalence of the disease and match the technical 
expertise of the personnel and the availability of reagents and equipment 103. The selection criteria 
for a screening strategy must include simple techniques, reliability, sustainability, and cost-
effectiveness. Although they are not recommended for blood banks in Africa, rapid test techniques 
may be preferred because of their affordability, user-friendliness, the availability of test reagents, 
and good sensitivity and specificity; furthermore they do not require sophisticated laboratory 
materials 103. The WHO recommends that each country should decide on the TTIs to be screened 
for as part of the blood screening programme and develop a screening strategy appropriate to its 
specific situation, influenced by the incidence and prevalence of infection, the capacity and 
infrastructure of the blood service, and the costs of screening 255. The critical factor is the effective 
implementation of the strategy selected and the consistency of implementation within a well-
managed quality system. The NBSG does recommend standardized syphilis screening of all 
donated blood, but this survey revealed that the guidelines were not generally being followed and 
serves as an example of the consequences when national guidelines are made without structures to 
enforce them and without the resources needed to implement them locally.  
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4.5 Study limitations 
1. This survey was not able to reach all of the transfusion facilities in Ghana, especially those 
outside NBSG of which their workload was very minimal. Moreover, the facilities under 
the NBSG that were not able to provide data because they could not be reached were small 
villages in remote areas. As such, it is likely that the results provide close to a true reflection 
of the national situation.  
2. The study relied on information provided by telephone and e-mail. Resource constraints 
meant that it was not possible to substantiate the findings first-hand. More so, the 
respondents interviewed might be scared of releasing true available laboratory information 
that could paint a bad picture for the facilities. Nevertheless, this was considered the best 
methodology with the resources available because some transfusion facilities are located 
in remote areas with challenging road access.  
3. The estimated prevalence may not be a perfect reflection of the epidemiological situation 
in Ghana. This is because the donor population that was not screened could have had a 
higher or lower prevalence of syphilis than the screened population. For the population that 
was actually screened, variation in screening practices may have led to both under-
reporting due to a lack of sensitivity or over-reporting due to poor specificity of the 
screening tests used.  
4. None of the facilities were using a second test to re-test syphilis-reactive donations, for 
example a non-treponemal test to detect active infection. Therefore, it is difficult to 
estimate how many donations may have been infective, and how many patients receiving 
a blood transfusion are potentially at risk.  
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4.6 Conclusion 
There is a relatively high prevalence of syphilis reactivity in the blood donor populations in Ghana, 
as elsewhere in sub-Saharan Africa. However, there is a low syphilis testing rate and a relatively 
high use of non-approved, non-validated test kits (RDTs) for syphilis screening, obtained at 
different costs, in Ghana. If these rapid tests are effectively validated and managed, they could be 
incorporated into the existing guidelines to enhance blood safety. However, the considerable 
mismatch between recommendations and actual practice for, or absence of, syphilis screening may 
compromise blood safety. Further studies on syphilis RDTs for blood donors are suggested, in 
order to improve their application in resource-poor settings. 
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CHAPTER 5 
5. Improving the screening of blood donors with syphilis rapid diagnostic test (RDT) and 
rapid plasma reagin (RPR) in low- and middle-income countries (LMIC) 
5.1 Introduction 
5.1.1 Study background 
The work described in this chapter has been published in Transfusion Medicine Journal. 
1. A novel strategy for screening blood donors for syphilis at Komfo Anokye Teaching 
Hospital, Ghana - doi: 10.1111/tme.12279 (appendix 1.2). 
2. Improving the screening of blood donors with syphilis rapid diagnostic test (RDT) and 
rapid plasma reagin (RPR) in low- and middle-income countries (LMIC) - doi: 
10.1111/tme.12363 (appendix 1.3). 
Objective 2: To determine the positive predictive value of the RDT that is most commonly used 
in KATH and Ghana for syphilis testing.  
Objective 3: To estimate the proportion of blood donors in KATH, Kumasi who are really 
infectious through blood transfusion.  
Syphilis screening is a big challenge in many low and middle-income countries (LMIC) that have 
a limited capacity for testing. High syphilis prevalence among healthy blood donors in Africa 
aggravates the problem in this region. Techniques for syphilis testing are very problematic and 
conventionally rely on a combination of non-treponemal and treponemal tests.  
The non-treponemal antibody tests for donor screening include the VDRL 256 and the RPR 257. The 
advantages are that these tests are inexpensive, fast, simple to perform and have acceptable 
sensitivity 258. They are able to identify infected blood donors a few days before the treponemal 
test and thus are useful for acute infection. However, VDRL and RPR cannot be automated and 
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are therefore time-consuming if used for large-scale testing. Another major problem when using 
non-treponemal tests is the possibility of biological false positive reactions due to cross-reactivity 
with other conditions, such as viral infections, pregnancy, malignant neoplasms, autoimmune 
diseases and advanced age 51,166. 
Treponemal tests for donor screening classically included the TPHA, TP-PA, FTA-ABS 259. 
Treponemal tests typically remain positive even after treatment 257,260,261, implying that a donor 
previously diagnosed with syphilis who has been treated, or in whom the infection has resolved, 
cannot be distinguished from a new or untreated case of syphilis. However, newer, treponemal 
tests can be automated and therefore have low running costs and provide objective readings, 
making them useful for large blood centres. 
5.1.2 Syphilis as a major concern 
Syphilis is a major concern as a TTI in Ghana, including Kumasi, and as previously described in 
chapter four, the current guidelines for screening of syphilis in blood donors are in need of revision. 
This includes which methods may be applicable and affordable, as outlined in the following 
sections. 
5.1.3 Syphilis RDT for Transfusion-transmitted infections (TTI) 
RDTs for TTI screening are often preferred in LMIC as they are affordable, quick, require limited 
expertise and are therefore suitable for screening blood donors’ pre-donation on mobile blood 
drives. Pre-donation screening of blood donors for TTI is the practice by which a prospective donor 
is tested at the donation site for the presence of one or more of the TTI agents by a rapid or quick 
method. Donation is deferred if the test is reactive for any of the TTI markers but on the other hand 
the donor is allowed to donate if the test is nonreactive for all available TTI markers 262. Pre-
donation testing of blood donors for TTIs is done in most developing countries because substantial 
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cost savings are made from resources, materials, and man-hours which would have been spent to 
obtain infected blood units which would later be discarded. Pre-donation screening where TTI 
seroprevalence is high is attractive as the costs of collection are avoided and the risk of mixing up 
screen positive and screen negative blood units’ post collection in blood bank refrigerators is 
reduced. Pre-donation testing also allows the donor to be informed of any positive test on the spot 
and referred for confirmation and, if necessary, clinical follow up.  
In developing countries and areas with limited resources, laboratory facilities are often unavailable 
for standard automated syphilis tests. Given the barriers to automated testing, many resource-
limited countries are resorting to syphilis RDTs for TTI screening 101. Although RDTs hold 
potential for increasing the safety of the region's blood supply compared to no testing at all, 
uncertainty surrounding the performance of some of the RDTs which are available has increased 
debate regarding their application to TTI screening 263-265. Some rapid tests are highly sensitive 
and specific 22,166 but cannot differentiate between active and treated syphilis; others may give 
false positive reactions 199. Irrespective of the advantages of these rapid tests, if they have a low 
positive predictive value (PPV) (i.e. a high false positive rate) and are used in blood banks, then 
many donors will be deferred when they carry no risk to the blood supply. Conversely, if the PPV 
is high (i.e. a low false positive rate), then few donors with no risk to the blood supply will be 
deferred. This is really important in LMIC settings where blood is often in critical short supply, 
coupled with a high burden of TTIs among donors and the general population. 
At KATH, blood donors have been screened for HIV 1 and 2, HBV, and HCV by pre-donation 
RDT since 2001, and approximately 10% of donors are deferred 22. There is currently no post-
donation testing unless there is a power shortage onsite during the donor session. This is because 
when blood donations are carried out in schools and public places (public drives), the centrifuges 
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use electricity in spinning blood samples before the tests are carried out using serum. If there is 
power shortage, blood units are collected onsite without the screening of the donors. Screening is 
performed as soon as the blood units reach the blood bank in the hospital.  
KATH was previously not testing for syphilis because of constrained resources and presumptions 
that transmission risk is low and refrigerated storage renders the causative organism inactive. 
However, a study carried out at the hospital in 2011 identified a case of transfusion-transmitted 
syphilis (TTS) in an 8-year old girl. In investigating this case it was found that 57% of donations 
were stored for less than 4 days before being transfused 6. This is important to know because T. 
pallidum survives for few days at 4∘C, thereafter,  it is considered killed if blood products are 
refrigerated for over 4 days 40.  
As a consequence, the hospital transfusion committee (HTC) at KATH, whose role is defined 
earlier in chapter two of this thesis, recommended the introduction of syphilis screening. The 
introduction of syphilis testing with RDT demonstrated a seroreactivity rate of 7.0%, and this had 
a critical and negative effect on the blood supply for the hospital since all these donors had to be 
deferred. 
5.1.4 Novel algorithm for syphilis testing at KATH 
The TMU implemented an algorithm (figure 5.1) which consisted of syphilis testing by Fortress 
RDT before blood collection followed by rapid plasma reagin (RPR) - IMMUTREP RPR, Omega 
Diagnostics – Scotland, UK - testing of syphilis RDT reactive donors 44. The presumption was that 
by deferring only donors who were RDT positive and also positive for RPR, only donors suspected 
of active syphilis were rejected. Donors with previously treated syphilis could continue to donate 
and their blood would be released for transfusion. One of the risks of this strategy was that by 
combining two different syphilis tests, the algorithm might still defer too many blood donors, due 
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to false reactivity in the two tests. In that case, the algorithm would still unnecessarily reduce blood 
supply and it would expose donors to unneeded worries, stigma, and therapy. 
 
Therefore, the following study was undertaken. 
5.2 OBJECTIVE and METHODS  
5.2.1 Study objective 
The present study aimed to validate the positive predictive value (PPV) of the newly implemented 
algorithm by applying a gold standard retest algorithm combining two different automated anti-
Screen positive 
Screen 
negative 
Release to blood stock for 
transfusion 
 
Screen negative 
Donor health questionnaire, 
physical examination, Hb 
screen 
Screening for HIV, HBV, 
HCV by RDT 
 
Screening for Syphilis by 
RDT 
Defer and refer for 
health advice 
Defer and refer for health 
advice 
Screening for syphilis by 
RPR 
Defer and refer for 
health advice 
Health check fail 
Screen positive 
Screen 
positive 
Figure 5.1  Algorithm for syphilis screening of blood donors, TMU-KATH (new pathway shown in red) 
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TP immune assays and an immunoblot of syphilis RDT reactive donors to improve blood donor 
screening.   
5.2.2 Study design 
This was a descriptive cross-sectional study conducted in the TMU of KATH. The purpose of the 
study was to improve the screening of blood donors in TMU with the use of syphilis RDT and 
RPR by validating PPVs of both test kits. The study algorithm was to screen prospective blood 
donors initially tested with a treponemal RDT (Fortress® Diagnostics Limited – Antrim, UK) 
according to routine standard operational procedures. Blood donors who were initially syphilis 
RDT sero-reactive were selected for further testing. Sero-reactive samples from all consenting 
donors were further tested according to routine standard procedures with RPR (BD Macro-VueTM 
Card test, New Jersey, USA) at KATH/TMU laboratory to identify potential active syphilis 
infections. 
For gold standard confirmation of the Fortress® RDT, al1 RDT reactive samples were 
subsequently retested in an algorithm combining two automated treponemal immunoassays and a 
treponemal immunoblot. Initial retesting was performed by Vitros® syphilis Treponema pallidum 
antibody (TPA) chemiluminescence immunoassay using the Vitros ECi/ECiQ Immunodiagnostic 
Systems as described in chapter two, under treponemal automated (Enzyme immunoassay) of this 
thesis 181.  All the confirmatory testing was performed at the department of Clinical Immunology, 
Copenhagen university hospital, Denmark. 
For samples where the cut-off value was equals to, or higher than, 100 (S/CO≥100) with Vitros 
TPA, the result was declared confirmed positive and the sample was not tested further (figure 5.2). 
All Vitros low positive samples (S/CO <100) were additionally tested with another qualitative 
anti-TP immunoassay Architect® Syphilis TP (Abbott Diagnostics, Wiesbaden, Germany) which 
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also detects antibodies binding to the recombinant TP antigens TpN15, TpN17 and TpN47 (figure 
5.2).  
Thus, a reactive Fortress® RDT sample was considered confirmed positive for specific anti-TP 
antibodies, if the Vitros syphilis TPA were highly reactive (S/CO ≥ 100) or if Vitros syphilis TPA 
was low reactive (1< S/CO <100) but the sample was also reactive in Architect (figure 5.2). 
Figure 5.2 A flowchart of syphilis confirmatory testing 
 
 
5.2.3 Sample size 
The prevalence of syphilis antibodies within the Ghanaian blood donor population has been 
estimated to be between 3.0% and 8.0% 6,7. For the purpose of power estimation, we assumed a 
prevalence of syphilis antibody around 4.0%. We aimed to determine the prevalence of syphilis 
antibodies among blood donors using Ortho Vitros® TPA, Architect syphilis TP assay, with a 
confidence limit of +/- 0.5%.  
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With this expected prevalence, we needed to test 18,000 potential blood donors to be able to arrive 
at a sample size of 640 syphilis reactive blood donors to obtain a confidence limit of +/- 0.5 %. 
The specificity of the Fortress quick test is reported to be 99.6% (Fortress® Diagnostics Limited 
– Antrim, UK). With a false positive rate of 2.6 (640 X 0.4%) i.e.  3 false positive samples, the 
positive predictive value would be estimated to be between 97.4 and 99.9% 266. 
5.2.4 Hospital training 
Study assistants including nurses, phlebotomists and laboratory staff were recruited, briefed and 
trained for data/blood sample collection, labelling, and storage of samples for testing. Written 
SOPs were developed, reviewed and approved by study investigators. 
5.2.5 Laboratory case definitions 
All specimen collection and testing was conducted within the hospital, with donor care provided 
by the experienced nurse practitioners, laboratorians, and phlebotomists. Participants were 
prospective blood donors who had already been tested and were RDT sero-reactive for syphilis. A 
nurse assisted the participants in reading the consent forms or explained to them in one local dialect 
(Twi) before signature or thumbprint. Specimens were then taken from participants by a 
phlebotomist after they had agreed to be included in the study. Specimen collection was done by 
the healthcare professionals, and all screening and bio-data to be used for the analysis were 
collected from the participants and recorded on a pre-designed spreadsheet. 
5.2.6 Study population 
5.2.6.1 Syphilis RDT testing 
The sampling frame was drawn from prospective blood donors, both VNRD and FD, who were 
willing to donate blood for KATH blood bank. These were blood donors aged between 17 and 59 
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years who had filled in their donor health questionnaire, and weighed over 50Kg, with blood 
pressure below 140/90 mm/Hg and Hb screened with Copper Sulphate solution above 13.0 g/dL.  
Between a time period of February 2014 and January 2015, 16,016 prospective blood donors who 
came to donate blood for the KATH blood bank were initially tested for T. pallidum antibodies 
using plasma or serum as part of the routine pre-donation system. The syphilis screen was 
performed with a treponemal RDT (Fortress® Diagnostics Limited – Antrim, UK) according to 
routine SOPs to detect antibodies (IgG and IgM). These blood donors were from Kumasi and its 
environs. Approximately 30% were FD who came to the hospital premises to donate blood to 
replace that which had been given to their sick relatives, while 70% were VNRD mostly from 
second cycle schools, religious institutions, and public drives.  
5.2.6.2 Principles of syphilis RDT test  
The syphilis Fortress® Ultra RDT test strip with the use of whole blood/serum/plasma is a rapid 
chromatographic immunoassay for the qualitative detection of antibodies to T. pallidum in whole 
blood, serum or plasma in blood donor samples.  
In the RDT test procedure, recombinant syphilis antigen is immobilized in the test region of the 
strip. After a donor specimen is added to the specimen pad, the specimen antibodies (IgG and IgM) 
react with the syphilis antigen coated particles applied to the specimen pad. 
The mixture migrates chromatographically along the length of the test strip and interacts with the 
immobilized syphilis antigen. The double antigen test format can detect both IgG and IgM in the 
specimen. If the specimen contains TP antibodies, a red line will appear in the test region, 
indicating a reactive result (Figure 5.4). 
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Figure 5.3 Syphilis Fortress test kit for testing blood donors 
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Figure 5.4 A picture of syphilis RDT of a blood donor in the TMU, KATH, showing a 
nonreactive and reactive result 
 
If the specimen does not contain TP antibodies, a red line will not appear in this region indicating 
a negative result. To serve as a procedural control, a purple line will always appear in the control 
line region which indicates that appropriate volume of specimen has been added. 
5.2.6.3 Laboratory testing of blood donors 
All the test strips, specimen from blood donors, and buffer were allowed to equilibrate to room 
temperature (15-300 C) prior to testing. 
1. All test strips were removed from the sealed foil pouch and used as soon as possible. 
2. Samples were centrifuged and serum or plasma was separated from the cells. Serum or 
plasma were used for the testing. 
3. Two drops of serum or plasma (approximately 50µL) was transferred from a dropper onto 
the specimen pad of the test strip. 
4. A drop of buffer (approximately 40 µL) was added to the specimen pad and results were 
available in 10 minutes. Results were interpreted within 30 minutes. 
Reactive Non- Reactive 
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5.2.6.4 Interpretation of RDT results 
1. REACTIVE – Two distinct lines appear. One line is in the control region (C) and the other 
line in the test region (T).  The intensity of the red colour in the test region varies depending 
on the concentration of TP antibodies present in the specimen. 
2. NEGATIVE – One purple line appears in the control region (C). No apparent red line 
appears in the test line. 
3. INVALID – Control line fails to appear.  
Sensitivity and specificity of the Fortress® RDT using serum or plasma are stated to be 99.7% and 
99.6% respectively - for the qualitative detection of antibodies (IgG and IgM) to T. pallidum in 
serum or plasma. 
5.2.7 Inclusion criteria 
1. Blood donors who were eligible to donate blood according to KATH/national standards 
(weight >50kg, systolic blood pressure ≤ 140mmHg and age 17 to 60 years).  
2.   Reactive sample on syphilis RDT 
3. Donor consented to participate in the study 
5.2.8 Exclusion criteria 
1. Blood donors who were reactive for syphilis but also reactive on tests for other TTIs. 
2. Blood donors who were reactive but unable to provide a blood sample. 
3. Consent not given to participating in the study. 
5.2.9 Sample taking and storage 
All blood donors who were declared initially syphilis seroreactive with Fortress RDT were asked 
to report to the TMU donor clinic head nurse for interpretation of their results and for advice. 
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These donors on arrival were offered to be participants of the study. The syphilis sero-reactive 
blood donors to be included in the study were informed about the study aims and objectives, and 
the possible benefits and any negative aspects. Concerning negative aspects, it was explained to 
them that, there was the possibility of feeling pain and bruises at the place when blood samples 
were taken. For the benefits, it was explained to them that there was the direct access to a medical 
doctor in the event that there was a true positivity and active infection at no extra expense.  
After the explanation of the study and assessment of their understanding, participants were 
requested to sign or thumbprint an informed consent form (appendix 5.1) Upon their consent, 5 
mL of whole blood was collected from 526 blood donors. After collection, the samples were 
centrifuged and serum was separated. To avoid repeated freezing and thawing of samples, each 
sample was aliquoted into 5 vials and labelled with the following purposes;  
1. Vial 1 was labelled for RPR testing which was performed at the study site. 
2. Vial 2 was labelled for Treponema pallidum haemagglutination assay (TPHA) also 
performed at study site as a local gold standard. 
3. Vial 3 was labelled for confirmatory testing which was performed at Copenhagen with 
Vitros TPA and Architect. 
4. Vial 4 was labelled for quality control testing which was performed at 4 different testing 
sites in the Kumasi transfusion facilities. 
5. Vial 5 was labelled as a spare.  
These samples were stored, deep-frozen (-20 to -700C) until further testing.  
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5.2.10 Potential Active syphilis test 
5.2.10.1 RPR testing 
The Macro-Vue™ RPR 18 mm circle card test (figure 5.5) is a nontreponemal testing procedure 
for the serologic detection of syphilis. This card test was originally developed for field use where 
testing could be performed without laboratory equipment 267. 
Figure 5.5 An RPR Card test kit for testing initially reactive blood donor samples in the study 
 
 
5.2.10.2 Principles of the RPR test  
The RPR card antigen suspension is a carbon particle cardiolipin antigen (figure 5.5) which detects 
“reagin”, an antibody-like substance present in serum or plasma of persons with syphilis, and 
occasionally in serum or plasma of persons with other acute or chronic conditions. The reagin 
binds to the test antigen, consisting of cardiolipin-lecithin-coated cholesterol particles, causing 
macroscopic flocculation. When a specimen contains an antibody, flocculation occurs with a co-
agglutination of the carbon particles of the RPR card antigen, which appear as black clumps against 
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the white background of the plastic-coated card. In comparison, nonreactive specimens appear to 
have an even light-grey colour (fig 5.6). 
5.2.10.3 Test procedure with 18 mm BD Macro-Vue™ RPR card test  
 As part of the study procedure, the labelled vial 1 for RPR for each of 526 consenting blood donors 
who was sero-reactive with the Fortress® RDT syphilis test were taken from the fridge and thawed. 
All these samples were then tested according to routine standard procedures with RPR (BD Macro-
VueTM Card test, New Jersey, USA) to identify potential active syphilis infections. 
1. A serologic pipette was used to remove 0.05 mL of the specimen (serum or plasma) from 
the blood collecting tube and care was taken not to transfer cellular elements.  
2. Specimen taken was placed onto the circle of the diagnostic test card.  
3. Using a new dispenstirs device, each specimen was spread to fill the entire circle. 
Dispenstirs device was discarded after spreading. The procedure was repeated for each 
specimen tested.  
4. The antigen dispensing bottle was gently shaken before use. Holding it in a vertical 
position, several drops were dispensed in dispensing bottle cap to make sure the needle 
passage was clear. One “free-falling” drop (20 G, yellow hub needle) was placed onto each 
test area. Mixing of antigen and specimen was accomplished by rotation.  
5. The test card with mixed antigen and specimen was rotated for 8 min (± 30 s) under a 
humidifying cover, on a mechanical rotator at 100 ± 2 rpm.  
Following rotation, to help differentiate nonreactive from minimally reactive results, a brief 
rotation and tilting of the card by hand (3 or 4 to-and-from motions) was made. Immediately, the 
card was read macroscopically in the “wet” state under a high-intensity incandescent lamp or 
strong daylight. 
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5.2.10.4 Reading and reporting the BD Macro-Vue™ RPR card test 
 As seen in the picture below (figure 5.6), individual reactions were evaluated in the “wet” state, 
under a high-intensity luminous lamp or strong sunshine. Immediately following rotation, cards 
were read and recorded as positive (i.e. black clumps) or negative (i.e. even light grey). 
 
5.2.10.5 Clinical handling of RPR positive blood donors 
Blood donors who were syphilis sero-reactive by RDT which indicated possible past or current 
infection, were not deferred. Rather, blood units were collected and then quarantined until an 
additional screening test in the form of RPR was performed. This non-treponemal syphilis test 
identified possible active infection and, therefore, a potential for transmission of syphilis to the 
recipient of the blood unit. Units that tested positive by RPR were discarded and the relevant 
donors were contacted and referred for further investigation and/or treatment. For transfusion 
purposes, the referred donors are not allowed to donate blood for a period of three years even if 
they undergo successful treatment (i.e. they are temporarily deferred). This is because syphilis is 
Figure 5.6 An RPR card test indicating positive and negative results 
 
 
 
 
 
Negative 
Positive 
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fully treatable with antibiotics, usually by injection. After 3 years with evidence of treatment, these 
donors may be allowed to donate blood again 268.  
Conversely, syphilis RDT sero-reactive units testing negative by RPR were released for 
transfusion. 
5.2.11 Syphilis confirmatory testing 
5.2.11.1 Vitros® Syphilis TPA assay 
Vitros® Syphilis TPA chemiluminescence immunoassay using the Vitros ECi/ECiQ 
Immunodiagnostic Systems is a qualitative assay that detects total antibodies (IgG and IgM) to TP 
reacting with biotinylated and horseradish peroxidase (HRP)-labelled recombinant TP antigens 
TP15, TP17, TP47 and bound to streptavidin-coated wells. The assay was mainly validated in a 
western population with a specificity of 99.8% (CI 98.7-100%) and a sensitivity of 100% using 
Syphilis Mixed Titre Performance Panel PSS202 (BBI Diagnostics) and clinical samples from 
known syphilis treated patients of both Caucasian and African origin.  
5.2.11.1.1 Principles of the Vitros® Syphilis TPA   
An immunometric immunoassay technique was used which involves the reaction of IgG, IgM or 
IgA antibodies present in the sample with a biotinylated TP antigen and a horseradish peroxidase 
(HRP)-labelled TP antigen conjugate. The antibody-antigen complex is captured by streptavidin 
on the wells. Unbound materials are removed by washing. The bound HRP conjugate is measured 
by a luminescent reaction. A reagent containing luminogenic substrates (a luminol derivative and 
a peracid salt) and an electron transfer agent is added to the wells. The HRP in the bound conjugate 
catalyses the oxidation of the luminol derivative, producing light. The electron transfer agent (a 
substituted acetanilide) increases the level of light produced and prolongs its emission. The light 
signals are read by the system. The illuminating reaction detected from the bound HRP-conjugates 
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is directly proportional to the concentration of anti-TP antibodies, and high signal samples (signal 
at Cut-off (S/CO) >100) were considered confirmed positive. 
 
5.2.11.2 ARCHITECT Syphilis TP 
All Vitros low reactive samples (S/CO <100) were additionally tested with another qualitative 
anti-TP immunoassay Architect® Syphilis TP (Abbott Diagnostics, Wiesbaden, Germany) also 
detecting antibodies binding to the recombinant TP antigens TpN15, TpN17, and TpN47. This is 
a chemiluminescent microparticle immunoassay (CMIA) for the qualitative detection of antibody 
to TP in human serum/plasma as an aid to diagnose syphilis and as a screen, for donated blood and 
plasma to prevent transmission of TP to recipients of blood and blood products. 
 
5.2.11.2.1 Principles of the ARCHITECT Syphilis TP  
The Architect® Syphilis TP is a two-step immunoassay for the qualitative detection of antibody 
to TP in donor serum or plasma using CMIA technology with flexible assay protocols. In the first 
step, donor sample, microparticles coated with recombinant TP antigens (TpN15, TpN17, and 
TpN47) and assay diluent are combined. Anti-TP antibodies present in the donor sample bound to 
the TP coated microparticles. After washing, the anti-human IgG and IgM conjugate is added to 
the second step. Following another wash cycle, a pre-trigger and trigger solutions are added to the 
reaction mixture. The resulting chemiluminescent reaction is measured as relative light units. The 
presence or absence of anti-TP antibodies in the donor sample is determined by the 
chemiluminescent signal in the reaction to the cut-off signal. The donor is considered reactive for 
anti-TP if the chemiluminescent signal in the sample is greater than or equal to the cut-off signal.  
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5.2.11.3 INNO-LIA Syphilis Score 
As quality control (QC) measure, 78 out of 526 (15%) syphilis RDT sero-reactive samples 
randomly selected, were further tested with a line immunoassay (LIA) (Furijebio, Ghent, 
Belgium). These samples comprised of 24 Vitros high positives, 26 Vitros low positives and 28 
Vitros negatives. This assay detects antibodies binding to the same recombinant TP antigens 
TpN15, TpN17 as well as to TpN47 and a synthetic peptide TmpA derived from T. pallidum 
proteins 187. The INNO-LIA Syphilis kit used in this study is an easy methodology that makes use 
of colour-coded reagents and simple interpretation criteria. It shows a high degree of performance 
as a multi-parametric conﬁrmation method. The assay was used as a QC measure to conﬁrm the 
presence or absence of speciﬁc antibodies to T. pallidum antigens in a sub-set (15%) of initially-
reactive blood donor sera and plasma.  
 
5.2.11.3.1 Principle of the INNO-LIA  
The line immunoassay was based on the enzyme immunoassay (EIA) principle. Three recombinant 
proteins (TpN15, TpN17, and TpN47) and one synthetic peptide (TmpA) are coated as distinct 
lines on a nylon strip with plastic backing. In addition to these syphilis antigens, four control lines 
are coated on each strip: background control lines, 3+ positive control which was also used as 
sample addition control line, 1+ positive control, and cut-off line.  
The donor samples were incubated in a test trough together with the multiple antigen-coated test 
strips. Specific T. pallidum antibodies, if present in the sample, bound to the individual syphilis 
antigen lines on the strip. Afterwards, a goat anti-human IgG labelled with alkaline phosphatase 
was added. This was bound to any syphilis antigen/antibody complex previously formed. 
Incubation with a substrate produced a dark brown colour in proportion to the number of specific 
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antibodies present in the sample. Colour development was stopped with sulphuric acid after the 
substrate was added for 30 minutes. 
 
5.2.11.3.2 Interpretation of the INNO-LIA results 
A sample was considered NEGATIVE for T. pallidum antibodies if all syphilis antigen lines had 
a negative reactivity rating or if one syphilis antigen line scored ±. 
A sample was considered POSITIVE for T. pallidum antibodies if two or more syphilis bands 
showed a reactivity of ± or higher. 
A sample was considered INDETERMINATE for T. pallidum antibodies if one syphilis band 
showed a reactivity of 1+ or higher. 
N/B The results were read by the person who performed the test and read secondly by another 
person in the laboratory blinded to the first reader’s results. If both agreed, then the final results 
were recorded. If both do not agree, a third person is called to read as a tie breaker. 
 
5.2.12 Data management and analysis  
5.2.12.1 Data Management 
Data obtained from the study participants were double-entered, given code numbers for referral 
purposes on the spreadsheet and checked every day at KATH study site. Validation of the data 
entry was done at the end of every week to make sure they were properly recorded from the clinical 
forms and donor testing books. Confirmatory data entry was done at Copenhagen Rigshospitalet 
and sent to Kumasi, the study site. Data recorded from the blood donor testing books in the 
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laboratory and computer spreadsheet (confirmatory data included) were compared and 
discrepancies resolved by referring back to the original clinical forms of the blood donors. 
5.2.12.2 Data Analysis 
Background data consisting of sex, age, number of donations, donor type and routine testing results 
were recorded on a spreadsheet. Data were then exported into STATA SE version 12 
(STATACORP, College station, Texas USA) which was the statistical software used for the 
analysis. All string variables (e.g. reactive and nonreactive, voluntary and replacement, male and 
female etc.) were converted to numerical values (0 and 1) for easy analysis and interpretation. 
Descriptive statistics of the variables were presented in the form of tables, pie charts, and figures. 
Proportions for the various potential predictor variables (independent) and the outcome variable 
(dependent) were calculated as means and proportions. We estimated positive predictive values 
(PPV) by calculating proportions and providing their respective confidence intervals. Multi-
variable logistic regression was performed on syphilis reactivity as an outcome variable. Age, sex 
and donor type were included as potential predictor variables (independent) with results presented 
as odd ratios and 95% Confidence Intervals. A p-value of <0.05 denoted a statistically significant 
difference in all statistical comparisons. 
 
5.3 Results 
5.3.1 Syphilis prevalence of blood donors in the study population 
599 out of study population of 16,016 prospective blood donors reacted to the syphilis Fortress® 
RDT test making an estimated sero-reactivity rate of 3.7% (95% [CI] 3.5 - 4.1). Of these, 526 
(3.3%) syphilis seroreactive blood donors were included in the study of which 199 (37.8%) of 
them were VNRD (95% [CI] 33.8 - 42.1) and the rest were FD. 
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5.3.2 Exclusions in the study population due to co-infections 
Seventy-three (12.2%) out of the 599 were blood donors who reacted with the Fortress syphilis 
test but were excluded from the study (figure 5.7). This is because 41 (6.8%) of them were co-
infected with HBV, 15 (2.8%) were co-infected with HIV and seven (1.2%) were co-infected with 
HCV, while ten (1.7%) did not consent.  
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5.3.3 Age of the study population 
 The blood donors tested were aged 16 to 59 years with a mean age of 25 (SD=9.1) compared with 
the sub-group of syphilis sero-reactive donors who showed a range of 17 to 53 years with a mean 
age of 31 years (p<0.001). Generally, the proportion of blood donors aged 16-25 years (59%) was 
127/172 
(73.8%) 
131/354 
(37.0%) 
40/172 
(23.3%) 
180/354 
(50.8%) 
Vitros® (1<S/CO 
<100) Architect® Pos 
 
167/172 
(97.1%) 
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172/526 (32.7%) 354/526 (67.3%) RPR 
Confirmed  
Vitros® (S/CO≥100) 
 Negative  Positive 
RDT; - rapid diagnostic test, RPR; - rapid plasma reagin, S/CO-; sample over cut-off   
N/B-Architect® was performed on specimen that were low reactive with Vitros® (1< S/CO <100) 
 
Figure 5.7 Algorithm for syphilis confirmatory testing of sero-reactive blood donors at KATH/TMU 
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higher among syphilis RDT negative donors (figure 5.8) than among syphilis RDT positive donors 
aged 26-35 years (42%) (figure 5.9).  
Figure 5.8 Age group distribution of the study population (blood donors) 
 
 
Figure 5.9 Age group distribution of the syphilis RDT positive blood donors 
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5.3.4 PPV of Syphilis Fortress RDT according to donor type 
Of the total (16,016) blood donors tested, 10,218 (63.8%) were VNRD, of which 199 (1.95%) 
were syphilis sero-reactive by RDT (95% [CI] 1.73 - 2.28) as shown in table 5.2. Of the 5,798 FD 
tested, 327 were syphilis sero-reactive, which was significantly higher [5.64% (95% [CI] 5.08 - 
6.26)] p<0.001 compared to VNRD.  
Of the 526 RDT syphilis sero-reactive samples tested with Vitros®, 478 were reactive and 
confirmed by the algorithm (both Vitros and ARCHITECT TPA), making a PPV of 90.9% (table 
5.1) and confirmed syphilis seroprevalence of 2.98% (95% [CI] 2.73 - 3.25). The proportion of 
sero-reactive FD (309/327, 94.5%) by RDT who were confirmed by Vitros TPA (table 5.2) was 
statistically significantly higher than that of confirmed sero-reactive VNRD (169/199, 84.9%), 
(p=0.001).  
5.3.5 PPV of syphilis RDT and RPR test kits for sero-reactive blood donors 
Of the 526 syphilis RDT reactive donor samples, 172 (32.7%) were RPR positive (95% [CI] 28.8 
- 36.8). Out of these, 167 were confirmed with Vitros making a PPV of 97.1% (table 5.1). Thus, 
the PPV was higher among syphilis Fortress RDT and RPR reactives (97.1%) than in the total 
population of RDT reactives (90.9%) as shown in table 5.1. Conversely, the PPV was significantly 
higher among RPR reactive FD (99.1%) than among RPR reactive VNRD (93.3%) (p=0.001).  
More FD and more donors aged 26 or over were RPR positive and RPR positivity increased with 
age (table 5.2). Similarly, the PPV of combining RDT and RPR testing was highest among FD and 
among donors aged 26 or above (table 5.2).  Out of the five RPR false positives, four were VNRD 
of whom three were aged between 16 and 25 years and one was aged between 26 and 35 years. 
The RPR false positive FD was aged between 26 and 35 years. 311 out of 354 (87.8%) RPR 
negative donors tested positive with Vitros®. 
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Table 5.1 Syphilis RDT and RPR sero-reactive blood donors 
 
RDT reactive 
Blood donors 
 
RPR 
 
 
TOTAL (%) 
Positive (%) 
 
Negative (%) 
 
 
Confirmed with 
Vitros/Architect 
 
167 (97.1) 
 
311 (87.8) 
 
478 (90.9) 
 
Unconfirmed with 
Vitros/Architect 
 
5 (2.9) 
 
43 (12.2) 
 
48 (9.1) 
 
TOTAL 
 
172 (32.7) 
 
354 (67.3) 
 
526 
RDT; -rapid diagnostic test, RPR; -rapid plasma reagin, %; -percentage 
 
 
5.3.6 PPV of syphilis RDT according to donor age 
Syphilis RDT sero-reactive donors showed a range of 17 to 53 years with a mean age of 31 years. 
The PPV of the Fortress RDT when testing VNRD ranged from 74.4% to 100% for the ages 
ranging between 17 and 55 years whilst that of FD ranges from 91.2% to 100% for the same age 
groups (table 5.2). Generally, the PPVs of the RDT for syphilis confirmed positive donors 
increased with age for both donor types. Although syphilis confirmed sero-prevalence of FD was 
5.33%, there was higher prevalence as the age increases (table 5.2). The prevalence of syphilis 
confirmed VNRD was 1.65%, but there was a higher prevalence of 5.24% among the 36-45 age 
group.    
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Table 5.2 Syphilis RDT and RPR sero-reactive blood donors confirmed with Vitros® TP 
stratified according to age 
Blood donors Total RDT 
tested   
 (%) 
RDT +   
 (% )  
RDT+, Vitros®+ 
(%, PPV) 
RDT+, RPR+  
(%) 
RDT+, RPR+, Vitros®+ 
 (%, PPV) 
VNRD 
Age group (yrs.) 
16-25 
26-35 
36-45 
46-55 
56-59 
 
GENDER 
Females 
Males 
10218 (63.8) 
 
7525 (73.6) 
1750 (17.1) 
687 (6.7) 
221 (2.2) 
35 (0.4) 
 
 
3477 (34.0) 
6741 (66.0) 
199 (1.95) 
 
78 (1.04) 
76 (4.34) 
38 (5.53) 
7 (3.17) 
0 
 
 
24 (0.69) 
175 (2.60)  
169 (1.65, 84.9) 
 
58 (0.77, 74.4) 
68 (3.89, 89,5) 
36 (5.24, 94.7) 
7 (3.17, 100.0) 
0 
 
 
16 (0.46, 66.7) 
153 (2.27, 87.4) 
60 (0.59) 
 
27 (0.36) 
23 (1.31) 
9 (1.31) 
1 (0.30) 
0 
 
 
6 (0.17) 
54 (0.80) 
56 (0.55, 93.3) 
 
24 (0.32, 88.9) 
22 (1.26, 95.7) 
9 (1.31, 100.0) 
1 (0.30, 100.0) 
0 
 
 
6 (0.17, 100.0) 
50 (0.74, 92.6) 
FD 
Age group (yrs.) 
16-25 
26-35 
36-45 
46-55 
56-59 
 
GENDER 
Females 
Males 
5798 (36.2) 
 
1869 (32.2) 
2405 (41.5) 
1186 (20.4) 
321 (5.5) 
18 (0.4) 
 
 
538 (9.3) 
5260 (90.7) 
327 (5.64) 
 
57 (3.05) 
148 (6.15) 
95 (8.01) 
27 (8.41) 
0 
 
 
13 (2.42) 
314 (5.97) 
309 (5.33, 94.5) 
 
52 (2.78, 91.2) 
139 (5.78, 93.9) 
91(7.67, 95.8) 
27 (8.41, 100.0) 
0 
 
 
13 (2.42, 100.0) 
296 (5.63, 94.1) 
112 (2.12) 
 
24 (1.28) 
48 (2.00) 
32 (2.70) 
8 (2.50) 
0 
 
 
4 (0.74) 
108 (2.05) 
111 (1.91, 99.1) 
 
23 (1.23, 95.8) 
48 (2.00, 100.0) 
32 (2.70, 100.0) 
8 (2.50, 100.0) 
0 
 
 
4 (0.74, 100.0) 
107 (2.03, 99.1) 
 
TOTAL 
 
16016 
 
526 (3.28) 
 
478 (2.98, 90.9) 
 
172 (1.07) 
 
167 (1.04, 97.1) 
 
RPR; - rapid plasma reagin, %; -percentage, VNRD; - voluntary non-remunerated blood donors, FD; - family 
donors, RDT; - rapid diagnostic test, +; - positive, -; negative, PPV; - positive predictive value. 
 
5.3.7 The effect of age, sex and donor type on syphilis reactivity 
By multivariable logistic regression, we showed a positive association between syphilis reactivity 
and the following parameters: increased age, male sex, and FD status (table 5.3). Syphilis sero-
reactive effects of male sex and FD status were similar whether a positive endpoint was defined as 
RDT+, RDT+ Vitros®+, RDT+ RPR+ or RDT+ Vitros®+ RPR+ (table 5.3).  The sero-reactive 
effect of age was weaker for endpoints including RPR reactivity (table 5.3). Male sex was a 
stronger predictor of syphilis reactivity than status as FD (Table 5.3). This was estimated from the 
odd ratios which were higher in males compared to FD. 
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Table 5.3 Multiple variable logistic prediction of syphilis reactivity 
RDT + 
526/16016 (3.28%) 
 
Odds Ratio 
 
P-values 
 
[95% Conf.  Interval] 
Age (years) 1.04 <0.001                                      1.03    1.05 
Gender (male) 2.99 <0.001  2.11     4.04 
Donor type (FD) 1.92 <0.001 1.60    2.30 
RDT+, Vitros®+ 
478/16016 (2.98%) 
   
Age (years) 1.05 <0.001 1.04     1.06 
Gender (males) 3.41 <0.001 2.29    5.08 
Donor type (FD) 1.75 <0.001 1.44    2.14 
RDT+, RPR+  
172/16016 (1.07%) 
   
Age (years) 1.03 <0.001 1.02   1.05 
Gender (male) 3.22 <0.001 1.67    6.22 
Donor type (FD) 2.04 <0.001 1.45    2.88 
RDT+, RPR+, Vitros®+ 
167/16016 (1.04%) 
   
Age (years) 1.03 <0.001 1.02     1.05 
Gender (male) 2.72 <0.001 1.49    4.99 
Donor type (FD) 2.06 <0.001 1.46    2.89 
 
RPR; - rapid plasma reagin, %; -percentage, FD; - family donors, RDT; - rapid diagnostic test, +; - positive, PPV; - 
positive predictive value. 
 
5.3.8 Samples tested with INNO-LIA as quality control 
Twenty-eight (58%) out of 48 syphilis Fortress RDT samples which were negative with Vitros® 
test were tested with INNO-LIA (figure 5.10). Twenty-five of them were negative while the rest 
were inconclusive.  
28 
tested 
24 
tested 
26 
tested 
3 24 25 25 1 
Vitros® S/CO≥100 Vitros® Negative 
Positive 
Positive Negative     IC IC 
INNO-LIA 
Approximately 15 % of the samples tested with Vitros® were further tested with INNO-LIA as a quality control of the 
validation algorithm. 
IC; - Inconclusive, S/CO-; sample over cut-off 
 
Figure 5.10 Quality control with INNO-LIA for syphilis testing of sero-reactive blood donors 
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All 24 (~9%) samples which were Vitros® high positives were confirmed with INNO-LIA and 25 
of 26 with low reactivity with Vitros® were confirmed with LIA, and one was inconclusive 
although the Architect signal was positive. 
 
5.3.9 Testing syphilis RDT reactive donors with TPHA as an alternative gold standard  
Further tests were performed using a specific serological Chromatest Treponema Pallidum 
haemagglutination assay (TPHA, Linear Chemicals, Barcelona) on syphilis sero-reactive blood 
donor samples. This was because, in our previous studies 93, 31.3% of total donations in Ghana 
were tested for syphilis with TPHA as WHO recommended assay. It was based on this that if this 
assay is validated with good PPV, it can be used as a gold standard in our local settings. 
We compared the performance of the RDT syphilis seroreactivity with TPHA to determine the 
predictive values of both. Of the total of 526 RDT positive blood donors, 501(95.2%) were positive 
with TPHA with syphilis donor reactivity of 3.13% (table 5.4). Out of these, 315 (with a sample 
reactivity of 5.43%) were from FD and 186 (with a sample reactivity of 1.82%) were from VNRD 
(table 5.4). A total 170 (33.9%) TPHA positives were confirmed with RPR signifying potential 
active/recent syphilis infection whereas two (8.0%) of the TPHA negatives were RPR positive. 
Additionally, all the FD who were TPHA negative were also negative with RPR. Significantly, of 
the 501 TPHA reactive blood donor samples tested, a total of 475 (sample reactivity of 2.97%) 
were confirmed with Ortho-Vitros having a PPV of 94.8%. 
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Table 5.4 Sample reactivity of TPHA with syphilis RDT and Ortho-Vitros 
Blood donors Total tested 
with RDT 
(%) 
Total reactive with 
RDT + TPHA   
(%) 
Total reactive with 
RDT+TPHA+ Ortho-
Vitros®    
 (% )  
Total reactive with 
RDT+ Ortho-Vitros 
(%) 
VNRD 10218 
(63.8) 
186 
(1.82) 
169 
(1.65)  
169 
(1.65) 
FRD 5798 
(36.2) 
315 
(5.43) 
306 
(5.28) 
309 
(5.33) 
TOTAL 16016 501 
(3.13) 
475 
(2.97) 
478 
(2.98) 
%; -percentage, VNRBD; -voluntary non-remunerated donors, FD; - family donors, TPHA; - Treponema pallidum 
Haemagglutination Assay, RDT, rapid diagnostic test, %; -Percentage. 
 
5.4 Discussion 
5.4.1 PPV of syphilis RDT 
Of the 526 syphilis sero-reactive participants, there was RDT PPV of 90.9% and RPR PPV of 
97.1% when confirmed with Vitros TPA. In effect, 172 (1.07%) out of 16,016 blood donors were 
suspected to have active syphilis and thus their blood units were discarded. 
Syphilis infection in blood donors continues to pose a major threat in many developing countries 
including Ghana 7,93. The Fortress syphilis RDT which was used for this study has a sensitivity 
and specificity of 99.7% and 99.6% respectively according to the manufacturer. When compared 
to the gold standard Vitros® TPA, the Fortress RDT had a PPV of 90.9%. Similar syphilis RDTs 
in other studies 269 have a PPV of 95.2% with sensitivity and specificity of 93.6% and 92.5% 
respectively. As PPV relies on both test specification and disease prevalence it is not surprising 
that other studies have shown PPVs of some RDTs to be both lower and higher than ours 270. When 
we combined an RDT with the nonspecific RPR syphilis test, a much higher PPV was achieved 
(97.1%) compared to single RDT (90.9%). Thus, by combining both RDT and RPR, donors with 
confirmed previous or treated syphilis infections and donors with non-specific RDT reactions 
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could avoid deferral and they could therefore still contribute to the blood supply. Consequently, 
instead of discarding the 526/16,016 (3.28%) blood units which were syphilis positive by RDT 
over 11-month period, only 172 (1.07%) (i.e. those which were RPR positive and thus possibly 
actively infected) would be discarded and the rest (354/16,016=2.2%) of the blood units could be 
released for transfusion thereby contributing to improving blood supply.  
The key concept underlying blood safety especially in Africa and LMIC is the balance between 
blood supply and blood safety in the context of an inadequate blood supply, high prevalence of 
TTI and limited resources. As stated earlier, if there is a low PPV (i.e. high false positive rate) then 
many donors will be deferred when they carry no risk to the blood supply. Furthermore, a screening 
test with a low PPV/high false positive rate has the potential to cause unnecessary harm to blood 
donors by creating unnecessary doubts and providing wrong information about their infection 
risks.  
In Ghana, there can be potential saving in blood units each year if the NBSG could adopt this 
strategy of combining syphilis RDT with RPR. For example, the survey study in the chapter four 
of this thesis reported that, 3,371 out of 91,386 units were syphilis reactive. From this study, we 
can estimate that if 32.7% out of 3,371 (1,102 units) were suspected active syphilis, then, 2,269 
units of blood could be released for transfusion to increase blood supply in the country. 
5.4.2 The use of syphilis RDTs in resource-poor settings 
Pre-donation screening for TTIs with syphilis RDTs is an approach that has been proposed for use 
in resource-poor, high-prevalence settings without access to a stable pool of low-risk donors 271. 
One of the reasons behind pre-donation testing is that it reduces blood bag wastage and the 
associated costs of consumables in collecting blood from donors which is then not used because 
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of positive screening tests. One study in Ghana demonstrated savings of more than $11,000 in 
blood bags and testing costs over a 1-year period using pre-donation screening 22.  
5.4.3 Syphilis prevalence in Kumasi blood donors 
In this study, we found the prevalence of syphilis in Kumasi blood donor population (FD and 
VNRD) with the use of RDT to be 3.7% which is not different from previous studies in Ghana 6,7. 
Like other studies, we found a higher rate of syphilis reactivity among FD than among VNRD. 
This was additionally confirmed with the use of Vitros (table 5.4) where the sero-reactivity among 
FD was significantly higher than that of VNRD (p=0.001). This was only partly explained by the 
higher age and more males among FD since FD status was an independent positive predictor of 
syphilis reactivity in logistic regression analysis. There is an ongoing initiative to have 100% 
VNRD in Ghana and elsewhere in Africa which if successful may reduce syphilis sero-reactivity. 
This is because a high proportion of voluntary donations are collected from students in high 
schools, though overall family donors remain dominant on the African continent. The positive 
association between age and syphilis reactivity is most likely caused by a longer period of sexual 
exposure in older donors. However, a cohort phenomenon with older donors being more exposed 
to yaws in childhood may also contribute. The data confirm that younger donors are safer than 
older donors with respect to syphilis prevalence whereas the highest safety both with regards to 
infection risk and blood supply lies in a system of repeat donations as the main source of blood for 
transfusion 42. 
5.4.4 Syphilis seroreactivity and active syphilis in blood donors 
Our data showed that a total of 167 (1%) of 16016 tested blood donors were confirmed syphilis 
RDT and RPR reactive. Our logistic regression data additionally indicated that for both RDT and 
RPR positive donors, there are independent effects of age, male sex and FD donor type on syphilis 
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seroreactivity. These data excluded 73 (0.5%) blood donors with other TTI co-infections, which, 
if included, would have increased the rates of confirmed syphilis RDT and RPR reactivity over the 
11-month period of study.  The study did not include relatively more or less women discarded 
because of other TTI than men. 
Of the 16,016 prospective blood donors tested with syphilis Fortress® test, there was an estimated 
sero-prevalence of 3.7% (599/16016). The syphilis seroprevalence in this study (3.7%) was 
different from our previous study (7.0%) in the same study site 44 although the same Fortress test 
was used in both studies. This was possibly because those donors with positive syphilis screening 
tests did not turn up to donate again. Again, in our previous study from Ghana 44, we found that 
when the syphilis RDT seroreactive samples were tested with RPR, the reactivity rate was not the 
same with this present study. This considerable discrepancy was probably due to changes in RPR 
test kits.  The RPR test kit used in the previous study, (IMMUTREP RPR, Omega Diagnostics – 
Scotland, UK) differed in sensitivity and specificity from the one used in this study (BD Macro-
VueTM Card test – New Jersey, USA).  This could have reduced the measured RPR prevalence. 
Additionally, testing errors on the part of the laboratory scientists in both testing procedures could 
contribute to the discrepancy. This could be explained that the RPR test kit used in the previous 
study will diagnose more donors of having suspected active infections which in public health wise, 
will have doubts in their minds although not confirmed.  
Our data thus support the combined use of RDT and RPR to detect active syphilis in potential 
blood donors, which would enable more focused, deferral of potential active syphilis cases for 
treatment. These cases of suspected active syphilis can be identified with a minimal loss of donors 
as within the 11-month period of this study, the hospital was able to save 354 units of blood to 
save lives. Thus, choosing the combined syphilis RDT and RPR could be cost effective. In effect, 
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the use of RPR as a second test will not only increase blood availability, but, blood donors with 
suspected active syphilis will be identified and referred for treatment, and blood donors with 
positive RDT tests that are not confirmed by the RPR test will not be needlessly worried.  
5.4.5 Syphilis automation and RDT in LMIC 
Automated serologic testing platforms require proper training, reagent management, and laborious 
quality systems to ensure output reliability. The purchase of automated equipment for syphilis 
testing like Vitros ECi/ECiQ Immunodiagnostic Systems and ARCHITECT TPA which are able 
to provide effective and reliable results for blood donors for safe transfusion, may be very 
expensive and time-consuming and require staff training in LMIC. Even automated, highly 
sensitive, expensive and technically difficult laboratory screening methods - e.g. nucleic acid 
testing (NAT) - are not routinely available in resource-constrained settings 272. In resource-
restricted settings where syphilis prevalence is high, expensive automated equipment for testing 
may not be affordable. In practice, it is likely that LMICs will need to rely on RDTs and RPR test 
kits with relatively good sensitivities and specificities which are user-friendly, of good quality and 
efficacious. It is important to repeat this study in other resource-poor settings where syphilis 
prevalence is high. Apart from specificity, sensitivity and cost in considering RDT, another 
relevant aspect is the rapid availability of results (within about 15 minutes) from syphilis RDTs 
and RPR tests compared to automated machines.  
The strength of this study is the description of a real-life performance with regards to the PPV of 
a newly suggested combined syphilis testing algorithm, combining an RDT and RPR for the 
identification of potential active syphilis. The algorithm used for gold standard confirmation was 
robust as it involved two different Treponema-specific tests used sequentially to confirm weak 
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and negative results. The INNO-LIA assay has been shown to provide highly reliable confirmatory 
diagnostic information of anti-TP antibodies as it was used as a quality control for the confirmation 
algorithm of anti-TP antibodies. 
5.4.6 Limitations of the study 
1. The assumption that RDT positive donors testing negative in RPR were without significant 
risk for transfusion was not tested by recipient look back or by molecular testing of donors. 
2. The proportion of truly syphilis-reactive donors missed by the initial RDT (sensitivity and 
specificity) was not evaluated because of resource constraints. 
3. We cannot assume infectivity among all confirmed RPR reactive donors. Additionally, 
infectivity among seroreactive blood donors who were positive with RPR was not 
determined. 
4. By excluding donors with other TTI, the performance of the used tests when co-infected 
cannot be deducted from the present study. 
 
5.5 Conclusion 
In a blood bank system like the one in Kumasi, Ghana, with a relatively high prevalence of syphilis 
and where infrastructure to support formal laboratory testing is often lacking, syphilis screening 
with RDTs may provide a reasonable technology. We believe that screening blood donors for 
syphilis with RDT with proper validation in settings similar to ours can contribute to improving 
blood safety without jeopardizing the blood supply. The combination of both RDT and RPR 
reduces the loss of donors and increases the blood available for transfusion. The combined RDT 
and RPR testing has a satisfactory high PPV, meaning that unnecessary discarding of blood for 
transfusion and false syphilis diagnoses of donors are minimized. The high PPV of a combined 
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RDT and RPR algorithm suggests that further routine confirmation of a donor deferred with dual 
RDT and RPR reactivity is not needed. This adds to the robustness and cost efficiency of the 
suggested syphilis screening algorithm. 
The hospital transfusion committee in the study area was instrumental in initiating the combined 
strategy of syphilis testing with RDT and RPR, showing the critical role, such committees can play 
in the implementation of evidence-based measures to improve blood safety and availability even 
when resources are limited. 
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CHAPTER 6 
6. Performance of a syphilis RDT in selected transfusion facilities in Ghana. 
6.1 Introduction  
6.1.1 Syphilis RDTs 
This chapter relates to objective 4, which is to determine the performance of a widely used syphilis 
RDT in selected transfusion facilities in Ghana.  
In Ghana and many developing countries, syphilis testing is usually performed using rapid 
diagnostic tests (RDT) 19,93. This technique is preferred over the conventional assays like EIA, 
TPHA, and RPR because RDTs are simple to perform, give quick responses, are affordable, are 
readily available in the market and do not require skilled labour 44. Another advantage of the 
syphilis RDT is their flexibility in terms of using both whole blood and serum/plasma samples 
from subjects as stated in chapter two 192. With an increasing population size and expansion of 
blood donor facilities to rural areas, the demand for these RDT kits has increased in Ghana and 
many developing countries. 
It is the responsibility of the laboratory to ensure that test kits for the syphilis RDTs are of good 
quality and standard reactivity. The investigation of syphilis infection is important for both 
detection and exclusion of blood donors. As such, the poor effectiveness of less sensitive 
diagnostic kits could pose a significant risk to blood recipients. Similarly, low specificity can cause 
unneeded loss of donors and thus hamper blood supply. Although most RDTs do contain an 
internal quality control (QC) in the form of a control line in the strip or cassette, periodic external 
QC using laboratory-based tests is recommended. 
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The syphilis RDT method can be completed in 10–30 minutes depending on the manufacturer’s 
instructions and can be used in rural and peri-urban areas for the screening of blood donors because 
of its user-friendliness. The first objective of this thesis about the survey screening practices in 
Ghana 93, reported the variation in cost per test strip for syphilis screening which varied 10-fold, 
from US$ 0.2 to US$ 2.0 which is generally considered to be affordable. However, the influx of 
various brands of these RDTs into the Ghanaian market without appropriate evaluation 273 is 
worrying and could pose a risk to the health of the entire country in terms of transfusion safety. 
In Ghana, our study, as described in previous chapters, has shown that two-thirds of the facilities 
testing for syphilis are using RDTs which are not recommended by the WHO 93. Some of the 
syphilis RDTs that are available in Ghana include; ACON, ABON, Determine, First response, 
Fortress, and Wondfo. Although a study we performed in 2016 (chapter 4 of this thesis) reported 
ACON as the predominant RDT used 93,  this has recently been replaced by ABON (Abon 
Biopharm Company Limited, Hangzhou, China) as the RDT which is reportedly used by most of 
the facilities in Ghana. This has led to the need to develop a local QC panel for evaluating the 
performance of the ABON syphilis RDT. There is currently no commercially available panel for 
quality checks on syphilis RDTs.  
This study was therefore undertaken to set up a QA process and to evaluate the performance of the 
ABON syphilis RDT kit used in selected blood transfusion facilities in Ghana. Fortress, another 
syphilis RDT in Ghana for the qualitative detection of antibodies (IgG and IgM) to T. pallidum in 
serum or plasma was used in the study site at KATH (sensitivity 99.7%), as a screening test for 
this ABON evaluation study 112 whilst Vitros TPA was used as the gold standard.  The information 
provided from this study will be useful as a model for ensuring that reliable and reproducible 
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syphilis RDT results are obtained consistently within a laboratory and among different laboratories 
performing the same tests.  
6.1.2 Type of study 
This was a cross-sectional study conducted to set up a QA process to evaluate the performance of 
a syphilis RDT (ABON) used for screening blood donors and to determine the PPV, sensitivity 
and specificity of the test kit when used by transfusion facilities in Ghana. 
6.1.3 Study area 
This cross-sectional study was carried out at four different hospital facilities with laboratories for 
testing blood samples for TTIs. These facilities were located in Ashanti region of Ghana and were; 
Ankaase Mission Hospital, The University hospital (KNUST), Mampong Government hospital, 
and Gary Marvin Memorial hospital. These four facilities were chosen based on the criteria that 
they were: 
1. Already using rapid tests to screen for syphilis – Our previous study 93 which forms part of 
this thesis, found that more than two-thirds of the facilities were using RDTs for syphilis 
testing.  
2. From different districts within Ashanti region, Ghana and accessible within 2 hours 
traveling distance from the teaching hospital. 
3. Tested more than 500 blood donors annually. 
 
6.1.4 Description of the four study facilities 
Ankaase Mission Hospital – is located in Ankaase town near the city of Kumasi in the Ashanti 
region of central Ghana. It is a general district hospital started in 1991 with assistance from the 
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Methodist Church Ghana and the mission society. Currently, it provides medical care for more 
than 10,000 inhabitants in the surrounding towns and villages with a capacity of 90 beds. The 
hospital has a pharmacy, X-ray and ultrasound, laboratory with blood transfusion capability, and 
endoscopy capabilities. The hospital tests roughly 4000 blood donors annually for TTIs (HIV, 
HBV, HCV, and syphilis) all with RDTs of whom 20% are from voluntary donations whilst the 
rest (80%) are from family/replacement donations. The hospital also offers obstetrics, general 
surgery, urology, and optometric service. An average of 150-200 outpatients is seen daily in the 
clinic. In addition, the hospital reaches out to the broader community through nutrition education, 
literacy classes, and care for persons living with HIV/AIDS. Preventive healthcare at Ankaase 
Methodist hospital is a high priority and guided by a health board instituted by the community. 
The public health unit which is staffed by the community, provides immunizations, general health 
education, health screens for mothers and babies, and particular interventions against Buruli ulcer, 
malaria, hepatitis B, and HIV infection. 
The University hospital (KNUST) - started as a dressing station in 1952 and has grown by 
additions and modifications into a full-fledged 100-bed hospital. The hospital currently caters for 
a population of over 200,000 made up of students, staff, and dependents, while the rest are from 
surrounding communities, including Ayigya, Bomso, Ayeduase, Kotei, and Boadi. It is the medical 
arm of the KNUST. It is located in the northwest part of Kumasi, Ashanti Region, playing the role 
of a district hospital. The University hospital offers services in the general medical care as well as 
specialist services. The facilities at the hospital comprise of medical records, a dispensary, and 
mini-laboratory among others. The hospital screens blood donors for HIV, HBV, and HCV but 
started testing for syphilis in 2013, all with RDTs. Roughly 3000 blood donors are being tested 
annually of which 70% are FD. The students’ clinic (which is part of the university hospital to ease 
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congestion) has a stand–by ambulance and a power plant to provide emergency services. Work is 
progressing steadily on the construction of the first phase of an 800-bed teaching hospital for the 
KNUST in Kumasi. 
Mampong Government hospital – was established in the year 1973, serving people from 
Mampong, Pru, Atebubu, Nkoransa and Offinso districts. The hospital is located in the town of 
Mampong and it is the only hospital serving the entire Mampong municipality (population: 
88,625). Mampong is a 60 to 90-minute drive from KATH, one of the major tertiary referral centres 
in Ghana.  
The hospital has 98 beds in the general wing and an additional 56 beds located one kilometre away 
in the maternity wing, however, the maternity wing effectively functions as a separate hospital. 
The emergency ward has 14 beds and there are a modern laboratory and theatre, a physiotherapy 
department, a back-up generator and a water system. The Mampong Government hospital operates 
on total family replacement blood donation where approximately 1000 prospective blood donors 
are tested annually with RDTs for all TTIs 
Gary Marvin Memorial hospital - is a private maternity hospital in Kumasi, Ghana. This hospital 
is located in the township of Kotwi, on the outskirts of Kumasi road leading to Obuasi. It is the 
only referral hospital in the district of Atwima-Kwanwoma, which has a semi-rural population of 
98,167 inhabitants.  
The hospital which was first established in 2004 as a maternity home currently has 36 beds and an 
outpatient department. The average attendance is 3000 patients/month. Every month, an average 
of 60 babies are delivered, mostly by normal delivery but also by caesarean section. This centre 
was chosen particularly because syphilis congenitally affects 500,000 or more infants annually in 
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SSA 66, wherefore including a hospital with focus on deliveries would be important. They also 
perform various operations such as hysterectomies, emergency treatment for miscarriages and 
ectopic pregnancies, hernia repairs and laparotomies. Their in-patient facilities include a maternity 
ward, labour ward, paediatrics ward, surgical male and female wards, as well as special wards for 
single patient occupancy. 
 
6.2 Methods 
6.2.1 Study design 
ABON, (Abon Biopharm Company Limited, Hangzhou, China) is a syphilis RDT kit commonly 
used by blood donation facilities to screen blood for syphilis in Ghana. ABON syphilis RDT was 
chosen for this evaluation study because it is the predominant RDT used by the facilities in Ghana 
93. The four selected facilities were supplied with identical ABON test kits which were purchased 
from a local supplier. The facilities were also supplied with ‘already tested’ (i.e. known syphilis 
status) samples (see 6.2.2). These samples were blindly tested by the facility laboratory scientists 
with the same conditions prevailing in all the facilities, and the results were recorded on 
spreadsheets and returned to the researcher.  
6.2.2  Sample collection and preparation of a panel of samples of known syphilis status 
526 syphilis initially reactive blood donor samples were collected from prospective blood donors 
who came to KATH to donate blood between February 2014 and January 2015 after they were 
informed of the study and consented. For details, please refer to Chapter 5. The samples were 
collected into ethylenediaminetetraacetic acid (EDTA) tubes, centrifuged and plasma was 
separated from the whole blood and stored at −20°C. All these samples were tested with Vitros 
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syphilis TPA to verify their true positivity. The samples were again tested with RPR to detect 
suspected active infections which could infect transfusion recipients of the unit. 
A QA panel was made comprising of 100 samples already tested with Fortress syphilis RDT. Of 
these, 70 were syphilis Fortress RDT sero-reactive and thirty were syphilis Fortress seronegative 
(figure 6.1).  
Of the 70 samples tested with Fortress RDT and RPR, a confirmatory testing with Vitros assay 
was performed on them, and 60 were confirmed positive whilst 10 were negative (figure 6.1). For 
each sample, its degree of reactivity (negative, low positive, medium positive, strong positive) 
with Vitros was noted.  
Multiple aliquots of the 100 samples were made so that each of the four study facilities was 
provided with the following; 20 strong Vitros positives, 20 medium Vitros positives, 20 low Vitros 
positives, 10 Vitros negatives and 30 known Fortress RDT negatives. These were sent as a blinded 
test panel so the receiving laboratories were unaware of the status of the samples. They were asked 
to test the 100 samples using the ABON RDT kits provided through the project.   
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Figure 6.1: A flowchart of samples selected for the syphilis quality assurance study 
 
6.3 Results 
To maintain confidentiality, the facilities have been anonymised in this section. Of the 70 QC 
samples that were syphilis sero-reactive by Fortress RDT, overall 67 [(95.7%), 95% CI 88.1-98.5] 
of them were found to be positive by the 4 facilities using the ABON test (table 6.2). Of the 60 
samples that were confirmed positive with Vitros TPA, 2 facilities had all 60 being positive with 
ABON while the other 2 facilities had 59 out of the 60 being positive (table 6.2). Of the 30 samples 
that were negative with Fortress, each of the four facilities found that 28 were confirmed negative 
with ABON while two were positive (table 6.2). Thus, the overall sensitivity for the ABON when 
20 strong 
positive samples 
20 medium 
positive samples 
20 low positive 
samples 
100 blood 
samples selected 
30 negative samples 
tested with Fortress RDT  
70 sero-reactive samples 
tested with Fortress RDT  
60 confirmed 
positive with Vitros 
10 non-confirmed  
with Vitros 
30 RPR positives and 
40 RPR negatives 
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compared with Vitros as gold standard was 99.2% [(59.5/60) ×100]. The total number of negative 
samples was 40 whilst ABON detected 33 as negative samples. Thus, the overall specificity was 
82.5% [(33/40) ×100] as seen in table 6.1.  
Table 6.1 Sensitivity and specificity of the ABON test kit used in the selected facilities 
 Vitros TPA  
ABON 
syphilis 
RDT 
Results Positive Negative Total 
Positive 59.5 7 66.5 
Negative 0.5 33 33.5 
 Total 60 40 100 
RDT, rapid diagnostic test; TPA, Treponema pallidum assay 
Of the 30 RPR positive samples that were included in the study, 2 of the facilities had all the 30 
being positive while each of the other 2 facilities had 29 being positive.  
Table 6.2 Comparison of results from four facilities of blind testing of samples with ABON 
compared to Vitros and RPR results 
  Fortress RDT Fortress+ tested with Vitros RPR (N=70) 
 
Total found 
positive 
Negative 
High 
positive 
Medium 
positive 
Low 
positive 
Unconfirmed Positive Negative 
Facilities (N=70) (N=30) (N=20) (N=20) (N=20) (N=10) (N=30) (N=40) 
Facility 1 67/3 2/28 20 20 20 3/7 29/1 2/38 
Facility 2 67/3 2/28 20 20 19/1 2/8 30 3/37 
Facility 3 67/3 2/28 20 20 20 3/7 29/1  2/38 
Facility 4 67/3 2/28 20 20 19/1 2/8 30 3/37 
Average 
(%) 95.7 6.7 100 100 97.5 25 98.3 6.3 
RPR, rapid plasma reagin; N, number; RDT, rapid diagnostic test 
 
6.3.1 Facility 1 
At this facility, all the 60 Vitros confirmed samples, whether strong, medium and low positives, 
were found to be positive (100%) with ABON (table 6.2). Of the 30 samples that were negative 
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with Fortress RDT, this facility found that 28 (93.3%) were negative with ABON. It was 
additionally found that 60 (89.6%) out of the 67 ABON positive samples were confirmed with 
Vitros (p=0.001) (table 6.2). At this facility, 29 of the 30 (96.7%) RPR positive samples were 
positive with ABON whilst 38 of the 40 (95%) RPR negative samples were positive with ABON 
(Table 6.2) 
Table 6.3 Comparison of results from four facilities of blind testing of samples with ABON 
compared to Fortress RDT and Vitros results 
Fortress 
RDT 
Facility 1 (ABON) 
 
 
Total 
Facility 2 (ABON) 
 
 
Total 
Facility 3 (ABON) 
 
 
Total 
Facility 4 (ABON) 
 
 
Total 
Positive Negative Positive Negative Positive Negative Positive Negative 
Positive 
 
67 3 70 67 3 70 67 3 70 67 3 70 
Negative 
 
2 28 30 2 28 30 2 28 30 2 28 30 
Total 
 
69 31 100 69 31 100 69 31 100 69 31 100 
 
VTROS 
 
60 10 70 60 10 70 60 10 70 60 10 70 
P value 
 
0.001 0.001 0.001 0.001 
RDT, rapid diagnostic test 
 
6.3.2 Facility 2 
At facility 2, all the 40 Vitros confirmed samples which were made up of strong and medium 
positives were positive with ABON (table 6.2). However, this facility recorded 19 positive samples 
tested with ABON out of the 20 low positives from Vitros (table 6.2). Thus, of the 60 samples that 
were confirmed with Vitros, 59 (98.3%) were positive with ABON. In this facility, all the RPR 
positive samples were positive with ABON whereas 37 of the 40 RPR negative samples were 
positive with ABON (table 6.2). Of the 30 Fortress negative samples, 28 (93.3%) of them were 
negative with ABON.  
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6.3.3 Facility 3 
At this facility, all the 60 Vitros confirmed samples, whether strong, medium and low positives, 
were found to be positive (100%) with ABON (table 6.2). However, seven of the 10 unconfirmed 
with Vitros were positive with ABON, making the total ABON positives to be 67 out of 70 of the 
Fortress RDT sero-reactive samples. Of the 30 RPR positive samples, 29 (96.7%) were positive 
with ABON whilst 38 (95%) of the 40 RPR negative samples were positive with ABON (table 
6.2). Of the 30 Fortress RDT negative samples, two of them were positive with ABON making the 
total positives at this facility to be 69 out of 70 (98.6%) and total negatives to be 31 as seen in table 
6.3.  
6.3.4 Facility 4 
At facility 4, all the 40 Vitros confirmed samples that were strong and medium positives, were  
found to be positive with ABON; for the low positive samples, 19 out of 20 were positive with 
ABON (table 6.2). With the 10 samples that were not confirmed with Vitros, eight of them (80%) 
were positive with ABON as seen in table 6.1. However, all the 30 RPR positive samples were all 
positive with ABON; but 37 of the 40 RPR negative samples were positive with ABON. 
Of the 30 samples that were negative with both Fortress RDT, 28 (93.3%) of them were negative 
with ABON at this facility.  
6.4 Discussion 
Syphilis infection continues to pose a major threat in many developing countries including Ghana. 
Few studies have attempted to describe the prevalence of syphilis among blood donors in different 
parts of SSA including Ghana 4,6,274 and the majority of these estimates were based on the use of 
syphilis RDTs.  
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The sensitivity and specificity of the ABON RDT used in this study by the 4 facilities performing 
syphilis screening was found to be 99.2% and 82.5% respectively when compared with the gold 
standard (Vitros TPA). Overall, it was a satisfactory performance when compared with Fortress 
RDT which has a sensitivity of 99.7%, and is similar to syphilis RDT performance reported in 
other studies. When the WHO compared the performance of 8 rapid syphilis tests to a combined 
reference standard of TPHA/TPPA, they reported sensitivities of 84.5%–97.7% 197,198 which were 
similar to our findings.  
In a survey of syphilis testing practices in Ghana in 2016 93 which forms part of this thesis in 
chapter four, the prevalence of syphilis was found to be 3.7%. Two-thirds of the facilities involved 
in the study used RDTs for testing but the screening was neither repeated nor confirmed with a 
different test. An evaluation of pre-donation screening in Mozambique using RDTs also found 
syphilis prevalence to be 1.2% 8. Their testing strategy was to use the RPR test BD Macro-Vue 
RPR and they confirmed positive samples with SERODIA®- TPPA which was considered as their 
reference diagnostic method 8. 
Overall there was good consistency between the ABON RDT results and the confirmatory tests 
which indicated the efficaciousness of the test. There were a few small differences in results on 
the same samples depending on the test used (table 6.2). These discrepancies could be due to a 
number of reasons such as poor detection limit, and poor storage conditions by the suppliers, users, 
and during transportation. Most rapid syphilis test kit manufacturers specify storage temperatures 
between 4-30ºC 275. If the facility temperature is above 30ºC, periodic quality control checks to 
ensure the ongoing validity of the tests is especially important. There are some facilities in Ghana 
with storage challenges especially inconsistent power supply where room temperatures can rise 
above 30ºC and even lack of storage facilities where refrigerators are not available for test kits. In 
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this case, facilities should make sure proper storage conditions are met (4-30ºC) so as not to affect 
kit performance. 
Transport can also impact on the performance of test kits because of potential variability in the 
duration and temperature conditions. For example, test kits that are transported by road in Ghana 
and elsewhere may be exposed to temperatures that might exceed 40oC, while others that are 
transported by air may be exposed to temperatures below –40oC 276. It is important that the 
packaging reasonably protects the kits from extreme conditions during transportation, since this 
can affect detection limits. This would result in blood recipients being at risk of receiving blood 
which is ‘false negative’ for syphilis testing and failure to identify donors who may have syphilis 
infection. 
The use of only one type of serological RDT may be insufficient for syphilis diagnosis and blood 
donor testing since this study found evidence of false sero-positivity during confirmation tests 
using Vitros TPA as the gold standard (table 6.2) This indicates that the use of syphilis treponemal 
RDT alone cannot be recommended in the transfusion facilities as donors will be deferred 
unnecessarily, but it should be complemented with a second test to confirm the syphilis sero-
reactive as well as potentially infectious blood donors. Also, not all the 30 RPR positive samples 
were positive with ABON which also indicate that in the facilities, recipients could be at risk of 
being transfused with potential active syphilis blood units. Both nontreponemal and treponemal 
serological tests should be carried out in all suspected donor cases to ensure that truly infected 
donors and potential active infections are identified.  
Although quick, easy to perform and affordable, syphilis RDT kits with low sensitivity could miss 
some positive samples and the recipients could be at risk of being transfused with infected blood. 
Highly sensitive RDTs may be used as first-line screening kits but all reactive samples should be 
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confirmed using commercially available RPR kits to detect potential active infections. This is 
because the study showed a Vitros positive sample which was missed by the ABON kit but was 
RPR positive. Thus, for blood donors, it is very important to have highly sensitive test kits to 
reduce chances of infectious blood being transfused into patients. 
This ABON syphilis test kit used in this study like other syphilis RDTs is ideal for use in outreach 
and hospital facilities where syphilis testing is being offered to potential blood donors. This is a 
treponemal test, and blood donors who have a known history of syphilis infection without 
treatment should be advised not to have this test as results will continue to be positive. They should 
instead have a routine serologic specimen drawn for the standard lab-based syphilis testing, tested 
with RPR to monitor treatment. If they are not on treatment, the results of the RPR test will indicate 
positivity, and as such, will be deferred again.   
6.4.1 Establishment of external quality assessment systems for syphilis rapid testing 
Quality systems are the organizational structure and resources needed to implement quality 
requirements and include management, training, standards, documentation, traceability, and 
evaluation 277.  Quality systems are important for all tests including syphilis testing to ensure the 
accuracy, consistency, and reliability of test results. In this study we set up and piloted a new 
external quality systems (EQA) scheme to evaluate the syphilis RDT kits and to promote proper 
QA processes. EQA, which is the process that allows testing conducted by a laboratory, testing 
site or individual user to be compared to that of a source outside the laboratory, needs to be 
established for syphilis testing across Ghana. If properly established, the EQA can provide 
objective data on the quality of delivered services, and can reflect the quality of testing of blood 
donor specimens 276,278.  
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As far as I am aware this is the first time a QA testing panel has been set up in Ghana for syphilis. 
In Accra, there is a public health reference laboratory (PHRL) in Korle-Bu teaching hospital which 
deals with HIV QA but not syphilis. The influx of syphilis rapid kits on the market should be 
adequately controlled and kits need to be evaluated by the standards authority to ensure that they 
are of high quality. There should be a monitoring and evaluation system from the Food and Drugs 
Authority (FDA) in Ghana to regulate the use of these test kits and for ongoing review of their 
performance. The WHO has evaluated some commercially available rapid treponemal tests for 
performance and reproducibility 275. This evaluation includes test performance, ease of use, the 
condition of use, storage conditions, shelf life, and price. It may be possible to work with the Public 
Health and Reference Laboratory (PHRL) and the FDA in Ghana so that they can build on this 
syphilis testing panel for national use. Scaling up syphilis EQA across Ghana will also need a 
specifically designed in-service continuing education program for laboratory personnel, and 
should be instituted at the various regions in the country to refresh the continuing laboratory 
personnel in carrying out effective duties 277.   
6.5 Study limitations 
1. One major limitation of the study is the small sample size of our study facilities that 
performed the testing. This was due to logistic constraints.  
2. Of the 40 negative samples for the study, 30 of them were not tested with the gold standard 
but were assumed to be negative by the gold standard. This is because the study looked at 
the PPV, and al1 RDT negative samples were not sent to be retested with Vitros® TPA at 
the Department of Clinical Immunology, Copenhagen university hospital, Denmark. More 
so, the fact that these samples were retested with TPHA as WHO recommendation and 
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found all to be negative was the justification for the assumption that they would be negative 
with Vitros TPA. 
We therefore, recommend that future studies be performed by more facilities and that other brands 
of syphilis RDT kits should also be evaluated.  
6.6 Conclusion 
The detection of markers of syphilis infection in blood donors is important to avoid potentially 
transmitting syphilis to a recipient and for making appropriate referrals for donors for clinical 
review and possible treatment. However, the use of insufficiently sensitive diagnostic kits could 
pose a significant risk to both blood donors and blood recipients. This study evaluated the 
performance of the syphilis ABON RDT, which is widely used in Ghana and other developing 
countries.  By comparing Vitros TPA as gold standard, the respective sensitivity and specificity of 
the ABON syphilis screening kit was found to be 99.2% and 82.5%. Its performance was found to 
be satisfactory because of its relatively good sensitivity and specificity when compared with other 
syphilis rapid tests. However, the use of only one type of serological RDT may be insufficient for 
syphilis diagnosis and blood donor testing. Thus, a confirmatory test or a second test, preferably 
nontreponemal, is required to confirm the sero-reactive samples 44,112. This confirmatory/second 
test will help detect truly syphilis positive as well as potentially infectious blood donors. 
Laboratories that are committed to the principles of quality assurance generate relevant, reliable, 
and cost-effective results. A lack of quality assurance systems, as well as poor storage and transport 
of test kits, can contribute to poor test performance and affect detection limits of the test kits if not 
followed properly. Periodic external QA using laboratory-based tests should be carried out on all 
RDTs including those used for syphilis, by blood transfusion facilities. In this study, we have 
demonstrated how such a system can operate in Ghana. Lastly, national organisations such as the 
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FDA needs to be engaged to monitor the influx and quality of these RDTs to ensure they are of 
good quality and standard reactivity for their effective use. 
Lastly, I would also advice the T-REC, - an international consortium of academics and health 
practitioners working to strengthen the capacity of African researchers to do research on blood 
transfusion, - to foster collaboration between countries like Ghana, Zimbabwe and others in 
performing quality testing to enhance blood safety for transfusion.
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CHAPTER 7 
7. Recall of symptoms and treatment of syphilis and yaws by healthy blood donors screening 
positive for syphilis in Kumasi, Ghana 
The work described in this chapter has been published by the International Journal of Infectious 
Diseases (appendix 1.4) (http://creativecommons.org/licenses/by- nc-nd/4.0/). 
7.1 Introduction 
7.1.1 Study background 
The objective of this study (objective 5) is to determine the relative proportions of those with 
clinical histories attributable to yaws rather than syphilis in confirmed syphilis antibody positive 
donors. 
Yaws is an often ignored non-venereal endemic treponematosis. It causes significant morbidity in 
patients but has a low mortality because treatment can be effected with the use of azithromycin 
which is a central component of the new World Health Organization (WHO) strategy to eradicate 
yaws.  
.  
The clinical manifestations of yaws include multiple papillomas, non-tender ulcers, sores, plantar 
hyperkeratosis, and pigmentation of  the palms and soles, followed by gummata in the last phase 
14. 
The site of infection in an individual depends upon the living habits and environmental conditions 
in the area where they live because even breaks in the skin caused by injuries, bites, or excoriations 
can precipitate this disease 279. It particularly affects children aged 2–5 years living in poor 
socioeconomic conditions in certain rural, wet, and tropical areas of West and Central Africa, 
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South East Asia, and the South Pacific islands 280 ; these are areas where conditions of 
overcrowding, poor water supply, and lack of sanitation and hygiene prevail.   
.  
Figure 7.1 Yaws lesions before and after treatment with antibiotics 
Favourable climate conditions such as humidity and a constant warm temperature appear to be 
especially important factors for yaws to flourish 15. Presently, little is heard about this disease 
because it occurs in remote areas where health service coverage is very low. 
Africa is the continent most affected by yaws based on the WHO estimates from the 1990s. India 
reported its last cases in 2003, while Indonesia and Timor-Leste still have some cases left. Papua 
New Guinea and two other Pacific island countries, Solomon Islands and Vanuatu have reported 
cases and there are some pockets in the Amazon region 281.   
A major campaign in the 1950s and 1960s to eradicate yaws by means of community-wide 
treatment with long-acting, injectable penicillin reduced the number of cases of the disease by 95% 
from 50 million to 2.5 million worldwide; however, yaws was not eradicated 282. The problem was 
nearly solved, but there were resurgences particularly in the 1970s and in 2006 281 
Before 
After 
Recall of symptoms and treatment of syphilis and yaws -Sarkodie thesis 
126 
 
According to the WHO ‘Some of the issues and challenges that have hampered yaws eradication 
historically include the lack of an effective device for surveillance as well as case detection, limited 
political commitment and resources, limited capacity of general health staff to recognize and treat 
yaws, ensuring drug supply and logistics management, creating community awareness through 
appropriate advocacy campaigns and extending the services to remote and hard to reach areas 202.  
The Eastern, Central and Western regions of Ghana are the most affected places but all the 10 
regions and nearly 170 districts have reported yaws cases. In Ghana, a total of 28 000 cases were 
reported in 2008 and 25 000 in 2010 202 (table 7.1). In the context of neglected tropical diseases, 
the WHO launched the global yaws elimination initiative in 2007 to address the persistence and 
resurgence of this disease. Again in 2012, the WHO launched a new initiative to eradicate yaws 
globally by 2020 using not only the  new azithromycin-based treatment policy in 2012, but also, 
the initial mass treatment and biannual resurveys (the Morges strategy) 202. This was based on the 
discovery that a single dose of oral azithromycin is at least as effective as injectable penicillin G 
benzathine 283. 
Table 7.1 Annual (2002-2008) yaws case notification rates by region per 100,000 population 
Regions 2002 2003 2004 2005 2006 2007 2008 
Western 157 239 581 224 153 153 136  
Central 628 501 665  172 211 194 136 
Greater Accra - 12 169 13 7 10 11 
Eastern 931 516 393 141 228 415 619 
Volta 67 360 - 584 88 283 33 
Ashanti 79 71 134 55 55 47 50 
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Brong Ahafo 205 133 202 69 84 63 92 
Northern - - 60 55 4 5 30 
Upper East 24 5 7 4 2 7 34 
Upper West 517 14 30 10 60 41 68 
TOTAL 241 189 229 120 87 113 118 
Source: Yaws situation in Ghana, 2008 
Ghanahttp://www.who.int/yaws/resources/Yaws_Ghana_2008.pdf?ua=1 
This strategy provided two simplified treatment policies: 
a. Total community treatment (TCT): this was recommended for treatment of an entire 
endemic community, irrespective of the number of active clinical cases. 
b. Total targeted treatment (TTT): this was recommended for treatment of all active clinical 
cases and their contacts (household, school, and playmates). This was used during repeat 
surveys or retreatment or in response to a localized outbreak and was also applicable for 
imported cases. 
The purpose of these new policies was to ensure a more pragmatic, aggressive approach of dealing 
with cases and all contacts, so that transmission can be interrupted in a reasonably short time, 
leading to eradication. As oral drugs are easier to administer than injection penicillin, it is 
recommended, if practicable, to undertake large-scale treatment once a community is identified as 
endemic. 
7.1.2 Yaws and syphilis relationship 
The relationship of T. pallidum subsp. pertenue, the causative agent of yaws and T. pallidum subsp. 
pallidum, the causative agent of syphilis, has been the subject of much debate for more than 300 
years 284. There is today a progressively increasing recognition, continually supported by new 
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developments, that syphilis and yaws should be regarded as a closely related group of infections 
which, under different environmental influences, may develop into essentially similar or even 
identical clinical syndromes 15,285.  
7.1.3 Similarities of yaws and syphilis 
Since endemic syphilis and yaws are both non-venereal treponematoses they have a close 
similarity in their epidemiological pattern 15. On one hand, both are prevalent in under-developed 
regions among rural populations with low economic and social standards and poor education and 
sanitation; on the other hand, with increasing industrialization, social development, and education 
both will progressively decline and eventually disappear as endemic diseases but may linger on as 
small foci in isolated inaccessible hamlets and villages. The greatest clinical similarities between 
yaws and syphilis are seen in the late gummata and ulcerating lesions which result from the 
affected state of the tissues. Both T. pallidum subsp. pallidum and T. pallidum subsp. pertenue are 
non-cultivable and morphologically indistinguishable even by fluorescent or treponemal 
immobilization tests 144. Early stages of yaws and syphilis bear some resemblances, but late lesions 
of yaws are believed to be restricted to skin, bones, and joints. Indeed, there is a proposed theory 
by several investigators that the T. pallidum subsp. pallidum and T. pallidum subsp. pertenue have 
grew from a common ancestor but are now, in fact, different diseases 286,287. 
In both yaws and syphilis, the amount of reagin - the substance in the blood which is responsible 
for a positive response to the Wassermann test - decreases with time and is lower in the latent stage 
in older persons than in younger people, corresponding to the onset of the infection in the 
childhood 288. Because of these similarities, the measures for controlling endemic syphilis and 
analogous conditions such as yaws can follow the same or similar principles 289.  
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7.2 Methods 
7.2.1 Study Design 
This was a cross-sectional study conducted in the TMU of KATH and involved interviewing blood 
donors who were syphilis seropositive. In West Africa where yaws is prevalent, it is assumed that 
previous yaws infections may also contribute considerably to the high proportion of blood donors 
being screened positive for syphilis. Unfortunately, serological test for syphilis cannot distinguish 
blood donors who are infected with syphilis or yaws. Traditionally, individuals in whom 
seropositivity for syphilis correlated with clinical signs and symptoms of yaws were presumed to 
have yaws. The study therefore aimed to investigate whether donors who were syphilis 
seropositive could recall any signs or symptoms of yaws infection that might indicate a positive 
syphilis test could be due to cross reaction with yaws.  
The study algorithm was to interview prospective blood donors initially tested with a treponemal 
RDT according to routine SOP, further tested with RPR to identify potential active syphilis 
infections, and finally confirmed with a gold standard algorithm combining two automated 
treponemal immunoassays 112. 
7.2.2 Donor recruitment 
Between February 2014 and January 2015, 16,016 blood donors were tested for syphilis as 
described in chapter 5. Out of these, 478 cases were confirmed with the Ortho-Vitros Syphilis TP 
test as the gold standard and based on their address on clinical forms, they were invited to be 
interviewed to determine clinical history after they were consented based on ethical approval.  
7.2.3 Development of the interview questions on consented donors 
An interview guide was developed to interview confirmed syphilis seroreactive blood donors to 
determine the past or present clinical manifestations of yaws and syphilis. We developed a working 
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definition of yaws which included the fact that a donor had signs or symptoms when they were 
below 15 years of age which included presence of current or past sores or skin ulcers, and skin 
lesions/bumps on the face, hands, feet or genitals. 
The interview was conducted by two trained health professionals with syphilis positive blood 
donors. The questions covered the presence or absence of current or previous sores or skin ulcers, 
and skin lesions/bumps on the face, hands, feet or genitals. They were also asked about slow-
healing sores and at what age they had experienced symptoms. Furthermore, they were asked about 
any treatment given at the time of these symptoms. A pilot study was performed on seven blood 
donors who were initially syphilis reactive which led to the revised and final version of the 
interview guide. Contact numbers, e-mail addresses and residential addresses for the confirmed 
blood donors were documented from the clinical forms in the donor clinic of TMU.  
7.2.4 Interview training 
Two research assistants who were employees of KATH/TMU and were already familiar with blood 
donor clinic processes, were recruited and trained to perform the interviews and telephone calls as 
well as data entry. It was ensured that their involvement in this project did not disrupt their regular 
working activities.  
7.2.5 Inclusion Criteria 
1. Blood donors who were eligible to donate blood according to KATH/national standards 
(weight >50kg, systolic blood pressure ≤ 140mmHg and age 18 to 60 years).  
2.   Blood donors who were sero-reactive with syphilis RDT, and confirmed with Ortho-
Vitros Syphilis TP test as the gold standard. 
3. Consented to be in the study. 
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7.2.6 Exclusion criteria 
Blood donors who were reactive for syphilis but also reactive for either HIV, HBsAg or HCV. 
7.2.7 Data collection 
Confirmed syphilis sero-reactive blood donors included in the study were asked to report to the 
TMU donor clinic by telephone because their telephone numbers were recorded on the clinical 
questionnaire forms. They were informed about the study aims and objectives in the local dialect 
(Twi). Participants were informed of the possible benefits of participating in the study which 
included the direct access to a medical doctor in the event that there is a true positivity and active 
infection at no extra expense. After the explanation of the study and assessment of their 
understanding by a set of standard questions, participants were requested to sign or thumbprint an 
informed consent form (appendix 5.2)  
Four hundred and seventy-one out of the 478 confirmed syphilis seroreactive blood donors who 
were consented, were interviewed using a structured interview guide (appendix 4.2) to determine 
the past or present clinical manifestations of yaws and syphilis (Figure 7.2). Seven of syphilis 
confirmed blood donors could not turn up for the interview because three of the seven lived far 
away and could not be reached while four of them did not consent for the study.  
  
7.2.8 Data quality 
Data obtained from the study participants were checked every day for completeness. Validation of 
the data entry was done at the end of every week to make sure they were properly recorded from 
the interviews.  
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7.2.9 Data Analysis 
Background data were recorded into a spreadsheet consisting of sex, age, the number of donations, 
donor type and routine testing results. Data were then exported into STATA SE version 12 
(STATACORP, College station, Texas USA) which was the statistical software used for the 
analysis. All string variables were converted to numerical values for easy analysis and 
interpretation. Descriptive statistics of the variables were analysed and presented in the form of 
tables, pie charts, and figures. 
7.2.10 Differentiations 
The causative agents of both yaws and syphilis cannot be successively cultivated in vitro, are 
indistinguishable by dark field microscopy, and cannot be differentiated by classical syphilis 
serological methods 290,291. However, subspecies-specific genetic signatures permit molecular 
differentiation using methods that include PCR, restriction fragment length polymorphism 
(RFLP), and DNA sequencing. Besides, additional genetic differences have been recently observed 
by Izard et al 292 who compared the sequences of the cytoplasmic filament polypeptides (CfpA) of 
T. pallidum subsp. pallidum Nichols and T. pallidum subsp. pertenue Haiti B strain. Clearly, more 
extensive genetic studies are needed to solve the controversy that surrounds the relationship 
between yaws and syphilis. 
Traditionally, yaws and syphilis could only be distinguished by epidemiological characteristics 
and clinical manifestations 218. The clinical manifestations of yaws and syphilis differ in some 
respects, but these differences can be largely explained by different environmental influences and 
by the probable subsequent adoption of certain biological characteristics by the treponeme 285.  
Because of their serological similarities, it has been suggested that the relatively high prevalence 
of syphilis may be due to the cross reaction with yaws 293. Although there is no evidence that yaws 
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can be transmitted by blood transfusion 144, the cross-reactivity between yaws and syphilis leads 
to problems for blood services since yaws may cause false positive screening tests for syphilis. 
This results in unnecessary rejection of donors or discarding of blood units which reduce blood 
availability.  One question we need to ask ourselves is that do the presence of circulating syphilis 
antibodies (positive screening test) in donor blood provide evidence for the risk of transmitting the 
disease to recipients or could they sometimes represent a previous yaws infection? 
The objective of this study is to describe the recalled medical history, clinical manifestations, and 
treatment of yaws and syphilis by syphilis seroreactive blood donors in Kumasi, Ghana in an effort 
to see if there is any evidence of possible previous yaws infection in donors that test positive for 
syphilis. 
7.3 Results 
7.3.1 Study population 
The age of the 471 syphilis seroreactive subjects interviewed ranged from 17 to 53 years (mean 
age 31 years, standard deviation 8.6 years). In the total donor population of 16,016, 25% 
(4015/16016) were female while only one percent of the females (41/4015) were syphilis 
seroreactive (p<0.001). In this study, there were fewer females (29/471; 6.2%) than males 
(442/471; 93.8%) (p<0.006). 
Of the 471 respondents, 28 (5.9%) gave a past of skin lesions and sores (Figure 7.2). Four (14.3%) 
individuals out of the 28 donors with a history of skin lesions and sores – all male and RPR-positive 
– recalled a diagnosis of syphilis. These four donors had previously received penicillin treatment 
following their exposure to syphilis. All four men reported the appearance of lesions/bumps on the 
skin and slow-healing sores, but only one of them had had these symptoms before the age of 15 
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years. It could not be clarified whether this donor had had yaws or syphilis at this young age; he 
had received penicillin treatment. 
 
Figure 7.2 A flowchart of syphilis sero-reactive blood donors interviewed for clinical 
manifestations of yaws 
 
7.4 Discussion  
7.4.1 Clinical history of yaws among syphilis reactive blood donors 
Although yaws is a bacterial infection closely related to syphilis, data from this study suggest that 
a clinical history of yaws is not frequent among blood donors who screen positive on syphilis 
526 syphilis sero-reactive blood 
donors tested with RDT 
478 confirmed with Ortho 
Vitros® 48 not confirmed 
471 Interviewed (98.3%) 
443 had no history of 
skin lesion and sores 
28 had history of skin 
lesion and sores 
24 had no recall of 
syphilis exposure 
Four had a recall of 
syphilis exposure 
One donor had slow 
healing sores below 
15 years of age 
Three donors had slow 
healing sores after 15 
years of age 
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screening tests. Only a small proportion of confirmed sero-reactive donors had any recall of 
symptoms or treatment of yaws or syphilis, and only one of these had a slow healing sore below 
the age of 15 years. There was a poor correlation between the clinical history of yaws or syphilis 
infection and a positive screening test. Thus, the relative contribution of yaws and syphilis to 
frequent positive tests in endemic areas remains speculative. Traditionally, individuals in whom 
seropositivity for syphilis correlates with clinical signs and symptoms of yaws are presumed to 
have yaws. Children aged below 15 years are the most vulnerable to yaws infection 203 
predominantly living in remote, rural communities in tropical countries 294.  
7.4.2 Yaws diagnosis 
There is no specific blood test for yaws, but because it is closely related to the bacterium that 
causes syphilis, the blood tests for syphilis are diagnostic in yaws as well. The clinical diagnosis 
can be confirmed by examining a sample from a skin lesion under a special type of microscope 
(darkfield examination). 
The molecular methods to identify T. pallidum to the subspecies level has been previously reported 
15,224,295 which involved the use of nested PCR combined with sequencing and/or RFLP of multiple 
treponemal targets. These methods are costly, laborious, and time-consuming although useful. 
Additionally, they cannot be suitable for rapid screening applications as well as screening blood 
donors. The addition of serological tests that detect both treponemal and non-treponemal 
antibodies greatly improves the odds of identifying suspected yaws cases. 
Treatment of yaws is the same as syphilis where potent and cost-effective treatment with a single 
injection of long-acting Benzathine Penicillin is administered to infected people. 
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The present data suggest that adding clinical questioning to elucidate a possible clinical history of 
yaws or syphilis adds little further information to the ability of the current screening algorithm to 
differentiate between these two conditions as most syphilis seroreactive blood donors have no 
recall of yaws symptoms. 
7.5 Study limitations 
1. The study participants were interviewed after knowing that they had a positive test for 
syphilis. This represents a risk of recall bias, with reporting being influenced by the test 
results.  
2. The study participants were not asked the precise location of the sores but given the low 
level of association between a history of sores and positivity of tests for syphilis or yaws, 
it is unlikely that this would be helpful in the differential diagnosis 
3. There is furthermore a risk of misclassification bias, as many differential diagnoses exist 
for both syphilis and yaws. 
7.6 Conclusion 
A small proportion of confirmed seroreactive donors in this sample had any recall of symptoms or 
treatment for yaws or syphilis. These data suggest that clinical questioning may only add minimal 
further information to the current screening algorithm. The relative contribution of yaws and 
syphilis to frequent positive tests in endemic areas remains speculative.
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CHAPTER 8 
8. General conclusion and recommendations 
8.1 Conclusion 
Blood transfusion services and systems in developing countries are confronted with several 
challenges that threaten the availability, affordability, accessibility and safety of blood and blood 
components. Notable among these challenges is blood donor selection which comprises donor 
recruitment and donor testing. Syphilis is a very under-researched TTI yet it still poses a risk for 
recipients, particularly in poorer countries such as Ghana.    
The objective of my study was to investigate syphilis testing practices in transfusion facilities in 
Ghana, to guide transfusion policies and practices, and advance transfusion medicine research in 
Ghana.  
The inferences of this study and recommendations are presented objective by objective in the 
following chapter. 
8.1.1 Objective 1:  To investigate syphilis testing practices of transfusion facilities in 
Ghana. 
8.1.1.1 Conclusion 
This survey investigated syphilis screening practices and seroprevalence of syphilis in blood 
donors in 122 transfusion facilities in Ghana, resulting in an estimated seroprevalence of 3.7%. 
However, the teaching hospitals reported the lowest syphilis rate of seroreactivity (3.2%), with the 
highest resulting from the mission facilities (4.4%). the rate of syphilis seroreactivity from FD in 
its totality for this survey was significantly higher than the rate from VNRD. 
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This syphilis seroreactivity was relatively high in the blood donor populations in Ghana, and 
similar to elsewhere in SSA. However, there is a low syphilis testing rate as over a third of all 
donors were not screened for syphilis (63.6%, 91,386/143,787) during the period of survey. There 
was also a relatively high use of non-approved, non-validated test kits (RDTs) for syphilis 
screening, obtained at variable costs, in Ghana. If these rapid tests are effectively validated and 
managed, they could be incorporated into the existing guidelines to enhance blood safety. 
However, the substantial mismatch that existed between recommendations and actual practice for 
syphilis screening may compromise blood safety.  
8.1.2 Objectives 2: To determine the positive predictive value of the RDT that is most 
commonly used in KATH and Ghana for syphilis testing. 
8.1.2.1 Conclusion 
Between a time period of February 2014 and January 2015, 16,016 prospective blood donors who 
came to donate blood for the KATH blood bank were tested with syphilis Fortress RDT, and 599 
of these were syphilis seroreactive making an estimated sero-reactivity rate of 3.7%.  
526 (3.3%) out of the 599 syphilis seroreactive blood donors were included in the study. Of these, 
478 were confirmed by the algorithm (both Vitros and ARCHITECT TPA), making a PPV of 
90.9%. Multivariate logistic regression showed a positive association between syphilis reactivity 
and age, sex, and donor type.  
In a blood bank system like the one in Kumasi, Ghana, where syphilis prevalence is relatively high 
and resources are limited, syphilis screening with RDTs could provide a rational technology. We 
believe that screening blood donors for syphilis with RDT with proper validation in settings similar 
to ours can contribute to improving blood safety without threatening the blood supply.  
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The strength of this study is the description of a real-life performance with regards to the PPV of 
a newly suggested combined syphilis testing algorithm, combining an RDT and RPR for the 
identification of potential active syphilis. 
8.1.3 Objective 3: To estimate the proportion of blood donors in KATH, Kumasi who are 
really infectious through blood transfusion. 
8.1.3.1 Conclusion 
Syphilis sero-reactive samples from 526 consenting donors were further tested according to routine 
standard procedures with RPR at KATH/TMU laboratory to identify potential active syphilis 
infections. 
The RPR 18 mm circle card test, which is currently the most commonly used assay for donor 
screening, is a nontreponemal testing procedure for the serologic detection of suspected active 
syphilis. Of the 526 syphilis RDT reactive donor samples, 32.7% (172/526) were RPR positive. 
Out of these, 167 were confirmed with Vitros making a PPV of 97.1%. Thus, of the 478 confirmed 
Vitros positive samples, 34.9% (167/478) were suspected infectious. These blood units were 
removed from the refrigerator and discarded. Additionally, all the 167 blood donors who were 
RPR positive were recalled and referred to an internist for treatment. By using RPR as a second 
test, there are three benefits. Firstly, it reduces the number of blood units that are unnecessarily 
discarded due to false positive results. Secondly, blood donors who are identified as having 
suspected active syphilis can be referred for treatment. Finally, blood donors who are syphilis 
seroreactive but RPR negative (i.e. false positive) do not need to be notified thereby preventing 
unnecessary worry for them. Therefore, the combination of both RDT and RPR detects suspected 
active infections and reduces the loss of donors and consequently retaining more blood for 
transfusion. The combined RDT and RPR testing has a satisfactory high PPV so further routine 
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confirmation of a donor deferred with dual RDT and RPR reactivity is not needed. The hospital 
transfusion committee in the study area was instrumental in introducing the combined strategy of 
syphilis testing with RDT and RPR, showing the critical role, such committees can play in the 
implementation of evidence-based measures to improve blood safety and availability even when 
resources are limited. 
8.1.4 Objective 4: To determine the performance of a predominant syphilis RDT in 
selected transfusion facilities in Ghana. 
8.1.4.1 Conclusion 
100 QC samples of which 60 were positive with Vitros and 40 were negative were sent to 4 selected 
transfusion facilities to be tested with syphilis ABON RDT for quality assessment. The testing of 
these samples with ABON gave overall sensitivity and specificity of 99.2% and 82.5% respectively 
when compared with the gold standard (Vitros TPA). The study has for the first time in Ghana, 
developed a panel of samples of known syphilis status and used them to evaluate the quality and 
performance of the ABON syphilis RDT. The use of such a quality system for syphilis testing is 
important for any laboratory or testing site to ensure accuracy, consistency, and reliability of test 
results which directly contributes to the safety of blood supply. There are now many different, and 
un-validated, syphilis test kits in Ghana and this study has shown that it is important to control and 
validate these kits since. 
 Transfusion facility laboratories have the responsibility to ensure that test kits that are routinely 
used for syphilis testing are of good quality and standard reactivity. The effectiveness of less 
sensitive diagnostic kits could pose a significant risk to both blood donors and blood recipients. 
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8.1.5 Objective 5: In confirmed syphilis antibody positive donors, determine the relative 
proportions of those with clinical histories attributable to yaws rather than syphilis. 
8.1.5.1 Conclusion 
We interviewed 471 prospective blood donors who were treponemal RDT seroreactive, positive 
with RPR, and finally confirmed with a gold standard algorithm combining two automated 
treponemal immunoassays and a treponemal immunoblot. 28 of the 471 respondents (5.9%) gave 
a past history of skin lesions and sores. Four of the 28 respondents recalled a diagnosis of syphilis, 
of which only one of them, RPR positive male, had symptoms of yaws before the age of 15 years, 
and had received penicillin treatment. There was a poor relationship between the clinical history 
of sores or syphilis infection and a positive screening test so it is probably not worthwhile using 
clinical questioning as a means of differentiating yaws from syphilis in donors who screen positive 
with syphilis markers. 
8.2 Recommendations 
1. Teaching hospitals in Ghana should perform syphilis screening using current generation 
equipment for testing (e.g., TPHA or T. pallidum IgG-specific EIA), and that the smaller 
facilities use validated RDTs for testing. The challenge might be the cost implications, but 
this must be balanced against cost-effectiveness and public health benefits. 
2. NBSG should ensure that written SOPs for syphilis screening are developed and 
incorporated into the laboratory guidelines for screening blood donors.  
3. Highly sensitive RDTs may be used as first-line screening kits but all reactive samples 
should be confirmed using commercially available RPR kits to detect potential active 
infections. This will reduce unnecessary discarding of blood units and enable all infected 
donors to be referred for clinical advice. 
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4. A national quality assessment system should be established to evaluate and regulate 
syphilis RDTs to ensure that they have adequate sensitivity and specificity for use in 
screening blood donors. 
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2. Abstracts and Posters 
2.1  
Abstract accepted at the 23rd Regional Congress of the ISBT, held in Amsterdam, The 
Netherlands, from June 2 – 5, 2013.for ISBT 2013  
SYPHILIS TESTING AND ITS CROSS REACTIONS IN GHANAIAN BLOOD DONORS 
Francis Sarkodie1, Ib C. Bygbjerg2, Jorgen Skov Jensen3, Oliver Hassall4, Imelda Bates5, Alex 
Owusu-Ofori1, Justina K. Ansah5, Shirley Owusu-Ofori1, Henrik Ullum2. 
1Komfo Anokye Teaching Hospital, Kumasi, Ghana 2University of Copenhagen, Denmark 3Statens 
Serum Institut, Copenhagen 4Liverpool School of Tropical Medicine, UK.  5National Blood Service, 
Ghana. 
Background Information 
 Syphilis is a major public health problem worldwide but the prevalence of syphilis in Ghanaian blood 
donors vary. The continuing occurrence of syphilis illustrates that our control efforts still need to be 
improved. Published studies from Ghana show syphilis seroprevalence of between 7.5% and 13.5%. 
However, Accra Area Blood Centre, Korle Bu in Ghana has a prevalence rate of 1.23%, 2.89% and 4.86% 
among blood donors according to the 2009, 2010 and 2011 performance review respectively. Not all 
transfusion centers in Ghana are testing for syphilis in donated blood though it is mandatory. WHO 
recommends Treponema pallidum haemagglutination assay (TPHA) and Enzyme immuno assay (EIA) as 
screening tests that are specific serological markers of Treponema pallidum infections. However, majority 
of the centers use rapid tests for syphilis testing with higher risk of cross reactivity. Furthermore, all syphilis 
tests also detect antibodies against Treponema pallidum ssp. pertenue causing yaws. Syphilis and yaws can 
only be distinguished by epidemiological characteristics, clinical manifestations and several genetic 
signatures of the corresponding causative agents.  
Objective: The objective of this study is to determine the prevalence of syphilis, its cross reactions and the 
potential infectivity of the true positives in the Ghanaian blood donor population. 
Methodology: The study has been designed as a multicenter cross-sectional study which will involve a 
survey of the used methodologies and testing of their actual performance.  
1. Survey data on syphilis testing will be collected from all identified testing sites in the country by   
telephone interviews using semi-structured questionnaires. 
2. Within a period of 6 months, 5ml of serum shall be collected from 500 reactive blood donors tested with 
TPHA at Komfo Anokye Teaching Hospital, Kumasi. Of these reactive samples, hundred shall be aliquoted 
and sent to four different testing sites to be blindly tested by different personnel with TPHA. 
3. After the collection of the 500 initial reactive blood donors tested with TPHA, Abbott Architect syphilis 
TP assay which is chemiluminescent microparticle immunoassay(CMIA) for the qualitative detection of 
antibody to Treponema pallidum in human serum and plasma together with RPR testing will be used to 
identify true Treponema pallidum Ab. positivity and active infections respectively. 
4. Truly infected blood donors with Treponema pallidum Ab. shall be recalled for interview to identify 
histories of clinical manifestations of syphilis and yaws. This information will be useful in distinguishing 
yaws from Syphilis. 
Appendices- Sarkodie thesis 
197 
 
Preliminary Data/Results 
A total of 22 syphilis initially reactive blood samples tested with Treponema pallidum Heamagglutination 
Assay (TPHA) in Accra Area Blood Centre (AABC), Ghana were sent to Copenhagen University Hospital, 
Rigshospitalet Copenhagen, Denmark for further testing. After further testing with Architect TP, Vitros 
TPA, Inno-LiaTM and RPR Card test, the results showed that 82% (18 out of 22) were true positives and 
23% (5 out of 22) were reactive with RPR, signifying potentially active infectivity. (A table result is below). 
In conclusion, TPHA should be continued because of its good reactivity as the first line, and possibly 
repeated with RPR to reduce transmission of syphilis via blood transfusion. 
Expected Results  
It is expected that at the end of the study, the National prevalence of syphilis in the Ghanaian blood donors 
shall be known. The costs and performance of different testing regimes, the rate of false positives, the rate 
of active infections and the contribution of yaws would be further identified.  
 
Table.1 
EVALUATION OF SYPHILIS REAGENTS WITH SAMPLES FROM ACCRA AREA BLOOD CENTRE (AABC) - GHANA 
ASSAY TYPE 01 
 
02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 
 
TPHA 
Treponemal 
√ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ √ 
 
ARCHITECT 
TP 
Treponemal 
√ 
1.1 
√ 
11.
6 
√ 
3.4
5 
√ 
22.
7 
√ 
9.9 
√ 
1.7 
√ 
5.2 
√ 
28.
6 
√ 
10.
0 
√ 
1.5 
√ 
37.
0 
√ 
17.
1 
Ne
g 
√ 
1.3 
√ 
1.4 
 
√ 
2.2 
√ 
31.
0 
√ 
2.2 
 
√ 
 
√ √ √ 
 
VITROS TPA 
Treponemal 
Ne
g 
√ √ √ √ √ √ √ √ Ne
g 
√ √ Ne
g 
Ne
g 
Ne
g 
√ √ √ √ √ √ √ 
 
INNO-LIATM 
Treponemal 
IN
D 
√ √ √ √ √ √ √ √ Ne
g 
√ √ Ne
g 
Ne
g 
√ √ √ √ √ √ √ √ 
RPR Card test 
 Macro-Vue 
Non -
treponemal 
Ne
g 
Ne
g 
Ne
g 
Ne
g 
Ne
g 
Ne
g 
Ne
g 
√ Ne
g 
Ne
g 
√ √ Ne
g 
Ne
g 
√ Ne
g 
√ Ne
g 
Ne
g 
Ne
g 
Ne
g 
√ 
1:16 
 
NB – Reactive in Anti- treponemal test signifies Active or Previous infection 
         Reactive in non-treponemal test (RPR) signifies presumptive evidence of current infection, 
inadequately treated infection, persistent infection or reinfection. 
 
√ - Reactive 
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2.2  
Poster presented at the 23rd Regional Congress of the ISBT, held in Amsterdam, The Netherlands, 
from June 2 – 5, 2013.for ISBT 2013 
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2.3  
Abstract accepted for Oral Presentation at the 7th AfSBT congress held in collaboration 
with Zimbabwe Medical Association (ZiMA) and Zimbabwe Quality Assurance Programme 
(ZINQA) for 30 July – 02 August 2014, Victoria Falls, Zimbabwe. 
 
 
A NEW SCREENING STRATEGY FOR SYPHILIS AT KOMFO ANOKYE TEACHING 
HOSPITAL (KATH) IN KUMASI, GHANA  
Francis Sarkodie1, 2, Oliver Hassall2, Ellis Owusu-Dabo3, Shirley Owusu-Ofori1, Imelda Bates2, Ib 
C. Bygbjerg4, Henrik Ullum
4,5.   
1 Komfo Anokye Teaching Hospital, Kumasi, Ghana 2Liverpool School of Tropical Medicine, UK, 
3Kwame Nkrumah University of Science and Technology, Kumasi, Ghana 4University of 
Copenhagen, Denmark. 5Department of Clinical Immunology, Copenhagen University Hospital 
Denmark 
  Introduction: Until 2013 the Transfusion Medicine Unit (TMU) at KATH did not screen blood 
for syphilis before transfusion because of evidence that refrigerated storage of blood prevents 
transmission. However, recent data showed that 57% of blood transfused at KATH had been stored 
for less than four days, and a case of transfusion-transmitted syphilis was identified (Owusu-Ofori, 
2011).  As a consequence, pre-donation screening for syphilis using a treponemal rapid diagnostic 
test (RDT) was introduced. This demonstrated a syphilis sero-reactivity rate of 7%, resulting in a 
high donor deferral rate and a serious negative impact on the blood supply.  As syphilis sero-
reactivity by RDT does not necessarily correspond to infectivity, a new screening algorithm was 
implemented: prospective blood donors continue to be screened with a treponemal test for past or 
current infection with RDT at the time of donation;  blood is collected irrespective of these results 
and units screening positive quarantined  in a separate fridge; these units are then screened with a 
second, non-treponemal test (Rapid Plasma Reagin, RPR) for current or recent infection; RPR 
positive donations are presumed to have a higher infection risk and are therefore discarded; RPR 
negative donations are released for further processing and transfusion. Donors who were found to 
have a positive RPR are offered treatment and deferred for 12 months.  
Aims and Objective: The objective of this study is to report results of the implemented strategy 
for syphilis testing. 
Methods: Syphilis screening using the RDT (Fortress Quick Test, Fortress Diagnostics-UK) and 
RPR (IMMUTREP RPR, Omega Diagnostics-Scotland, UK) was done according to the 
manufacturers’ instructions and TMU-KATH standard laboratory procedures. Background data 
including donor type, age and gender were also recorded as part of standard blood donation 
practice at TMU-KATH. 
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Results: From July to September 2013, 4062 blood donations were screened of which 79.6% 
(3233/4062) were from male donors. Of these, 312 screened positive by RDT giving a sero-
reactivity rate of 7.7% (95% CI 0.069 to 0.085). Of these 52 (18.5%) were positive by RPR, 
presumed potentially infective and the donation was consequently discarded. Thus, 260 units 
which screened positive by RDT and negative by RPR were released for transfusion. 
Discussion and Conclusion: These data suggest that a reverse algorithm applying treponemal 
RDT as first line testing followed by a non-treponemal (RPR) test as second line may serve as a 
feasible screening strategy for syphilis. RDTs have several advantages, including user-
friendliness, affordability and availability in resource limited settings. As the majority of syphilis 
RDT positive donors were negative in RPR testing, the suggested strategy may be useful in 
balancing the risk of transfusion-transmitted syphilis with protection of the blood supply. 
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3. Ethics Approvals 
3.1  Ethics approval from LSTM, UK 
 
 
Francis Sarkodie  
Liverpool School of Tropical Medicine  
Pembroke Place  
Liverpool  
L3 5QA  
Wednesday, 19 February 2014  
Dear Mr Sarkodie,  
Re. Research Protocol (13.26RS) Syphilis Testing and its Cross Reactions in Ghanaian Blood 
Donors  
Thank you for your correspondence of the 18/02/2014 providing the necessary in-country ethical 
approval documents required for this study. The protocol now has formal ethical approval from 
the Chair of LSTM Research Ethics Committee.  
The approval is for a fixed period of three years and will therefore expire on 18/02/2017. The 
committee may suspend or withdraw ethical approval at any time if appropriate.  
Approval is conditional upon:  
• Continued adherence to all in-country ethical requirements.  
 
• Notification of all amendments to the protocol for approval before implementation.  
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• Notification of when the project actually starts.  
• Provision of an annual update to the Committee. Failure to do so could result in suspension of 
the study without further notice.  
• Reporting of new information relevant to patient safety to the Committee  
• Provision of Data Monitoring Committee reports (if applicable) to the Committee  
 
Failure to comply with these requirements is a breach of the LSTM Research Code of Conduct 
and will result in withdrawal of approval and may lead to disciplinary action. The Committee 
would also like to receive copies of the final report once the study is completed.  
Please quote your Ethics Reference number with all correspondence.  
Yours sincerely  
Dr Angela Obasi,  
 
 
Chair, LSTM Research Ethics Committee 
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3.2  Ethics approval from CHRPE, SMS/KNUST, Ghana 
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3.3  Ethics approval from NBSG 
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4. Data Collection Tools 
4.1  Semi-structured questionnaire 
QUESTIONNAIRE FOR BLOOD DONATION TESTING SITES 
TOPIC: A survey of syphilis testing in transfusion facilities in Ghana. 
 
N/B Please tick the box where applicable and fill in the space where you need to fill. 
 
 Name of Testing Site  
   
   
 Date  
   
  Yes No 
1. Is blood testing for transfusion transmissible infections done on all blood 
donations at this site before transfusion?   
    
 - If no, please give approximate percentages of tested donations 
 % 
   
    
2. 6. What types of blood testing are done routinely before blood is 
transfused? 
 
 
 
 
7. Anti-HIV Ab  
HBsAg  
Anti-HCV  
8. Anti-Syphilis  
9. HIV Ag+Ab  
   
 - If syphilis is not included, indicate reason:(You can tick more than one) 
 10.  - Syphilis testing is not mandatory according to WHO:  
- Syphilis testing is not necessary because of low risk of infection from blood 
products: 
 
 
- Lack of funds:  
- Other:  
   
  Yes No 
3. Has testing for syphilis ever been done at your site before blood transfusion?   
   
 - If yes, why was the testing for syphilis stopped? (You can tick more   than one) 
 11.  - Syphilis testing is not mandatory according to WHO:  
- Syphilis testing is not necessary because of low risk of infection from blood 
products: 
 
 
- Lack of funds:  
- Other:  
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4. How long have you been testing for syphilis in terms of years?  Years 
 
   
  Yes No 
5. Do you consider syphilis testing mandatory?   
   
 - If no, why is the site performing the test? 
 
   
   
   
6. What is the blood donor type at your site? - please give approximate percentages 
 12.  13. Type:  Percentages:  
 14.  15. Voluntary   % 
Replacement   % 
Walk - in   % 
16. Other   % 
   
   
7. In the years 2010 to 2012:  2010 2011 2012 
      
 - How many blood donations were tested for syphilis?  
     
     
      
 - How many were syphilis reactive?      
      
 - How many voluntary blood donations were tested for syphilis?      
      
 - How many voluntary blood donations was syphilis reactive?      
      
   
 - How many family replacement blood donations were tested for 
syphilis?      
      
 - How many family replacement blood donations was syphilis 
reactive?      
      
 - How many walk-in blood donations were tested for syphilis?      
 - How many walk-in blood donations was syphilis reactive?      
      
 - What type(s) of trade name for HIV testing did your site use?      
      
      
      
      
      
      
   2010 2011 2012 
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 - What type(s) of trade name for HCV testing did your site use?      
      
 - What type(s) of trade name for HBV testing did your site use?      
      
   
  Yes No 
8. Have you had co-infection of syphilis with other viral markers between 2010 
and 2012?   
   
  2010 2011 2012 
      
 17. - If yes, indicate the total 
positive numbers: 
 
18. Syphilis and HIV:      
     
Syphilis and HBV:      
     
Syphilis and HCV:      
 19.  20.  21.  22.  23.    
 24.  25. Syphilis, HBV and HIV: 26.  27.  28.    
 29.  30.  31.  32.  33.    
 34.  35. Syphilis, HCV and HIV: 36.  37.  38.    
 39.  40.  41.  42.  43.    
 44.  45. Syphilis, HCV and HBV: 46.  47.  48.    
 49.  50.  51.  52.  53.    
 54.  55. Syphilis, HCV, HBV and HIV: 56.  57.  58.    
   
   
9. 59. What type of reagent is used in your site for 
initial syphilis testing and who are the 
manufacturers? 
 60.  61. VDRL:  
 
 RPR:  
 
 TPHA:  
 
 62.  63.   TPPA:  
 
 64.  65.   Others:  
 
   
   
  Singles Duplicates 
10. Do you test for syphilis in singles or in duplicates?   
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  Yes No 
11. Do you repeat all positive results in your testing site?   
   
 66. - If yes what reagent is used in the repeat 
testing and who are the manufactures? 
 67.  68. VDRL:  
69.  
 RPR:  
 
 TPHA:  
 
 70.  71.   TPPA:  
 
 72.  73.   Others:  
 
   
   
  Yes No 
12. Is there any algorithm governing testing in your site i.e. type of test, 
singles or duplicate, repeat etc?   
   
 - If yes, what is the algorithm?         
 
   
   
   
13. What is the reagent cost per test for the various 
syphilis reagents you have been using? 
74.  75. VDRL:  
76.  
 RPR:  
 
 TPHA:  
 
 77.  78.   TPPA:  
 
 79.  80.   Others:  
 
   
   
   
14. What is the average resources used to perform syphilis testing per day? 
   
 81.  Number of employees perform syphilis testing per day:  
Number of hours used on syphilis testing per day:  
   
   
15. How is the reagent purchased? Hospital management  
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82. Donation from NBTS Headquarters              
83. Donations from external institutions  
84. Others (specify):                                            
   
   
   
16. How many test strips/reagents does the facility/site purchase for syphilis  
 testing in a year?  
   
   
  Yes No 
17. Did your site validate these test strips?   
   
 - If yes, how many test strips are used in the validation exercise?  
 
   
   
  Yes No 
18. After the testing do you invite donors whose test results are reactive to 
come back?   
   
 - If yes, what percentage of such donors comes back for management?   
 
   
   
   
  Yes No 
19. For syphilis reactive blood donors, does your site refer them to a 
clinician/clinical service?   
   
 - If yes, please state to whom / where:   
 
   
   
 - Do you get any feedback from the clinician/clinical service to know 
whether it is true syphilis? Yes               
 
No 
 
   
   
  Yes No 
20. For donors who reacted to syphilis, would you consider other potentially 
causes of reactivity?   
   
 - If yes, please state what other possible causes you consider: 
 
   
   
THANK YOU VERY MUCH                   
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4.2  Interview guide/checklist for yaws infection 
CHECKLIST FOR YAWS INFECTION 
Please notice, that the information given here will be kept strictly confidentially, and not be 
available for others! 
1. Have you ever been exposed to yaws or syphilis before? ?      Yes                     No  
2. Did you receive any sort of treatment? ?                                   Yes                     No  
3.  What drugs were given to you? 
4. Have you ever had sores or skin ulcer before?                          Yes                     No  
5. Have you ever had lesions that appear as bumps on the skin of the face, hands, feet, and 
genital area before?                                                                   Yes                      No  
If you have ever had sores, crusts or ulcers on the skin or on mucous membranes, please: 
Tick at the age in the box, when it began: 
Before the age of 15 years  
After the age of 15 years  
   
Have you ever had slowhealing sores, crusts or ulcers on the skin
like the ones on the photo below? or on mucous membranes
(mouth, genitals)?. If yes, please draw on the figure below.
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Thank you very much for your cooperation! 
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5. Consent forms 
5.1  Informed consent 1 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
Title of Research; 
Investigations of syphilis testing and of test cross reactions in Ghanaian blood donors 
Name of researcher: 
This study is being conducted by Mr Francis Sarkodie of the Komfo Anokye Teaching Hospital 
as part of requirement for an award of PhD in Public Health in Liverpool School of Tropical 
Medicine - UK 
Background; 
This study determines various syphilis test regiments and their performance across Ghana. It 
further describes the true prevalence of syphilis antibodies and their cross reactions in Komfo 
Anokye Teaching Hospital (KATH) blood donor population and intends to develop an appropriate 
algorithm for syphilis testing in donated blood. It is expected that at the end of the study, the costs 
and performance of different testing regimes, the rate of confirmed and false positives, the 
estimated rate of active infections and the contribution of yaws would be further known. The 
findings of this project will serve as a basis for further research in blood transfusion, and ultimately 
be used to improve and sustain the blood transfusion safety and services in Ghana and elsewhere. 
Purpose(s) of research:  
The purpose of this research is to determine the prevalence of syphilis, its cross reactions in 
Ghanaian blood donor population and the potential infectivity of the confirmed positives.  
Consent: 
Our screening indicates that you may have had syphilis. We ask for your consent to a research 
project where we will draw an extra blood sample of 5 ml. With this we will determine if you truly 
have had syphilis. We will also determine if there is a risk of active infection. If our tests indicate 
that you have active infection, we will refer you to a medical doctor in-charge of transfusion 
transmissible infections for further investigation and treatment. 
Risk(s): 
There will be no risk to the person to be interviewed as well as the participants because the research 
assistants have been trained for the interviews and blood collection. 
Benefit(s): 
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The goal of this study is to develop an appropriate algorithm for syphilis testing in donated blood 
and the findings of this project will serve as a basis for further research in blood transfusion, and 
ultimately be used to improve and sustain the blood transfusion safety and services in Ghana and 
elsewhere. The participants would be referred for clinical advice. 
Confidentiality: 
A coding system shall be introduced as part of quality assurance and control. The participants shall 
be systematically coded to prevent mixing of samples and results, and these shall be used as 
processing numbers. No name or identifier will be used in any publication or reports from this 
study. However, as part of our responsibility to conduct this research properly, we may allow 
officials from the National Blood Service and ethics committees to have access to your records. 
Voluntariness:  
Taking part in this study should be out of your own free will.  You are not under any obligation to 
participate.  Research is entirely voluntary. 
Alternatives to participation:  
If you choose not to participate, this will not affect the blood donor clinical services that shall be 
offered to you in this hospital in any way. 
Withdrawal from the research:  
You may choose to withdraw from the research at any time without having to explain yourself. 
You may also choose not to answer any question you find uncomfortable or private.   
Consequence of Withdrawal:  
There will be no consequence, loss of benefit or care to you if you choose to withdraw from the 
study.  Please note however, that some of the information that may have been obtained from you 
without identifiers (name etc), before you chose to withdraw, may have been modified or used in 
analysis reports and publications.  These cannot be removed anymore. We do promise to make 
good faith effort to comply with your wishes as much as practicable. 
Costs/Compensation:  
There shall be no cost or compensation for the participants. However, any Information that shall 
be received shall be conveyed to the participants. 
Contacts:  
 If you have any question concerning this study, please do not hesitate to contact Mr Francis 
Sarkodie (Name of Researcher or PI) on 0244371770. 
Further, if you have any concern about the conduct of this study, your welfare or your rights as a 
research participant, you may contact: 
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The Chairman 
Committee on Human Research and Publication Ethics 
Kumasi 
Tel: 22301-4 ext. 1098 or 020 5453785 
 
CONSENT FORM 
Statement of person obtaining informed consent: 
I have fully explained this research to ____________________________________ and have given 
sufficient information, including that about risks and benefits, to enable the prospective participant 
make an informed decision to or not to participate. 
 
DATE: _____________________         NAME: _________________________________ 
 
Statement of person giving consent: 
I have read the information on this study/research or have had it translated into a language I 
understand. I have also talked it over with the interviewer to my satisfaction.  
I understand that my participation is voluntary (not compulsory).  
I know enough about the purpose, methods, risks and benefits of the research study to decide that 
I want to take part in it.  
I understand that I may freely stop being part of this study at any time without having to explain 
myself.  
I have received a copy of this information leaflet and consent form to keep for myself. 
Name___________________________________________________________________ 
 
DATE: ____________           SIGNATURE/THUMB PRINT: ___________________ 
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5.2 Informed consent 2 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
Title of Research; 
Investigations of syphilis testing and of test cross reactions in Ghanaian blood donors 
Name of researcher: 
This study is being conducted by Mr Francis Sarkodie of the Komfo Anokye Teaching Hospital 
as part of requirement for an award of PhD in Public Health in Liverpool School of Tropical 
Medicine - UK 
Background; 
This study determines the relative proportions of those with clinical histories attributable to yaws 
rather than syphilis in confirmed syphilis antibody positive donors. 
It is expected that at the end of the study, the rate of confirmed and false positives, estimated rate 
of active infections and the contribution of yaws would be known. The findings of this project will 
serve as a basis for further research in blood transfusion, and ultimately be used to improve and 
sustain the blood transfusion safety and services in Ghana and elsewhere. 
Purpose(s) of research:  
The purpose of this research is to determine the prevalence of syphilis, test cross reactions in 
Ghanaian blood donor population and the potential infectivity of the confirmed positives.  
Consent: 
Our screening indicates that you have a suspected active syphilis. We ask for your consent to be 
interviewed. With this we will determine if you truly have had syphilis rather than yaws. We will 
refer you to a medical doctor in-charge of transfusion transmissible infections for further 
investigation and treatment after this interview. 
Risk(s): 
There will be no risk to the person to be interviewed as well as the participants because the research 
assistants have been trained for the interviews and blood collection. 
Benefit(s): 
 The participants would be referred for clinical advice for treatment. 
Confidentiality: 
A coding system shall be introduced as part of quality assurance and control. The participants shall 
be systematically coded to prevent mixing of results, and these shall be used as processing 
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numbers. No name or identifier will be used in any publication or reports from this study. However, 
as part of our responsibility to conduct this research properly, we may allow officials from the 
National Blood Service and ethics committees to have access to your records. 
Voluntariness:  
Taking part in this study should be out of your own free will.  You are not under any obligation to 
participate.  Research is entirely voluntary. 
Alternatives to participation:  
If you choose not to participate, this will not affect the blood donor clinical services that shall be 
offered to you in this hospital in any way. 
Withdrawal from the research:  
You may choose to withdraw from the research at any time without having to explain yourself. 
You may also choose not to answer any question you find uncomfortable or private.   
Consequence of Withdrawal:  
There will be no consequence, loss of benefit or care to you if you choose to withdraw from the 
study.  Please note however, that some of the information that may have been obtained from you 
without identifiers (name etc), before you chose to withdraw, may have been modified or used in 
analysis reports and publications.  These cannot be removed anymore. We do promise to make 
good faith effort to comply with your wishes as much as practicable. 
Costs/Compensation:  
There shall be no cost or compensation for the participants. However, any Information that shall 
be received shall be conveyed to the participants. 
Contacts:  
 If you have any question concerning this study, please do not hesitate to contact Mr Francis 
Sarkodie (Name of Researcher or PI) on 0244371770. 
Further, if you have any concern about the conduct of this study, your welfare or your rights as a 
research participant, you may contact: 
 
The Chairman 
Committee on Human Research and Publication Ethics 
Kumasi 
Tel: 22301-4 ext. 1098 or 020 5453785 
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CONSENT FORM 
Statement of person obtaining informed consent: 
I have fully explained this research to ____________________________________ and have given 
sufficient information, including that about risks and benefits, to enable the prospective participant 
make an informed decision to or not to participate. 
 
DATE: _____________________         NAME: _________________________________ 
 
Statement of person giving consent: 
I have read the information on this study/research or have had it translated into a language I 
understand. I have also talked it over with the interviewer to my satisfaction.  
I understand that my participation is voluntary (not compulsory).  
I know enough about the purpose, methods, risks and benefits of the research study to decide that 
I want to take part in it.  
I understand that I may freely stop being part of this study at any time without having to explain 
myself.  
I have received a copy of this information leaflet and consent form to keep for myself. 
Name___________________________________________________________________ 
 
DATE: ____________           SIGNATURE/THUMB PRINT: ___________________ 
 
 
 
 
 
 
 
 
